{
  "meta": {
    "id": "test10",
    "title": "H. Programs, Schemes, Acts",
    "category": "Subject Wise / Mixed"
  },
  "questions": [
    {
      "text": "A public health student is reviewing the goals of the global plan to end tuberculosis (TB) and comes across the 90-90-90 targets set forth by the Stop TB Partnership. These targets are a part of the ambitious strategy to end the TB epidemic by 2030. Which of the following is NOT one of the 90-90-90 targets in the global plan to end Tuberculosis by the Stop TB Partnership?",
      "options": [
        {
          "label": "A",
          "text": "Reach atleast 90% of all people with TB",
          "correct": false
        },
        {
          "label": "B",
          "text": "Reach at least 90% of the key population",
          "correct": false
        },
        {
          "label": "C",
          "text": "Achieve at least 90% treatment success rate",
          "correct": false
        },
        {
          "label": "D",
          "text": "Achieve at least 90% reduction in TB prevalence",
          "correct": true
        }
      ],
      "correct_answer": "D. Achieve at least 90% reduction in TB prevalence",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/26/screenshot-2024-08-26-110148.png"
      ],
      "explanation": "<p><strong>Ans. D. Achieve at least 90% reduction in TB prevalence</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Global plans targets: 90-90-90 target for Tuberculosis:</li><li>\u2022 Global plans targets: 90-90-90 target for Tuberculosis:</li><li>\u2022 Option A. Correct . Reach at least 90% of all people with TB and place all of them on appropriate therapy first- line, second-line and preventive therapy as required.</li><li>\u2022 Option A.</li><li>\u2022 Correct</li><li>\u2022 Option B . Correct . As a part of this approach, reach at least 90% of the key populations the most vulnerable, underserved, at-risk populations.</li><li>\u2022 Option B</li><li>\u2022 Correct</li><li>\u2022 Option C . Correct . Achieve at least 90% Treatment success for all people diagnosed with TB through affordable treatment services, adherence to complete and correct treatment, and social support.</li><li>\u2022 Option C</li><li>\u2022 Correct</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Global plans targets: 90-90-90 target for Tuberculosis:</li><li>\u27a4 Global plans targets: 90-90-90 target for Tuberculosis:</li><li>\u27a4 Ref : Park 26 th edition (page 234)</li><li>\u27a4 Ref : Park 26 th edition (page 234)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1c0bf9d2",
      "audio": ""
    },
    {
      "text": "In the plains region of a country working under the National Tuberculosis Elimination Program (NTEP), health administrators are tasked with ensuring adequate laboratory supervision for TB diagnostics. They are currently planning the deployment of Senior TB Laboratory Supervisors (STLS) to various districts. What is the maximum population coverage assigned to one Senior TB Laboratory Supervisor (STLS) in the plains for effective oversight under the National Tuberculosis Elimination Program (NTEP)?",
      "options": [
        {
          "label": "A",
          "text": "30000",
          "correct": false
        },
        {
          "label": "B",
          "text": "100000",
          "correct": false
        },
        {
          "label": "C",
          "text": "200000",
          "correct": false
        },
        {
          "label": "D",
          "text": "500000",
          "correct": true
        }
      ],
      "correct_answer": "D. 500000",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D. 500000</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The RNTCP designated \u2018 Microscopy Centre\u2019 is established for approx. 100,000 populations (50,000 in hilly and mountainous areas)</li><li>\u2022 RNTCP</li><li>\u2022 Microscopy Centre\u2019</li><li>\u2022 approx. 100,000 populations</li><li>\u2022 Senior TB Laboratory Supervisor (STLS) is one for every 5 microscopy centres - 1 STLS per 5 lac population (2.5 lac in hilly and mountainous areas)</li><li>\u2022 Senior TB Laboratory Supervisor</li><li>\u2022 5 microscopy centres</li><li>\u2022 STLS rechecks all +ve slides and 10% of all \u2013ve slides</li><li>\u2022 all +ve slides and 10% of all \u2013ve slides</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 1 STLS - on 5 Microscopic centre (MC) {1 MC for approx. 100,000 population plains /50,000 in hilly and mountainous areas}</li><li>\u27a4 1 STLS</li><li>\u27a4 5 Microscopic centre</li><li>\u27a4 Ref : Park 26 th edition (page 478)</li><li>\u27a4 Ref : Park 26 th edition (page 478)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0ba43ad7",
      "audio": ""
    },
    {
      "text": "A medical resident is assigned to a public health center focusing on Tuberculosis (TB) control. Part of the task is to identify key populations who are at increased risk for TB due to their living or working conditions, as these groups require targeted interventions and screening protocols. Which of the following populations is NOT typically considered at increased risk for exposure to Tuberculosis due to their living or work environments?",
      "options": [
        {
          "label": "A",
          "text": "People in urban slums",
          "correct": false
        },
        {
          "label": "B",
          "text": "People in poorly ventilated or dusty conditions",
          "correct": false
        },
        {
          "label": "C",
          "text": "People who live in homes for elderly",
          "correct": true
        },
        {
          "label": "D",
          "text": "Work in hospital or health care professionals",
          "correct": false
        }
      ],
      "correct_answer": "C. People who live in homes for elderly",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. People who live in homes for elderly</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Correct: People living in urban slums are at a higher risk for TB exposure due to factors such as overcrowding , poor ventilation , and limited access to healthcare services.</li><li>\u2022 Option A. Correct:</li><li>\u2022 People living in urban slums</li><li>\u2022 higher risk for TB exposure</li><li>\u2022 overcrowding</li><li>\u2022 poor ventilation</li><li>\u2022 Option B. Correct : Working or living in poorly ventilated or dusty conditions can increase the risk of TB exposure.</li><li>\u2022 Option B. Correct</li><li>\u2022 Working or living in poorly ventilated</li><li>\u2022 increase</li><li>\u2022 TB exposure.</li><li>\u2022 Option D. Correct: Healthcare professionals and those working in hospitals are at an increased risk for TB exposure . They are often in close contact with patients who may have TB, especially in settings without adequate infection control measures.</li><li>\u2022 Option D. Correct:</li><li>\u2022 Healthcare professionals</li><li>\u2022 hospitals</li><li>\u2022 increased risk for TB exposure</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 People who have Increased exposure to TB due to where they live or work:</li><li>\u27a4 Increased exposure to TB</li><li>\u27a4 where they live or work:</li><li>\u27a4 live in urban slums live in poorly ventilated or dusty conditions are contacts of TB patients, including children work in environments that are overcrowded work in hospitals or are health care professionals</li><li>\u27a4 live in urban slums</li><li>\u27a4 live in poorly ventilated or dusty conditions</li><li>\u27a4 are contacts of TB patients, including children</li><li>\u27a4 work in environments that are overcrowded</li><li>\u27a4 work in hospitals or are health care professionals</li><li>\u27a4 People who have limited access to quality TB services :</li><li>\u27a4 People</li><li>\u27a4 limited access to quality TB services</li><li>\u27a4 are from tribal populations or indigenous groups are homeless live in hard-to-reach areas live in homes for the elderly have mental or physical disabilities face legal barriers to access care are lesbian, gay, bisxeual or transgender.</li><li>\u27a4 are from tribal populations or indigenous groups</li><li>\u27a4 are homeless</li><li>\u27a4 live in hard-to-reach areas</li><li>\u27a4 live in homes for the elderly</li><li>\u27a4 have mental or physical disabilities</li><li>\u27a4 face legal barriers to access care</li><li>\u27a4 are lesbian, gay, bisxeual or transgender.</li><li>\u27a4 Ref : Park 26 th edition (page 235)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 235)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "85858006",
      "audio": ""
    },
    {
      "text": "In a resource-limited setting, healthcare workers are discussing innovative methods to ensure adherence to long-term treatment regimens for diseases like tuberculosis (TB). They are interested in a cost-effective, scalable solution that utilizes widely available technology to monitor patient compliance. Which of the following is a low-cost, mobile phone-based technology that allows for real-time remote monitoring of patients\u2019 daily treatment intake?",
      "options": [
        {
          "label": "A",
          "text": "99 DOTS",
          "correct": true
        },
        {
          "label": "B",
          "text": "DOTS plus",
          "correct": false
        },
        {
          "label": "C",
          "text": "Medication Event Reminder Monitor (MERM)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Nikshay Yojana",
          "correct": false
        }
      ],
      "correct_answer": "A. 99 DOTS",
      "question_images": [],
      "explanation_images": [
        "https://lh7-us.googleusercontent.com/ay1WKXU6ti_MS3bVBiddv5ZwZLEfe2nDpThUFOfeGNsVRp9-HtbXduAv8T7_Jw5T4Xo_VDB5KdTpODBm7yZL8I-DFhIdZoJ08XUN_v85MJPR-dOhG3K6lHoYIv8lUSN7OMBw92EC2ZzqWTQYMLN5dNY",
        "https://www.ntep.in/sites/default/files/h5p/content/1427/images/file-64358b1d59ddc.jpg"
      ],
      "explanation": "<p><strong>Ans. A. 99 DOTS</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. DOTS plus - refers to the treatment of MDR-TB (Category IV): MDR/XDR treatment is started at the DOTS-plus sites where the patient is admitted for treatment for 2/3 weeks ; After adjusting the medication the patient is sent back to continue his/her treatment at his respective chest clinic/DOTS provider</li><li>\u2022 Option B. DOTS plus - refers to the treatment of MDR-TB (Category IV): MDR/XDR treatment</li><li>\u2022 DOTS-plus sites</li><li>\u2022 patient is admitted for treatment for 2/3 weeks</li><li>\u2022 Option C. Medication Event Reminder Monitor (MERM) : Is an electronic pill box specially designed to monitor Multidrug-resistant TB (MDR-TB) treatment . Medications are dispensed in blister packs and each drug is placed in a different partitioned compartment within the pillbox .</li><li>\u2022 Option C. Medication Event Reminder Monitor (MERM)</li><li>\u2022 electronic pill box</li><li>\u2022 designed to monitor Multidrug-resistant TB</li><li>\u2022 treatment</li><li>\u2022 .</li><li>\u2022 Option D. Nikshay Yojana - Nikshay Poshan Yojana -</li><li>\u2022 Option D. Nikshay Yojana - Nikshay Poshan Yojana -</li><li>\u2022 Financial incentive of Rs.500/- per month for each notified TB patient for duration for which the patient is on anti-TB treatment All TB patients notified on or after 1st April 2018 including all existing TB patients under treatment are eligible to receive incentives</li><li>\u2022 Financial incentive of Rs.500/- per month for each notified TB patient for duration for which the patient is on anti-TB treatment</li><li>\u2022 Financial incentive of Rs.500/-</li><li>\u2022 each notified TB patient</li><li>\u2022 duration</li><li>\u2022 patient is on anti-TB treatment</li><li>\u2022 All TB patients notified on or after 1st April 2018 including all existing TB patients under treatment are eligible to receive incentives</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 DOTS 99 - Low-cost , mobile phone-based technology that enables real-time remote monitoring of daily intake of treatment</li><li>\u27a4 DOTS 99</li><li>\u27a4 Low-cost</li><li>\u27a4 mobile phone-based technology</li><li>\u27a4 real-time remote monitoring</li><li>\u27a4 daily intake of treatment</li><li>\u27a4 NIKSHAY : ICT-based Surveillance Support ICT enabled state-of-art surveillance system (Online monitoring software) to get notification of TB cases at diagnosis from both public and private sector including drug resistant TB patients Continuous monitoring and treatment adherence for all TB patients registered Enable tracking of all notified TB patients across TB care cycle, geographies, transfers and referrals.</li><li>\u27a4 NIKSHAY : ICT-based Surveillance Support ICT enabled state-of-art surveillance system (Online monitoring software) to get notification of TB cases at diagnosis from both public and private sector including drug resistant TB patients</li><li>\u27a4 NIKSHAY</li><li>\u27a4 ICT-based Surveillance Support</li><li>\u27a4 Continuous monitoring and treatment adherence for all TB patients registered</li><li>\u27a4 Enable tracking of all notified TB patients across TB care cycle, geographies, transfers and referrals.</li><li>\u27a4 Ref : https://www.99dots.org/</li><li>\u27a4 Ref : https://www.99dots.org/</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "02bda6be",
      "audio": ""
    },
    {
      "text": "When was the Iodine deficiency disorders programme launched?",
      "options": [
        {
          "label": "A",
          "text": "1960",
          "correct": false
        },
        {
          "label": "B",
          "text": "1961",
          "correct": false
        },
        {
          "label": "C",
          "text": "1962",
          "correct": true
        },
        {
          "label": "D",
          "text": "1963",
          "correct": false
        }
      ],
      "correct_answer": "C. 1962",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. 1962</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 National Goitre Control Programme (NGCP) launched in 1962 (100% centrally sponsored).</li><li>\u2022 National Goitre Control Programme</li><li>\u2022 1962</li><li>\u2022 National Iodine Deficiency Disorders Control Programme (NIDDCP) was launched in 1992.</li><li>\u2022 National Iodine Deficiency Disorders Control Programme</li><li>\u2022 1992.</li><li>\u2022 Global Iodine Deficiency Disorders (IDD) Day: 21st October</li><li>\u2022 Global Iodine Deficiency Disorders</li><li>\u2022 21st October</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 National Goitre Control Programme (NGCP) launched - 1962</li><li>\u27a4 National Goitre Control Programme</li><li>\u27a4 1962</li><li>\u27a4 Ref : Park 26 th edition (page 494)</li><li>\u27a4 Ref : Park 26 th edition (page 494)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c60e715f",
      "audio": ""
    },
    {
      "text": "While attending a public health seminar, a medical student views several logos related to various nutritional programs in India. One of the logos is meant to represent a program that addresses the widespread issue in India. Which nutritional program in India is associated with this logo?",
      "options": [
        {
          "label": "A",
          "text": "Vitamin A prophylaxis programme",
          "correct": false
        },
        {
          "label": "B",
          "text": "Anaemia Mukt Bharat",
          "correct": false
        },
        {
          "label": "C",
          "text": "National Iodine deficiency disorder control programme",
          "correct": true
        },
        {
          "label": "D",
          "text": "Mid-day meal programme",
          "correct": false
        }
      ],
      "correct_answer": "C. National Iodine deficiency disorder control programme",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/14/picture44.jpg"
      ],
      "explanation_images": [
        "https://4.bp.blogspot.com/-8lR48LR1Hg8/WUFz0MhBhuI/AAAAAAAABWA/K0HAayBzQ3wHlOaTDlVCdBrgCjLAHaYMACLcBGAs/s640/Namak.jpg",
        "https://npcbvi.mohfw.gov.in/Image/logo1.png",
        "https://play-lh.googleusercontent.com/MVUfnbDvILIBylE0P851UfBI-s7hvzRIpzW4I2nASfOG8L74GFRwOUSKb17WpKEynt4",
        "https://w7.pngwing.com/pngs/697/822/png-transparent-midday-meal-scheme-school-government-of-india-primary-education-school-education-text-class-nutrition.png"
      ],
      "explanation": "<p><strong>Ans. C. National Iodine deficiency disorder control programme</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Vitamin A prophylaxis programme - No specific logo. The logo is for NPCBVI -</li><li>\u2022 Option A. Vitamin A prophylaxis programme - No specific logo. The logo is for NPCBVI -</li><li>\u2022 Option B. Anemia Mukt Bharat -</li><li>\u2022 Option B. Anemia Mukt Bharat -</li><li>\u2022 Option D. Mid-day meal Program</li><li>\u2022 Option D. Mid-day meal Program</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Indicators to Monitor Success of NIDDCP</li><li>\u27a4 Indicators</li><li>\u27a4 Monitor Success of NIDDCP</li><li>\u27a4 Process Indicators : Indicators to monitor and evaluate the salt iodization process Salt iodine content at the production site Salt iodine content at point of packaging Salt iodine content at wholesale and retail levels Salt iodine content in households</li><li>\u27a4 Process Indicators : Indicators to monitor and evaluate the salt iodization process Salt iodine content at the production site Salt iodine content at point of packaging Salt iodine content at wholesale and retail levels Salt iodine content in households</li><li>\u27a4 Process Indicators</li><li>\u27a4 monitor and evaluate</li><li>\u27a4 salt iodization process</li><li>\u27a4 Salt iodine content at the production site Salt iodine content at point of packaging Salt iodine content at wholesale and retail levels Salt iodine content in households</li><li>\u27a4 Salt iodine content at the production site</li><li>\u27a4 Salt iodine content at point of packaging</li><li>\u27a4 Salt iodine content at wholesale and retail levels</li><li>\u27a4 Salt iodine content in households</li><li>\u27a4 Impact Indicators : Indicators to assess baseline (Iodine Deficiency Disorders) IDD status and to monitor and evaluate the impact of salt iodization on the target population. Urinary Iodine Levels : The \u2018principal impact indicator\u2019 recommended once a salt iodization programme has been initiated Goitre assessment : (by palpation or by ultrasound) should remain a component of surveys to establish the baseline severity of IDD Neonatal thyroid stimulating hormone (TSH) levels Sustainability Indicators : Indicators to assess whether iodine deficiency has been successfully eliminated and maintained. Median urinary iodine levels in the target population Availability of adequately iodized salt at the household level Set of programmatic indicators (as evidence of sustainability).</li><li>\u27a4 Impact Indicators : Indicators to assess baseline (Iodine Deficiency Disorders) IDD status and to monitor and evaluate the impact of salt iodization on the target population. Urinary Iodine Levels : The \u2018principal impact indicator\u2019 recommended once a salt iodization programme has been initiated Goitre assessment : (by palpation or by ultrasound) should remain a component of surveys to establish the baseline severity of IDD Neonatal thyroid stimulating hormone (TSH) levels</li><li>\u27a4 Impact Indicators</li><li>\u27a4 assess baseline</li><li>\u27a4 IDD status</li><li>\u27a4 monitor and evaluate</li><li>\u27a4 impact of salt iodization</li><li>\u27a4 Urinary Iodine Levels : The \u2018principal impact indicator\u2019 recommended once a salt iodization programme has been initiated Goitre assessment : (by palpation or by ultrasound) should remain a component of surveys to establish the baseline severity of IDD Neonatal thyroid stimulating hormone (TSH) levels</li><li>\u27a4 Urinary Iodine Levels : The \u2018principal impact indicator\u2019 recommended once a salt iodization programme has been initiated</li><li>\u27a4 Urinary Iodine Levels</li><li>\u27a4 Goitre assessment : (by palpation or by ultrasound) should remain a component of surveys to establish the baseline severity of IDD</li><li>\u27a4 Goitre assessment</li><li>\u27a4 Neonatal thyroid stimulating hormone (TSH) levels</li><li>\u27a4 Neonatal thyroid stimulating hormone</li><li>\u27a4 Sustainability Indicators : Indicators to assess whether iodine deficiency has been successfully eliminated and maintained. Median urinary iodine levels in the target population Availability of adequately iodized salt at the household level Set of programmatic indicators (as evidence of sustainability).</li><li>\u27a4 Sustainability Indicators</li><li>\u27a4 Median urinary iodine levels in the target population Availability of adequately iodized salt at the household level Set of programmatic indicators (as evidence of sustainability).</li><li>\u27a4 Median urinary iodine levels in the target population</li><li>\u27a4 Availability of adequately iodized salt at the household level</li><li>\u27a4 Set of programmatic indicators (as evidence of sustainability).</li><li>\u27a4 Ref : https://nhm.gov.in/index1.php?lang=1&level=3&sublinkid=1054&lid=230</li><li>\u27a4 Ref : https://nhm.gov.in/index1.php?lang=1&level=3&sublinkid=1054&lid=230</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9491a3b4",
      "audio": ""
    },
    {
      "text": "A first-year PG resident is preparing a presentation on public health initiatives in India and comes across a logo that symbolizes a national campaign. With which of the following public health initiatives is this logo associated?",
      "options": [
        {
          "label": "A",
          "text": "Vitamin A prophylaxis programme",
          "correct": false
        },
        {
          "label": "B",
          "text": "Anaemia Mukt Bharat",
          "correct": true
        },
        {
          "label": "C",
          "text": "National Iodine deficiency disorder control programme",
          "correct": false
        },
        {
          "label": "D",
          "text": "Mid-day meal programme",
          "correct": false
        }
      ],
      "correct_answer": "B. Anaemia Mukt Bharat",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/14/picture43.jpg"
      ],
      "explanation_images": [
        "https://play-lh.googleusercontent.com/MVUfnbDvILIBylE0P851UfBI-s7hvzRIpzW4I2nASfOG8L74GFRwOUSKb17WpKEynt4",
        "https://npcbvi.mohfw.gov.in/Image/logo1.png",
        "https://4.bp.blogspot.com/-8lR48LR1Hg8/WUFz0MhBhuI/AAAAAAAABWA/K0HAayBzQ3wHlOaTDlVCdBrgCjLAHaYMACLcBGAs/s640/Namak.jpg",
        "https://w7.pngwing.com/pngs/697/822/png-transparent-midday-meal-scheme-school-government-of-india-primary-education-school-education-text-class-nutrition.png",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-131218.png"
      ],
      "explanation": "<p><strong>Ans. \u00a0B. Anaemia Mukt Bharat</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Vitamin A prophylaxis programme - No specific logo. The logo is for NPCBVI -</li><li>\u2022 Option A. Vitamin A prophylaxis programme - No specific logo. The logo is for NPCBVI -</li><li>\u2022 Option C. National Iodine deficiency disorder control programme -</li><li>\u2022 Option C. National Iodine deficiency disorder control programme -</li><li>\u2022 Option D. Mid-day meal Program</li><li>\u2022 Option D. Mid-day meal Program</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Anemia Mukt Bharat -</li><li>\u27a4 Anemia Mukt Bharat</li><li>\u27a4 Main Aim - To reduce prevalence of anemia by 3% points per year among children , adolescents and women in the reproductive age group (15\u201349 years), between the year 2018-2022</li><li>\u27a4 reduce prevalence of anemia</li><li>\u27a4 3% points per year among children</li><li>\u27a4 adolescents</li><li>\u27a4 women in the reproductive age group</li><li>\u27a4 2018-2022</li><li>\u27a4 Beneficiaries</li><li>\u27a4 Beneficiaries</li><li>\u27a4 Children (6\u201359 months) Children (5\u20139 years) Adolescent boys (10\u201319 years) Adolescent girls (10\u201319 years) Women of reproductive age (20\u201324 years) Pregnant women Lactating women</li><li>\u27a4 Children (6\u201359 months)</li><li>\u27a4 Children (5\u20139 years)</li><li>\u27a4 Adolescent boys (10\u201319 years)</li><li>\u27a4 Adolescent girls (10\u201319 years)</li><li>\u27a4 Women of reproductive age (20\u201324 years)</li><li>\u27a4 Pregnant women</li><li>\u27a4 Lactating women</li><li>\u27a4 Interventions</li><li>\u27a4 Interventions</li><li>\u27a4 Prophylactic Iron Folic Acid supplementation Deworming Intensified year-round BCC Campaign including ensuring delayed cord clamping Testing of anemia using digital methods and point of care treatment Mandatory provision of Iron Folic Acid fortified foods in public health programmes \u2022 Addressing non-nutritional causes of anemia in endemic pockets, with special focus on malaria, haemoglobinopathies and fluorosis</li><li>\u27a4 Prophylactic Iron Folic Acid supplementation</li><li>\u27a4 Deworming</li><li>\u27a4 Intensified year-round BCC Campaign including ensuring delayed cord clamping</li><li>\u27a4 Testing of anemia using digital methods and point of care treatment</li><li>\u27a4 Mandatory provision of Iron Folic Acid fortified foods in public health programmes \u2022 Addressing non-nutritional causes of anemia in endemic pockets, with special focus on malaria, haemoglobinopathies and fluorosis</li><li>\u27a4 Prophylactic Dose and Regime for Iron Folic Acid Supplementation</li><li>\u27a4 Prophylactic Dose and Regime for Iron Folic Acid Supplementation</li><li>\u27a4 Ref : https://anemiamuktbharat.info/</li><li>\u27a4 Ref :</li><li>\u27a4 https://anemiamuktbharat.info/</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ca89bb17",
      "audio": ""
    },
    {
      "text": "The following logo is associated with which of the following nutritional supplementation programme.",
      "options": [
        {
          "label": "A",
          "text": "Vitamin A prophylaxis programme",
          "correct": false
        },
        {
          "label": "B",
          "text": "ICDS programme",
          "correct": true
        },
        {
          "label": "C",
          "text": "National Iodine deficiency disorder control programme",
          "correct": false
        },
        {
          "label": "D",
          "text": "Mid-day meal programme",
          "correct": false
        }
      ],
      "correct_answer": "B. ICDS programme",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/14/picture42.jpg"
      ],
      "explanation_images": [
        "https://e7.pngegg.com/pngimages/832/488/png-clipart-integrated-child-development-services-all-india-federation-of-anganwadi-workers-and-helpers-child-child-text.png",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/10/image-20240110185917-1.png",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/10/image_xWWj4Wj.png",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/10/image_PlSWQBq.png",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-131644.png"
      ],
      "explanation": "<p><strong>Ans. \u00a0B. ICDS programme</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Vitamin A prophylaxis programme: No specific logo. The logo is for NPCBVI -</li><li>\u2022 Option A. Vitamin A prophylaxis programme:</li><li>\u2022 NPCBVI -</li><li>\u2022 Option C. National Iodine deficiency disorder control programme:</li><li>\u2022 Option C. National Iodine deficiency disorder control programme:</li><li>\u2022 Option D. Mid-day meal -</li><li>\u2022 Option D. Mid-day meal -</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Integrated Child Development Services (ICDS)</li><li>\u27a4 Integrated Child Development Services</li><li>\u27a4 ICDS (Anganwadi worker) covered under Ministry Women and Child Development ICDS is a centrally sponsored scheme Integrated Child Development Services (ICDS) launched in year 1975 ICDS Beneficiaries (Irrespective of income of family) Children 0 \u2013 6 years age Pregnant and lactating mothers Women in reproductive age group. Adolescent girls 11 \u2013 18 years ICDS provides an integrated package of services - Supplementary nutrition Immunization Health check-up Medical referral services Nutrition and health education for women Non-formal education for children aged 3 \u2013 6 years, and pregnant and nursing mothers in rural, urban and tribal areas \u2018 Heart of ICDS system\u2019 - Anganwadi Population covered by Anganwadi in tribal area - 300-800 Population covered by Anganwadi in plains area - 400-800 1 Mini-Anganwadi centre per 150\u2013400 population (rural/urban); 150-300 (tribal) 1 Anganwadi on Demand (AOD) for settlement \u2265 40 children under 6 years age Supplemental nutrition given through ICDS: 300 feeding days in a year [NEW 2014 GUIDELINES]</li><li>\u27a4 ICDS (Anganwadi worker) covered under Ministry Women and Child Development</li><li>\u27a4 ICDS</li><li>\u27a4 covered under Ministry Women</li><li>\u27a4 Child Development</li><li>\u27a4 ICDS is a centrally sponsored scheme</li><li>\u27a4 ICDS</li><li>\u27a4 centrally sponsored scheme</li><li>\u27a4 Integrated Child Development Services (ICDS) launched in year 1975</li><li>\u27a4 launched in year 1975</li><li>\u27a4 ICDS Beneficiaries (Irrespective of income of family) Children 0 \u2013 6 years age Pregnant and lactating mothers Women in reproductive age group. Adolescent girls 11 \u2013 18 years</li><li>\u27a4 ICDS Beneficiaries</li><li>\u27a4 Children 0 \u2013 6 years age Pregnant and lactating mothers Women in reproductive age group. Adolescent girls 11 \u2013 18 years</li><li>\u27a4 Children 0 \u2013 6 years age</li><li>\u27a4 Pregnant and lactating mothers</li><li>\u27a4 Women in reproductive age group.</li><li>\u27a4 Adolescent girls 11 \u2013 18 years</li><li>\u27a4 ICDS provides an integrated package of services - Supplementary nutrition Immunization Health check-up Medical referral services Nutrition and health education for women Non-formal education for children aged 3 \u2013 6 years, and pregnant and nursing mothers in rural, urban and tribal areas</li><li>\u27a4 Supplementary nutrition Immunization Health check-up Medical referral services Nutrition and health education for women Non-formal education for children aged 3 \u2013 6 years, and pregnant and nursing mothers in rural, urban and tribal areas</li><li>\u27a4 Supplementary nutrition</li><li>\u27a4 Immunization</li><li>\u27a4 Health check-up</li><li>\u27a4 Medical referral services</li><li>\u27a4 Nutrition and health education for women</li><li>\u27a4 Non-formal education for children aged 3 \u2013 6 years, and pregnant and nursing mothers in rural, urban and tribal areas</li><li>\u27a4 \u2018 Heart of ICDS system\u2019 - Anganwadi</li><li>\u27a4 Heart of ICDS system\u2019</li><li>\u27a4 Population covered by Anganwadi in tribal area - 300-800</li><li>\u27a4 Population</li><li>\u27a4 Anganwadi in tribal area</li><li>\u27a4 300-800</li><li>\u27a4 Population covered by Anganwadi in plains area - 400-800</li><li>\u27a4 Population</li><li>\u27a4 Anganwadi in plains area</li><li>\u27a4 400-800</li><li>\u27a4 1 Mini-Anganwadi centre per 150\u2013400 population (rural/urban); 150-300 (tribal)</li><li>\u27a4 1 Mini-Anganwadi centre</li><li>\u27a4 150\u2013400 population</li><li>\u27a4 1 Anganwadi on Demand (AOD) for settlement \u2265 40 children under 6 years age</li><li>\u27a4 1 Anganwadi on Demand</li><li>\u27a4 settlement \u2265 40 children</li><li>\u27a4 6 years age</li><li>\u27a4 Supplemental nutrition given through ICDS: 300 feeding days in a year [NEW 2014 GUIDELINES]</li><li>\u27a4 Ref : ICDS document, Ministry of Women & Child Development, Government of India</li><li>\u27a4 Ref : ICDS document, Ministry of Women & Child Development, Government of India</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d3d74ad0",
      "audio": ""
    },
    {
      "text": "A public health intern is given a task to develop educational materials for a nationwide campaign in India. As part of this task, the intern is reviewing various logos associated with different health programs. One particular logo that the intern has to work with is designed to represent the government's flagship program to improve nutritional outcomes for children, pregnant women, and lactating mothers. Which of the following national health programs does this logo represent?",
      "options": [
        {
          "label": "A",
          "text": "Poshan Abhiyaan",
          "correct": true
        },
        {
          "label": "B",
          "text": "ICDS programme",
          "correct": false
        },
        {
          "label": "C",
          "text": "National Iodine deficiency disorder control programme",
          "correct": false
        },
        {
          "label": "D",
          "text": "Mid-day meal programme",
          "correct": false
        }
      ],
      "correct_answer": "A. Poshan Abhiyaan",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/14/picture41.jpg"
      ],
      "explanation_images": [
        "https://static.virtubox.io/project/file/20220115-045727-dfhl-poshan-abhiyaan-logo.png",
        "https://e7.pngegg.com/pngimages/832/488/png-clipart-integrated-child-development-services-all-india-federation-of-anganwadi-workers-and-helpers-child-child-text.png",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/10/image_jx9eRYa.png",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/10/image_K6A2ZSV.png"
      ],
      "explanation": "<p><strong>Ans. \u00a0A. Poshan Abhiyaan</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. ICDS Programme</li><li>\u2022 Option B. ICDS Programme</li><li>\u2022 Option C. National Iodine deficiency disorder control programme</li><li>\u2022 Option C. National Iodine deficiency disorder control programme</li><li>\u2022 Option D. Mid-day meal programme</li><li>\u2022 Option D. Mid-day meal programme</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Poshan Abhiyaan / NNM -</li><li>\u27a4 Poshan Abhiyaan</li><li>\u27a4 Major impact : To reduce the level of stunting , under-nutrition , anemia and low birth weight babies. Components : Mapping of various Schemes contributing towards addressing malnutrition, Introducing a very robust convergence mechanism, ICT based Real Time Monitoring system, Incentivizing States/UTs for meeting the targets, Incentivizing Anganwadi Workers (AWWs) for using IT based tools, Eliminating registers used by AWWs, Introducing measurement of height of children at the Anganwadi Centres (AWCs), Social Audits, Setting-up Nutrition Resource Centres, involving masses through Jan Andolan Vision : To ensure attainment of malnutrition-free India by 2022 Targets : To reduce stunting, under- nutrition, anemia (among young children, women and adolescent girls) and reduce low birth weight by 2%, 2%, 3% and 2% per annum respectively Although the target to reduce Stunting is at least 2% p.a., Mission would strive to achieve reduction in Stunting from 38.4% (NFHS-4) to 25% by 2022 (Mission 25 by 2022)</li><li>\u27a4 Major impact : To reduce the level of stunting , under-nutrition , anemia and low birth weight babies.</li><li>\u27a4 Major impact</li><li>\u27a4 reduce</li><li>\u27a4 stunting</li><li>\u27a4 under-nutrition</li><li>\u27a4 anemia</li><li>\u27a4 Components : Mapping of various Schemes contributing towards addressing malnutrition, Introducing a very robust convergence mechanism, ICT based Real Time Monitoring system, Incentivizing States/UTs for meeting the targets, Incentivizing Anganwadi Workers (AWWs) for using IT based tools, Eliminating registers used by AWWs, Introducing measurement of height of children at the Anganwadi Centres (AWCs), Social Audits, Setting-up Nutrition Resource Centres, involving masses through Jan Andolan</li><li>\u27a4 Components</li><li>\u27a4 Vision : To ensure attainment of malnutrition-free India by 2022</li><li>\u27a4 Vision</li><li>\u27a4 Targets : To reduce stunting, under- nutrition, anemia (among young children, women and adolescent girls) and reduce low birth weight by 2%, 2%, 3% and 2% per annum respectively Although the target to reduce Stunting is at least 2% p.a., Mission would strive to achieve reduction in Stunting from 38.4% (NFHS-4) to 25% by 2022 (Mission 25 by 2022)</li><li>\u27a4 Targets</li><li>\u27a4 To reduce stunting, under- nutrition, anemia (among young children, women and adolescent girls) and reduce low birth weight by 2%, 2%, 3% and 2% per annum respectively Although the target to reduce Stunting is at least 2% p.a., Mission would strive to achieve reduction in Stunting from 38.4% (NFHS-4) to 25% by 2022 (Mission 25 by 2022)</li><li>\u27a4 To reduce stunting, under- nutrition, anemia (among young children, women and adolescent girls) and reduce low birth weight by 2%, 2%, 3% and 2% per annum respectively</li><li>\u27a4 Although the target to reduce Stunting is at least 2% p.a., Mission would strive to achieve reduction in Stunting from 38.4% (NFHS-4) to 25% by 2022 (Mission 25 by 2022)</li><li>\u27a4 Ref : https://wcd.nic.in/schemes/poshan-abhiyaan</li><li>\u27a4 Ref :</li><li>\u27a4 https://wcd.nic.in/schemes/poshan-abhiyaan</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6a2a26cc",
      "audio": ""
    },
    {
      "text": "A public health official is reviewing various nutritional programs to address child malnutrition in India. During a presentation, a specific logo is displayed that is representative of a national program. With which of the following national health programs is this logo associated?",
      "options": [
        {
          "label": "A",
          "text": "ICDS programme",
          "correct": false
        },
        {
          "label": "B",
          "text": "Anaemia Mukt Bharat",
          "correct": false
        },
        {
          "label": "C",
          "text": "Balwadi nutrition programme",
          "correct": false
        },
        {
          "label": "D",
          "text": "Mid-day meal scheme",
          "correct": true
        }
      ],
      "correct_answer": "D. Mid-day meal scheme",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/14/picture40.jpg"
      ],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/07/image-20231107205846-1.png",
        "https://e7.pngegg.com/pngimages/832/488/png-clipart-integrated-child-development-services-all-india-federation-of-anganwadi-workers-and-helpers-child-child-text.png",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/01/10/image_5kYEG43.png",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-132403.png"
      ],
      "explanation": "<p><strong>Ans. D. Mid-day meal scheme</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. ICDS programme -</li><li>\u2022 Option A. ICDS programme -</li><li>\u2022 Option B. Anemia Mukt Bharat -</li><li>\u2022 Option B. Anemia Mukt Bharat -</li><li>\u2022 Option C. Balwadi nutrition programme - No specific logo</li><li>\u2022 Option C. Balwadi nutrition programme - No specific logo</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Mid-day meal scheme (MDMS) (National Programme of Nutritional Support to Primary Education):</li><li>\u27a4 Mid-day meal scheme</li><li>\u27a4 Launched in 1995 Main objective : Universalisation of primary education by increasing enrolment, retention and attendance and simultaneously impacting on nutrition of students in primary classes. The mid-day meal should supply 1/3 of the total energy requirement and 1/2 of the total protein requirement A model menu for mid-day school meal -</li><li>\u27a4 Launched in 1995</li><li>\u27a4 1995</li><li>\u27a4 Main objective : Universalisation of primary education by increasing enrolment, retention and attendance and simultaneously impacting on nutrition of students in primary classes.</li><li>\u27a4 Main objective</li><li>\u27a4 The mid-day meal should supply 1/3 of the total energy requirement and 1/2 of the total protein requirement</li><li>\u27a4 mid-day meal</li><li>\u27a4 supply 1/3 of the total energy requirement</li><li>\u27a4 1/2 of the total protein requirement</li><li>\u27a4 A model menu for mid-day school meal -</li><li>\u27a4 Principles for formulating mid-day meals: Meal should be a supplement only not a substitute for home diet Meal should provide 1/3 calories and 1/2 proteins Meal cost should be low Complicated cooking process must not be involved Use locally available foods Keep changing menu frequently</li><li>\u27a4 Principles for formulating mid-day meals: Meal should be a supplement only not a substitute for home diet Meal should provide 1/3 calories and 1/2 proteins Meal cost should be low Complicated cooking process must not be involved Use locally available foods Keep changing menu frequently</li><li>\u27a4 Principles for formulating mid-day meals:</li><li>\u27a4 Meal should be a supplement only not a substitute for home diet Meal should provide 1/3 calories and 1/2 proteins Meal cost should be low Complicated cooking process must not be involved Use locally available foods Keep changing menu frequently</li><li>\u27a4 Meal should be a supplement only not a substitute for home diet</li><li>\u27a4 Meal should provide 1/3 calories and 1/2 proteins</li><li>\u27a4 Meal cost should be low</li><li>\u27a4 Complicated cooking process must not be involved</li><li>\u27a4 Use locally available foods</li><li>\u27a4 Keep changing menu frequently</li><li>\u27a4 Ref : https://en.wikipedia.org/wiki/Midday_Meal_Scheme</li><li>\u27a4 Ref :</li><li>\u27a4 https://en.wikipedia.org/wiki/Midday_Meal_Scheme</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "773feacc",
      "audio": ""
    },
    {
      "text": "Match the following programme's (Column A) with the respective ministries (Column B).",
      "options": [
        {
          "label": "A",
          "text": "a-iii, b-i, c-ii, d- iv",
          "correct": true
        },
        {
          "label": "B",
          "text": "a-iii, b-ii c-i, d- iv",
          "correct": false
        },
        {
          "label": "C",
          "text": "a-iii, b-iv, c-ii, d- i",
          "correct": false
        },
        {
          "label": "D",
          "text": "a-iii, b-iv, c-i, d- ii",
          "correct": false
        }
      ],
      "correct_answer": "A. a-iii, b-i, c-ii, d- iv",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/13/screenshot-2024-03-13-095743.jpg"
      ],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/26/screenshot-2024-08-26-111255.png",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/03/13/screenshot-2024-03-13-095910.jpg"
      ],
      "explanation": "<p><strong>Ans. \u00a0A. a-iii, b-i, c-ii, d- iv</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation :</li><li>\u2022 ICDS programme - iv. Ministry of Women and Child Development</li><li>\u2022 ICDS programme</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective :</li><li>\u27a4 Ministries to combat malnutrition:</li><li>\u27a4 Ministries to combat malnutrition:</li><li>\u27a4 Ref : Park 26 th edition (page 750)</li><li>\u27a4 Ref : Park 26 th edition (page 750)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3820ba3e",
      "audio": ""
    },
    {
      "text": "A public health resident is reviewing the history of health interventions in India and notes a significant reduction in the prevalence of xerophthalmia and child mortality due to vitamin A deficiency after the implementation of a national program. This program was initiated to provide vitamin A supplementation biannually to children aged 6 months to 5 years. In which year was this Vitamin A prophylaxis program launched?",
      "options": [
        {
          "label": "A",
          "text": "1970",
          "correct": true
        },
        {
          "label": "B",
          "text": "1971",
          "correct": false
        },
        {
          "label": "C",
          "text": "1972",
          "correct": false
        },
        {
          "label": "D",
          "text": "1973",
          "correct": false
        }
      ],
      "correct_answer": "A. 1970",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-144746.png"
      ],
      "explanation": "<p><strong>Ans. A. 1970</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Vitamin A prophylaxis programme was launched by the Ministry of Health and Family Welfare in 1970 on the basis of technology developed at the National Institute of Nutrition at Hyderabad .</li><li>\u2022 Vitamin A prophylaxis programme</li><li>\u2022 Ministry of Health and Family Welfare</li><li>\u2022 1970</li><li>\u2022 basis of technology</li><li>\u2022 National Institute of Nutrition at Hyderabad</li><li>\u2022 WHO recommended strategy for prevention of Xerophthalmia -</li><li>\u2022 WHO recommended strategy</li><li>\u2022 Xerophthalmia</li><li>\u2022 Short term action: Vitamin-A prophylaxis to vulnerable groups -</li><li>\u2022 Deworming Program in linkage with Vitamin A prophylaxis program . The dosage's are -</li><li>\u2022 Deworming Program</li><li>\u2022 linkage with Vitamin A prophylaxis program</li><li>\u2022 1\u20132 years age : Half tablet 400 mg Albendazole stat 2\u201319 years age : Full tablet 400 mg Albendazole stat</li><li>\u2022 1\u20132 years age : Half tablet 400 mg Albendazole stat</li><li>\u2022 1\u20132 years age</li><li>\u2022 2\u201319 years age : Full tablet 400 mg Albendazole stat</li><li>\u2022 2\u201319 years age</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Vitamin A prophylaxis programme was launched by the Ministry of Health and Family Welfare in 1970</li><li>\u27a4 Vitamin A prophylaxis programme</li><li>\u27a4 Ministry of Health</li><li>\u27a4 Family Welfare in 1970</li><li>\u27a4 Ref : Park 26 th edition (page 750)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 750)</li><li>\u27a4 Deworming Program in linkage with Vitamin A prophylaxis program. The dosage's are -</li><li>\u27a4 1\u20132 years age: Half tablet 400 mg Albendazole stat 2\u201319 years age: Full tablet 400 mg Albendazole stat</li><li>\u27a4 1\u20132 years age: Half tablet 400 mg Albendazole stat</li><li>\u27a4 Half tablet</li><li>\u27a4 2\u201319 years age: Full tablet 400 mg Albendazole stat</li><li>\u27a4 Full tablet</li><li>\u27a4 Educational Objective -</li><li>\u27a4 Educational Objective -</li><li>\u27a4 Vitamin A prophylaxis programme was launched by the Ministry of Health and Family Welfare in 1970</li></ul>\n<p><strong>References:</strong></p><ul><li>\u21b3 Reference: Park 26 th edition (page 750)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4b479641",
      "audio": ""
    },
    {
      "text": "A 9-month-old child presents to a healthcare clinic in India for a routine check-up. As part of the national health initiatives, the child is due to receive vitamin A supplementation. The healthcare worker prepares to administer the dose as per the national Vitamin A prophylaxis program guidelines. What is the recommended dose of vitamin A solution that should be given to this child?",
      "options": [
        {
          "label": "A",
          "text": "50000 IU",
          "correct": false
        },
        {
          "label": "B",
          "text": "100000 IU",
          "correct": true
        },
        {
          "label": "C",
          "text": "200000 IU",
          "correct": false
        },
        {
          "label": "D",
          "text": "500000 IU",
          "correct": false
        }
      ],
      "correct_answer": "B. 100000 IU",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. \u00a0B. 100000 IU</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The strategy in Vitamin A prophylaxis program is to administer a single massive dose of 200,000 IU of vitamin A in oil (retinol palmitate) orally every 6 months to preschool children (1 year to 5 years), and half that dose (100,000 IU) to children between 6 months and one year of age.</li><li>\u2022 strategy in Vitamin A prophylaxis program</li><li>\u2022 administer a single massive dose</li><li>\u2022 200,000 IU of vitamin A in oil</li><li>\u2022 orally</li><li>\u2022 6 months to preschool children</li><li>\u2022 half that dose</li><li>\u2022 children between 6 months and one year of age.</li><li>\u2022 Vitamin-A is given at 9th, 18th, 24th, 30th, 36th, 42th, 48th, 54th, 60th months (A total of 1 Lac + 2 Lac + 2 Lac + 2 Lac + 2 Lac + 2 Lac + 2 Lac + 2 Lac + 2 Lac = 17 Lac IU is given to a completely immunized child by 5 years of age)</li><li>\u2022 Vitamin-A is administered by a 2 mL spoon</li><li>\u2022 Vitamin-A</li><li>\u2022 administered</li><li>\u2022 2 mL spoon</li><li>\u2022 Strength of Vitamin-A solution : 1 lac IU per mL</li><li>\u2022 Strength of Vitamin-A solution</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The recommended dose of vitamin A solution for a 9-month-old child under the National Vitamin A Prophylaxis Program is 100,000 International Units (IU).</li><li>\u27a4 dose of vitamin A solution for a 9-month-old child</li><li>\u27a4 National Vitamin A Prophylaxis Program</li><li>\u27a4 100,000 International Units</li><li>\u27a4 Ref : Park 26 th edition (page 706)</li><li>\u27a4 Ref : Park 26 th edition (page 706)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "fb927037",
      "audio": ""
    },
    {
      "text": "A third-year medical student is rotating through a public health clinic in India and learns about the various strategies to combat nutritional deficiencies. One of the programs discussed is the National Nutritional Anaemia Prophylaxis Programme, which includes the fortification of salt with iron. Which form of iron is utilized for this fortification strategy in the program?",
      "options": [
        {
          "label": "A",
          "text": "Ferric ortho phosphate",
          "correct": true
        },
        {
          "label": "B",
          "text": "Ferrous phosphate",
          "correct": false
        },
        {
          "label": "C",
          "text": "Ferric chloride",
          "correct": false
        },
        {
          "label": "D",
          "text": "Ferrous sulphate",
          "correct": false
        }
      ],
      "correct_answer": "A. Ferric ortho phosphate",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. \u00a0A. Ferric ortho phosphate</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 National Institute of Nutrition , Hyderabad showed that simple addition of ferric ortho-phosphate or ferrous sulphate with sodium bisulphate was enough to fortify salt with iron .</li><li>\u2022 National Institute of Nutrition</li><li>\u2022 Hyderabad</li><li>\u2022 addition</li><li>\u2022 ferric ortho-phosphate</li><li>\u2022 sodium bisulphate</li><li>\u2022 fortify salt with iron</li><li>\u2022 Food fortification:</li><li>\u2022 Food fortification:</li><li>\u2022 Is a public health , measure where nutrients are added to food (in relatively small quantities), to maintain/improve the quality of diet of a group , community or a population. Food Fortification is an example of \u2018 Primary Level of Prevention\u2019 Criteria for food fortification: Vehicle to be fortified must be consumed regularly in diet by populations Amount of nutrient added must not cause deficiency or toxicity in consumers On addition of nutrient, there should be no change in taste, odour, consistency or appearance Cost of fortification must be affordable by consumers</li><li>\u2022 Is a public health , measure where nutrients are added to food (in relatively small quantities), to maintain/improve the quality of diet of a group , community or a population.</li><li>\u2022 public health</li><li>\u2022 nutrients are added to food</li><li>\u2022 maintain/improve the quality of diet</li><li>\u2022 group</li><li>\u2022 Food Fortification is an example of \u2018 Primary Level of Prevention\u2019</li><li>\u2022 Primary Level of Prevention\u2019</li><li>\u2022 Criteria for food fortification: Vehicle to be fortified must be consumed regularly in diet by populations Amount of nutrient added must not cause deficiency or toxicity in consumers On addition of nutrient, there should be no change in taste, odour, consistency or appearance Cost of fortification must be affordable by consumers</li><li>\u2022 Criteria for food fortification:</li><li>\u2022 Vehicle to be fortified must be consumed regularly in diet by populations Amount of nutrient added must not cause deficiency or toxicity in consumers On addition of nutrient, there should be no change in taste, odour, consistency or appearance Cost of fortification must be affordable by consumers</li><li>\u2022 Vehicle to be fortified must be consumed regularly in diet by populations</li><li>\u2022 Amount of nutrient added must not cause deficiency or toxicity in consumers</li><li>\u2022 On addition of nutrient, there should be no change in taste, odour, consistency or appearance</li><li>\u2022 Cost of fortification must be affordable by consumers</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Examples of Food Fortification :</li><li>\u27a4 Examples of Food Fortification</li><li>\u27a4 Iodisation of salt Vitamin A and Vitamin D in Vanaspati - Vanaspati is fortified with \u20182500 IU Vitamin A and 175 IU Vitamin D\u2019 per 100  grams Fluoridation of water</li><li>\u27a4 Iodisation of salt</li><li>\u27a4 Vitamin A and Vitamin D in Vanaspati - Vanaspati is fortified with \u20182500 IU Vitamin A and 175 IU Vitamin D\u2019 per 100  grams</li><li>\u27a4 \u20182500 IU Vitamin A and 175 IU Vitamin D\u2019 per 100  grams</li><li>\u27a4 Fluoridation of water</li><li>\u27a4 Ref : Park 26 th edition (page 733)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 733)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c5084ec8",
      "audio": ""
    },
    {
      "text": "As a medical officer in a rural health center in India, you are counseling a parent about the prophylactic administration of iron and folic acid to their 8-year-old child, in line with the National Nutritional Anaemia Prophylaxis Programme. What is the recommended daily dose of iron and folic acid to be administered to this child for a period of 100 days?",
      "options": [
        {
          "label": "A",
          "text": "100 mg of elemental iron and 0.5 mg of folic acid",
          "correct": false
        },
        {
          "label": "B",
          "text": "20 mg of elemental iron and 0.1 mg of folic acid",
          "correct": false
        },
        {
          "label": "C",
          "text": "30 mg of elemental iron and 0.25 mg of folic acid",
          "correct": true
        },
        {
          "label": "D",
          "text": "60 mg of elemental iron and 0.4 mg of folic acid",
          "correct": false
        }
      ],
      "correct_answer": "C. 30 mg of elemental iron and 0.25 mg of folic acid",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. 30 mg of elemental iron and 0.25 mg of folic acid</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 IFA Tablet</li><li>\u2022 IFA Tablet</li><li>\u2022 An adult tablet of IFA contains : 100 mg elemental Iron (300 mg ferrous sulfate) and 500 mcg Folic acid (to be given for 100 days minimum in pregnancy) and 100 days post-delivery \u2013 Schedule: 1 Tablet per day in 4-5-6 month POG (Total 100 tablets)</li><li>\u2022 adult tablet of IFA contains</li><li>\u2022 100 mg elemental Iron</li><li>\u2022 500 mcg Folic acid</li><li>\u2022 100 days post-delivery</li><li>\u2022 Adolescents are given the same dosage and duration as adults .</li><li>\u2022 Adolescents</li><li>\u2022 same dosage</li><li>\u2022 duration as adults</li><li>\u2022 Children 6-10 years of age are to be provided 30 mg elemental iron and 250 mcg folic acid per day for 100 days .</li><li>\u2022 Children 6-10 years of age</li><li>\u2022 30 mg elemental iron</li><li>\u2022 250 mcg folic acid</li><li>\u2022 100 days</li><li>\u2022 A pediatric tablet of IFA contains : 20 mg elemental Iron and 100 mcg Folic acid (to be given for 100 days minimum every year till 5 years age of child)</li><li>\u2022 pediatric tablet of IFA contains</li><li>\u2022 20 mg elemental Iron</li><li>\u2022 100 mcg Folic acid</li><li>\u2022 \u2018National Nutritional Anemia Prophylaxis Programme\u2019 was launched in 1970 to prevent nutritional anaemia in mothers and children . This programme is being taken up by MCH Division of Ministry of Health and Family Welfare; now it is part of RCH programme</li><li>\u2022 \u2018National Nutritional Anemia Prophylaxis Programme\u2019</li><li>\u2022 1970 to prevent nutritional anaemia</li><li>\u2022 mothers and children</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Iron and Folic Acid content per IFA tablet : Adult tablet : 100 mg elemental iron and 500 mcg folic acid Pediatric tablet : 20 mg elemental iron and 100 mcg folic acid For preterm infants, IFA tablet: 10 \u2013 15 mg elemental iron and 100 mcg folic acid</li><li>\u27a4 Iron and Folic Acid content per IFA tablet : Adult tablet : 100 mg elemental iron and 500 mcg folic acid</li><li>\u27a4 Iron and Folic Acid content per IFA tablet</li><li>\u27a4 Adult tablet</li><li>\u27a4 Pediatric tablet : 20 mg elemental iron and 100 mcg folic acid</li><li>\u27a4 Pediatric tablet</li><li>\u27a4 For preterm infants, IFA tablet: 10 \u2013 15 mg elemental iron and 100 mcg folic acid</li><li>\u27a4 For preterm infants, IFA tablet: 10 \u2013 15 mg elemental iron and 100 mcg folic acid</li><li>\u27a4 Ref : Park 26 th edition (page 733)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 733)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6da2eef6",
      "audio": ""
    },
    {
      "text": "A public health student is preparing a presentation on the \"Anaemia Mukt Bharat\" initiative, which aims to reduce the prevalence of anaemia across various age groups in India. She is outlining the key interventions promoted by this strategy. Which of the following is NOT an intervention included in the Anaemia Mukt Bharat strategy?",
      "options": [
        {
          "label": "A",
          "text": "Behaviour change communication for one month in a year",
          "correct": true
        },
        {
          "label": "B",
          "text": "Testing of anaemia using digital methods",
          "correct": false
        },
        {
          "label": "C",
          "text": "Addressing non nutritional causes of anaemia",
          "correct": false
        },
        {
          "label": "D",
          "text": "Provision of iron fortified foods in health programmes",
          "correct": false
        }
      ],
      "correct_answer": "A. Behaviour change communication for one month in a year",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/08/image_jQNMeyX.png",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/08/image.png"
      ],
      "explanation": "<p><strong>Ans. \u00a0A. Behaviour change communication for one month in a year</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 This is the intervention under AMB program .</li><li>\u2022 intervention under AMB program</li><li>\u2022 Interventions in Anaemia Mukt Bharat are -</li><li>\u2022 Interventions in Anaemia Mukt Bharat are</li><li>\u2022 1. Prophylactic Iron and Folic Acid supplementation</li><li>\u2022 Prophylactic Iron</li><li>\u2022 Folic Acid supplementation</li><li>\u2022 2. Deworming</li><li>\u2022 Deworming</li><li>\u2022 3. Intensified year-round Behaviour Change Communication Campaign (Solid Body, Smart Mind) including ensuring delayed cord clamping in newborns</li><li>\u2022 Intensified year-round Behaviour Change Communication Campaign</li><li>\u2022 4. Testing of anaemia using digital methods (Option B ) and point of care treatment</li><li>\u2022 (Option B</li><li>\u2022 5. Mandatory provision of Iron and Folic Acid fortified foods (Option D) in government-funded health programmes</li><li>\u2022 (Option D)</li><li>\u2022 6. Addressing non-nutritional causes of anaemia (Option C) in endemic pockets, with special focus on malaria, haemoglobinopathies and fluorosis</li><li>\u2022 (Option C)</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Anaemia Mukt Bharat Program</li><li>\u27a4 Anaemia Mukt Bharat Program</li><li>\u27a4 Main Aim - To reduce prevalence of anemia by 3% points per year among children , adolescents and women in the reproductive age group (15\u201349 years), between the year 2018-2022</li><li>\u27a4 Main Aim</li><li>\u27a4 reduce prevalence of anemia</li><li>\u27a4 3% points per year</li><li>\u27a4 children</li><li>\u27a4 Beneficiaries</li><li>\u27a4 Beneficiaries</li><li>\u27a4 Children (6\u201359 months) Children (5\u20139 years) Adolescent boys and girls (10\u201319 years) Women of reproductive age (20\u201324 years) Pregnant women Lactating women</li><li>\u27a4 Children (6\u201359 months)</li><li>\u27a4 Children (5\u20139 years)</li><li>\u27a4 Adolescent boys and girls (10\u201319 years)</li><li>\u27a4 Women of reproductive age (20\u201324 years)</li><li>\u27a4 Pregnant women</li><li>\u27a4 Lactating women</li><li>\u27a4 Institutional Mechanism -</li><li>\u27a4 Institutional Mechanism -</li><li>\u27a4 Anemia Mukt Bharat 6X6X6 Strategy</li><li>\u27a4 Anemia Mukt Bharat 6X6X6 Strategy</li><li>\u27a4 Ref : https://anemiamuktbharat.info/home/interventions/</li><li>\u27a4 Ref :</li><li>\u27a4 https://anemiamuktbharat.info/home/interventions/</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "19a5acce",
      "audio": ""
    },
    {
      "text": "You are a physician working on public health planning in a semi-urban district of Himachal Pradesh, India. Your current project involves implementing the \"Anaemia Mukt Bharat\" strategy, a key initiative of the government to combat anaemia. According to the program guidelines, which group of individuals is NOT a primary target for anaemia interventions under the \"Anaemia Mukt Bharat\" initiative?",
      "options": [
        {
          "label": "A",
          "text": "Children 6-59 months of age",
          "correct": false
        },
        {
          "label": "B",
          "text": "Children 5-9 years of age",
          "correct": false
        },
        {
          "label": "C",
          "text": "Adolescent girls and boy 10-19 years of age",
          "correct": false
        },
        {
          "label": "D",
          "text": "Women in age group of 50-60 years",
          "correct": true
        }
      ],
      "correct_answer": "D. Women in age group of 50-60 years",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/14/picture39.jpg",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/08/image-20231108094621-2.png",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/08/image-20231108094621-1.png",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/08/image-20231108094621-3.jpeg",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-145806.png"
      ],
      "explanation": "<p><strong>Ans. D. Women in age group of 50-60 years</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Beneficiaries in Anaemia Mukt Bharat</li><li>\u2022 Beneficiaries in Anaemia Mukt Bharat</li><li>\u2022 Anaemia Mukt Bharat Program</li><li>\u2022 Anaemia Mukt Bharat Program</li><li>\u2022 Main Aim - To reduce prevalence of anemia by 3% points per year among children , adolescents and women in the reproductive age group (15\u201349 years), between the year 2018-2022</li><li>\u2022 Main Aim</li><li>\u2022 reduce prevalence</li><li>\u2022 anemia by 3% points per year among children</li><li>\u2022 adolescents</li><li>\u2022 women in the reproductive age group</li><li>\u2022 2018-2022</li><li>\u2022 Anemia Mukt Bharat 6X6X6 Strategy</li><li>\u2022 Anemia Mukt Bharat 6X6X6 Strategy</li><li>\u2022 Institutional Mechanism -</li><li>\u2022 Institutional Mechanism -</li><li>\u2022 Interventions -</li><li>\u2022 Interventions -</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Anemia Mukt Bharat Beneficiaries are Children (6\u201359 months), Children (5\u20139 years), Adolescent boys & girls (10\u201319 years), Women of reproductive age (20\u201324 years), Pregnant and lactating women</li><li>\u27a4 Anemia Mukt Bharat Beneficiaries</li><li>\u27a4 Children</li><li>\u27a4 Children</li><li>\u27a4 Adolescent boys & girls</li><li>\u27a4 Women of reproductive age</li><li>\u27a4 Pregnant</li><li>\u27a4 lactating women</li><li>\u27a4 Prophylactic Dose and Regime for Iron Folic Acid Supplementation</li><li>\u27a4 Prophylactic Dose and Regime for Iron Folic Acid Supplementation</li><li>\u27a4 Ref : https://anemiamuktbharat.info/home/6x6x6-strategy/</li><li>\u27a4 Ref :</li><li>\u27a4 https://anemiamuktbharat.info/home/6x6x6-strategy/</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9eb1f9b3",
      "audio": ""
    },
    {
      "text": "A medical officer is evaluating the strategic areas of focus in the \"Anaemia Mukt Bharat\" initiative to organize a health camp in a rural district. Which of the following conditions is NOT given special focus under the \"Anaemia Mukt Bharat\" program?",
      "options": [
        {
          "label": "A",
          "text": "Malaria",
          "correct": false
        },
        {
          "label": "B",
          "text": "Hemoglobinopathies",
          "correct": false
        },
        {
          "label": "C",
          "text": "Fluorosis",
          "correct": false
        },
        {
          "label": "D",
          "text": "Tuberculosis",
          "correct": true
        }
      ],
      "correct_answer": "D. Tuberculosis",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/08/image-20231108095947-1.png",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/08/image-20231108095947-2.png",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/08/image-20231108095947-3.jpeg"
      ],
      "explanation": "<p><strong>Ans. D. Tuberculosis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Malaria:</li><li>\u2022 Option A. Malaria:</li><li>\u2022 Intensification of malaria prevention and control activities in integration with nutritional anemia . Fixed days for screening of anemia at PMSMA sites and annually by RBSK teams in schools for screening for malaria as per NVBDCP, MoHFW guidelines. Indoor Residual Spray (IRS) before and after the monsoon season in school premises and residential areas and provide Long Lasting Insecticide Nets (LLINs) in all high endemic areas esp. to all target groups pregnant mothers and under-five children</li><li>\u2022 Intensification of malaria prevention and control activities in integration with nutritional anemia .</li><li>\u2022 Intensification of malaria prevention</li><li>\u2022 control activities in integration</li><li>\u2022 nutritional anemia</li><li>\u2022 Fixed days for screening of anemia at PMSMA sites and annually by RBSK teams in schools for screening for malaria as per NVBDCP, MoHFW guidelines.</li><li>\u2022 Indoor Residual Spray (IRS) before and after the monsoon season in school premises and residential areas and provide Long Lasting Insecticide Nets (LLINs) in all high endemic areas esp. to all target groups pregnant mothers and under-five children</li><li>\u2022 Option B. Haemoglobinopathies:</li><li>\u2022 Option B. Haemoglobinopathies:</li><li>\u2022 Comprehensive prevention , screening and management of haemoglobinopathies - Pre-marital and pre-conception screening and counselling services Women identified with severe anemia should be referred to higher centres for further investigations and if found positive, the husband is to be screened for carrier status. If the couple is found positive, they are to be referred to a higher centre for prenatal diagnosis before twenty weeks of pregnancy. The treatment of anemia using parental iron administration is contraindicated in sickle cell disease patients.</li><li>\u2022 Comprehensive prevention , screening and management of haemoglobinopathies - Pre-marital and pre-conception screening and counselling services</li><li>\u2022 Comprehensive prevention</li><li>\u2022 screening</li><li>\u2022 management of haemoglobinopathies</li><li>\u2022 Pre-marital</li><li>\u2022 pre-conception screening</li><li>\u2022 counselling services</li><li>\u2022 Women identified with severe anemia should be referred to higher centres for further investigations and if found positive, the husband is to be screened for carrier status. If the couple is found positive, they are to be referred to a higher centre for prenatal diagnosis before twenty weeks of pregnancy.</li><li>\u2022 The treatment of anemia using parental iron administration is contraindicated in sickle cell disease patients.</li><li>\u2022 treatment of anemia</li><li>\u2022 parental iron administration</li><li>\u2022 sickle cell disease</li><li>\u2022 Option C. Fluorosis: The 3 key interventions are:</li><li>\u2022 Option C. Fluorosis: The 3 key interventions are:</li><li>\u2022 Identification of Fluoride-Affected Habitations : Activities for Anemia Control Due to Fluorosis : use of safe drinking water, focus on diet corrections (Calcium, Magnesium, Vitamin C) by dietary diversity, periodic check-up of haemoglobin in affected habitations and appropriate treatment, IFA supplementation. Capacity Building/Training of all public health staff</li><li>\u2022 Identification of Fluoride-Affected Habitations :</li><li>\u2022 Identification of Fluoride-Affected Habitations</li><li>\u2022 Activities for Anemia Control Due to Fluorosis : use of safe drinking water, focus on diet corrections (Calcium, Magnesium, Vitamin C) by dietary diversity, periodic check-up of haemoglobin in affected habitations and appropriate treatment, IFA supplementation.</li><li>\u2022 Activities for Anemia Control Due to Fluorosis</li><li>\u2022 Capacity Building/Training of all public health staff</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Anemia Mukt Bharat 6X6X6 Strategy</li><li>\u27a4 Anemia Mukt Bharat 6X6X6 Strategy</li><li>\u27a4 Beneficiaries</li><li>\u27a4 Beneficiaries</li><li>\u27a4 Children (6\u201359 months) Children (5\u20139 years) Adolescent boys and girls (10\u201319 years) Women of reproductive age (20\u201324 years) Pregnant women Lactating women</li><li>\u27a4 Children (6\u201359 months)</li><li>\u27a4 Children (5\u20139 years)</li><li>\u27a4 Adolescent boys and girls (10\u201319 years)</li><li>\u27a4 Women of reproductive age (20\u201324 years)</li><li>\u27a4 Pregnant women</li><li>\u27a4 Lactating women</li><li>\u27a4 Institutional Mechanism -</li><li>\u27a4 Institutional Mechanism -</li><li>\u27a4 Interventions in Anaemia Mukt Bharat</li><li>\u27a4 Interventions in Anaemia Mukt Bharat</li><li>\u27a4 Ref : https://anemiamuktbharat.info/home/6x6x6-strategy/</li><li>\u27a4 Ref</li><li>\u27a4 :</li><li>\u27a4 https://anemiamuktbharat.info/home/6x6x6-strategy/</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f884dd26",
      "audio": ""
    },
    {
      "text": "As a public health administrator, you are evaluating a proposal for establishing a new 'Anganwadi on demand' in a remote settlement. According to the guidelines, what is the minimum criterion regarding population or households for setting up an 'Anganwadi on demand'?",
      "options": [
        {
          "label": "A",
          "text": "10 children under 6 years of age",
          "correct": false
        },
        {
          "label": "B",
          "text": "20 children under 6 years of age",
          "correct": false
        },
        {
          "label": "C",
          "text": "30 children under 6 years of age",
          "correct": false
        },
        {
          "label": "D",
          "text": "40 children under 6 years of age",
          "correct": true
        }
      ],
      "correct_answer": "D. 40 children under 6 years of age",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D. 40 children under 6 years of age</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Anganwadi on demand - where a settlement has at least 40 children under 6 years but no Anganwadis centre .</li><li>\u2022 Anganwadi on demand</li><li>\u2022 settlement</li><li>\u2022 at least 40 children under 6 years</li><li>\u2022 no Anganwadis centre</li><li>\u2022 Heart of ICDS system : Anganwadi</li><li>\u2022 Heart of ICDS system</li><li>\u2022 Focal point for ICDS services delivery is Anganwadi Worker; Each Anganwadi has 1 Anganwadi worker and 1 helper</li><li>\u2022 Focal point</li><li>\u2022 Each Anganwadi has 1 Anganwadi worker</li><li>\u2022 1 helper</li><li>\u2022 1 Anganwadi centre per 400\u2013800 population in rural and urban areas 1 Anganwadi centre per 300\u2013800 population in tribal areas 1 Mini-Anganwadi centre per 150\u2013400 population (rural/urban); 150-300 (tribal) 1 Anganwadi on Demand (AOD) for settlement \u2265 40 children under 6 years age</li><li>\u2022 1 Anganwadi centre per 400\u2013800 population in rural and urban areas</li><li>\u2022 400\u2013800 population</li><li>\u2022 rural and urban areas</li><li>\u2022 1 Anganwadi centre per 300\u2013800 population in tribal areas</li><li>\u2022 300\u2013800 population</li><li>\u2022 tribal areas</li><li>\u2022 1 Mini-Anganwadi centre per 150\u2013400 population (rural/urban); 150-300 (tribal)</li><li>\u2022 150\u2013400 population</li><li>\u2022 150-300</li><li>\u2022 1 Anganwadi on Demand (AOD) for settlement \u2265 40 children under 6 years age</li><li>\u2022 1 Anganwadi on Demand</li><li>\u2022 settlement \u2265 40 children</li><li>\u2022 6 years age</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 1 Anganwadi on Demand (AOD) for settlement \u2265 40 children under 6 years age</li><li>\u27a4 1 Anganwadi on Demand</li><li>\u27a4 settlement \u2265 40 children</li><li>\u27a4 6 years age</li><li>\u27a4 Ref : Park 26 th edition (page 680)</li><li>\u27a4 Ref</li><li>\u27a4 Park 26 th edition (page 680)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d422a0b9",
      "audio": ""
    },
    {
      "text": "In your role as a healthcare planner for a village with a population of 2100 individuals, you are tasked with assessing the need for Anganwadi centers based on national guidelines. Given the current population, how many Anganwadi centers are required in the village as per the norms?",
      "options": [
        {
          "label": "A",
          "text": "1",
          "correct": false
        },
        {
          "label": "B",
          "text": "2",
          "correct": false
        },
        {
          "label": "C",
          "text": "3",
          "correct": true
        },
        {
          "label": "D",
          "text": "4",
          "correct": false
        }
      ],
      "correct_answer": "C. 3",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. \u00a0C. 3</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 For AWCs in rural/urban projects</li><li>\u2022 AWCs in rural/urban projects</li><li>\u2022 1 AWC for 400-800 population 2 AWCs for 800-1600 population 3 AWCs for 1600-2400 population</li><li>\u2022 1 AWC for 400-800 population</li><li>\u2022 1 AWC</li><li>\u2022 400-800 population</li><li>\u2022 2 AWCs for 800-1600 population</li><li>\u2022 2 AWCs</li><li>\u2022 800-1600 population</li><li>\u2022 3 AWCs for 1600-2400 population</li><li>\u2022 3 AWCs</li><li>\u2022 1600-2400 population</li><li>\u2022 Thereafter, one AWC for multiples of 800 population</li><li>\u2022 one AWC</li><li>\u2022 multiples of 800 population</li><li>\u2022 Some important Pointers related to Anganwadi -</li><li>\u2022 Heart of ICDS system: Anganwadi</li><li>\u2022 Focal point for ICDS services delivery is Anganwadi Worker; Each Anganwadi has 1 Anganwadi worker and 1 helper</li><li>\u2022 1 Anganwadi centre per 400\u2013800 population in rural and urban area 1 Anganwadi centre per 300\u2013800 population in tribal area 1 Mini-Anganwadi centre per 150\u2013400 population (rural/urban); 150-300 (tribal) 1 Anganwadi on Demand (AOD) for settlement \u2265 40 children under 6 years age</li><li>\u2022 1 Anganwadi centre per 400\u2013800 population in rural and urban area</li><li>\u2022 1 Anganwadi centre</li><li>\u2022 400\u2013800 population</li><li>\u2022 rural and urban area</li><li>\u2022 1 Anganwadi centre per 300\u2013800 population in tribal area</li><li>\u2022 1 Anganwadi centre</li><li>\u2022 300\u2013800 population</li><li>\u2022 tribal area</li><li>\u2022 1 Mini-Anganwadi centre per 150\u2013400 population (rural/urban); 150-300 (tribal)</li><li>\u2022 1 Mini-Anganwadi centre</li><li>\u2022 150\u2013400 population</li><li>\u2022 150-300</li><li>\u2022 1 Anganwadi on Demand (AOD) for settlement \u2265 40 children under 6 years age</li><li>\u2022 1 Anganwadi on Demand</li><li>\u2022 settlement \u2265 40 children</li><li>\u2022 6 years age</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 1 Anganwadi centre per 400\u2013800 population in rural and urban area</li><li>\u27a4 1 Anganwadi centre</li><li>\u27a4 400\u2013800 population</li><li>\u27a4 rural and urban area</li><li>\u27a4 Ref : Park 26 th edition (page 680)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 680)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b26830a7",
      "audio": ""
    },
    {
      "text": "A 2-year-old child with Severe Acute Malnutrition (SAM) has been identified at a local health clinic. As part of the Integrated Child Development Services (ICDS) scheme, you are required to provide supplementary nutrition. According to the ICDS guidelines, what is the recommended supplementary nutrition for a SAM child of this age?",
      "options": [
        {
          "label": "A",
          "text": "600 calories and 12-15 gms of protein",
          "correct": false
        },
        {
          "label": "B",
          "text": "600 calories and 20-25 gms of protein",
          "correct": false
        },
        {
          "label": "C",
          "text": "800 calories and 12-15 gms of protein",
          "correct": false
        },
        {
          "label": "D",
          "text": "800 calories and 20-25 gms of protein",
          "correct": true
        }
      ],
      "correct_answer": "D. 800 calories and 20-25 gms of protein",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-150731.png",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-150825.png"
      ],
      "explanation": "<p><strong>Ans. D. 800 calories and 20-25 gms of protein</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Severely malnourished child 6-72 months to get 800 calories and 20-25 grams protein</li><li>\u2022 Severely malnourished child 6-72 months</li><li>\u2022 800 calories</li><li>\u2022 20-25 grams protein</li><li>\u2022 ICDS in India is implemented by Ministry of Women and Child Development</li><li>\u2022 ICDS</li><li>\u2022 India</li><li>\u2022 implemented by Ministry of Women</li><li>\u2022 Child Development</li><li>\u2022 Supplemental nutrition given through ICDS : 300 feeding days in a year [NEW 2014 GUIDELINES]</li><li>\u2022 Supplemental nutrition given through ICDS</li><li>\u2022 300 feeding days</li><li>\u2022 year</li><li>\u2022 Revised norms for free food supplementation under ICDS -</li><li>\u2022 Revised Financial Norms -</li><li>\u2022 Revised Financial Norms -</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Severely malnourished child 6-72 months to get 800 calories and 20-25 grams protein (Revised Financial norm - 12 Rs/day/beneficiary)</li><li>\u27a4 Severely malnourished child 6-72 months</li><li>\u27a4 800 calories</li><li>\u27a4 20-25 grams protein</li><li>\u27a4 Ref : Park 26 th edition (page 680)</li><li>\u27a4 Ref : Park 26 th edition (page 680)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b2856c5f",
      "audio": ""
    },
    {
      "text": "As a physician overseeing nutritional programs at an Integrated Child Development Services (ICDS) center, you are tasked with prescribing supplementary nutrition for pregnant women registered at the center. According to the ICDS guidelines, what is the recommended supplementary nutrition for a pregnant mother?",
      "options": [
        {
          "label": "A",
          "text": "No supplementary nutrition",
          "correct": false
        },
        {
          "label": "B",
          "text": "500 calories and 18-20 gms of protein",
          "correct": false
        },
        {
          "label": "C",
          "text": "600 calories and 18-20 gms of protein",
          "correct": true
        },
        {
          "label": "D",
          "text": "800 calories and 18-20 gms of protein",
          "correct": false
        }
      ],
      "correct_answer": "C. 600 calories and 18-20 gms of protein",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/27/1.jpg",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/27/2.jpg"
      ],
      "explanation": "<p><strong>Ans. \u00a0C. 600 calories and 18-20 gms of protein</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Each pregnant and nursing woman to get 600 calories and 18-20 grams of protein</li><li>\u2022 Each pregnant</li><li>\u2022 nursing woman</li><li>\u2022 600 calories</li><li>\u2022 18-20 grams of protein</li><li>\u2022 ICDS in India is implemented by Ministry of Women and Child Development</li><li>\u2022 ICDS in India</li><li>\u2022 Ministry of Women</li><li>\u2022 Child Development</li><li>\u2022 Supplemental nutrition given through ICDS : 300 feeding days in a year [NEW 2014 GUIDELINES]</li><li>\u2022 Supplemental nutrition given through ICDS</li><li>\u2022 Revised norms for free food supplementation under ICDS -</li><li>\u2022 Revised norms for free food supplementation under ICDS -</li><li>\u2022 Revised Financial Norms -</li><li>\u2022 Revised Financial Norms -</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Each pregnant and nursing woman to get 600 calories and 18-20 grams of protein (Revised Financial norm - 9.5 Rs/day/beneficiary)</li><li>\u27a4 pregnant</li><li>\u27a4 nursing woman</li><li>\u27a4 600 calories</li><li>\u27a4 18-20 grams of protein</li><li>\u27a4 Ref : Park 26th edition (page 680)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26th edition (page 680)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "38c90e73",
      "audio": ""
    },
    {
      "text": "You are conducting a workshop for healthcare workers focusing on adolescent health. One of the initiatives you are discussing is a government scheme aimed at improving the self-development, nutrition, and health status of adolescents. Which scheme specifically addresses these needs?",
      "options": [
        {
          "label": "A",
          "text": "Beti Bachao Beti Padhao",
          "correct": false
        },
        {
          "label": "B",
          "text": "Poshan Abhiyan",
          "correct": false
        },
        {
          "label": "C",
          "text": "Kishori Shakti Yojana",
          "correct": true
        },
        {
          "label": "D",
          "text": "Indira Gandhi Matritva Sahyog Yojana",
          "correct": false
        }
      ],
      "correct_answer": "C. Kishori Shakti Yojana",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Kishori Shakti Yojana</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Beti Bachao Beti Padhao: This was launched on 22 January 2015 by Prime Minister Narendra Modi . It aims to address the issue of the declining child sex ratio image (CSR) and is a national initiative jointly run by the Ministry of Women and Child Development , the Ministry of Health and Family Welfare and the Ministry of Education . It mainly targets the clusters in Uttar Pradesh, Haryana, Uttarakhand, Punjab, Bihar and Delhi.</li><li>\u2022 Option A. Beti Bachao Beti Padhao:</li><li>\u2022 launched on 22 January 2015</li><li>\u2022 Prime Minister Narendra Modi</li><li>\u2022 aims to address the issue</li><li>\u2022 declining child sex ratio image</li><li>\u2022 national initiative</li><li>\u2022 Ministry of Women and Child Development</li><li>\u2022 Ministry of Health</li><li>\u2022 Family Welfare and the Ministry of Education</li><li>\u2022 Option B. Poshan Abhiyan: This was launched by Hon\u2019ble Prime Minister on 8th March, 2018 in Jhunjhunu district of Rajasthan . The focus of Abhiyaan is to lay emphasis on nutritional status of adolescent girls , pregnant women , lactating mothers and children from 0-6 years age. The programme, through use of technology, convergence and community involvement with a targeted approach strives to reduce the level of stunning, under-nutrition, Anemia and low birth weight in children, as also focus on adolescent girls, pregnant women and lactating mothers, thus holistically addressing malnutrition.</li><li>\u2022 Option B. Poshan Abhiyan:</li><li>\u2022 Hon\u2019ble Prime Minister on 8th March, 2018</li><li>\u2022 Jhunjhunu district of Rajasthan</li><li>\u2022 focus of Abhiyaan</li><li>\u2022 lay emphasis on nutritional status of adolescent girls</li><li>\u2022 pregnant women</li><li>\u2022 lactating mothers</li><li>\u2022 children from 0-6 years age.</li><li>\u2022 Option D. Indira Gandhi Matritva Sahyog Yojana: Renamed as Pradhan Mantri Matru Vandana Yojana (PMMVY) in 2017 , The scheme is implemented by the Ministry of Women and Child Development . It is a conditional cash transfer scheme for pregnant and lactating women of 19 years of age or above for the first live birth.</li><li>\u2022 Option D. Indira Gandhi Matritva Sahyog Yojana:</li><li>\u2022 Pradhan Mantri Matru Vandana Yojana</li><li>\u2022 2017</li><li>\u2022 Ministry of Women and Child Development</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 Kishori Shakti Yojana (KSY)</li><li>\u27a4 Kishori Shakti Yojana</li><li>\u27a4 Interventions:</li><li>\u27a4 Interventions:</li><li>\u27a4 Adolescent girls Scheme-I - \u2018Girl-to-girl Approach\u2019 (11 \u2013 15 years old girls) Adolescent girls scheme-II - \u2018Balika Mandals\u2019 (11 \u2013 18 years old girls)</li><li>\u27a4 Adolescent girls Scheme-I - \u2018Girl-to-girl Approach\u2019 (11 \u2013 15 years old girls)</li><li>\u27a4 Adolescent girls Scheme-I</li><li>\u27a4 Adolescent girls scheme-II - \u2018Balika Mandals\u2019 (11 \u2013 18 years old girls)</li><li>\u27a4 Adolescent girls scheme-II</li><li>\u27a4 Activities:</li><li>\u27a4 Activities:</li><li>\u27a4 Preventive health, hygiene & nutrition education Working on Anganwadi centre Family life education Participate in creative activities Skill development or vocational training Learn about significance of education & life skills, personal hygiene, environmental sanitation, nutrition, home nursing, first aid, communicable diseases, VPDs, family life, child care and development, constitutional rights & their impact on quality of life</li><li>\u27a4 Preventive health, hygiene & nutrition education</li><li>\u27a4 Working on Anganwadi centre</li><li>\u27a4 Family life education</li><li>\u27a4 Participate in creative activities</li><li>\u27a4 Skill development or vocational training</li><li>\u27a4 Learn about significance of education & life skills, personal hygiene, environmental sanitation, nutrition, home nursing, first aid, communicable diseases, VPDs, family life, child care and development, constitutional rights & their impact on quality of life</li><li>\u27a4 Ref : Park 26 th edition (page 681)</li><li>\u27a4 Ref : Park 26 th edition (page 681)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "34443b63",
      "audio": ""
    },
    {
      "text": "As part of your administrative duties in overseeing a rural healthcare delivery system, you need to familiarize yourself with the structural units of the Integrated Child Development Services (ICDS). Which of the following is the primary administrative unit of ICDS in a rural area?",
      "options": [
        {
          "label": "A",
          "text": "Village panchayat",
          "correct": false
        },
        {
          "label": "B",
          "text": "Health sub centre",
          "correct": false
        },
        {
          "label": "C",
          "text": "Community health centre",
          "correct": false
        },
        {
          "label": "D",
          "text": "Community development block",
          "correct": true
        }
      ],
      "correct_answer": "D. Community development block",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. \u00a0D. Community development block</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 An administrative unit of ICDS :</li><li>\u2022 An administrative unit of ICDS</li><li>\u2022 Community Development Block - each project covering a population of 1,00,000 (rural/urban) or 35,000 (tribal)</li><li>\u2022 Community Development Block</li><li>\u2022 1 CDPO (Community Development Project Officer) is in charge of 4 supervisors (Mukhyasevikas) and 100 Anganwadis (each supervisor for 25 Anganwadis)</li><li>\u2022 1 CDPO (Community Development Project Officer) is in charge of 4 supervisors (Mukhyasevikas) and 100 Anganwadis (each supervisor for 25 Anganwadis)</li><li>\u2022 1 CDPO</li><li>\u2022 in charge of 4 supervisors</li><li>\u2022 100 Anganwadis</li><li>\u2022 ICDS is one of the world\u2019s largest programs for early childhood development</li><li>\u2022 ICDS</li><li>\u2022 one of the world\u2019s largest programs</li><li>\u2022 early childhood development</li><li>\u2022 ICDS is a centrally sponsored scheme</li><li>\u2022 ICDS</li><li>\u2022 centrally sponsored scheme</li><li>\u2022 ICDS provides an integrated package of services :</li><li>\u2022 ICDS</li><li>\u2022 integrated package of services</li><li>\u2022 Supplementary nutrition Immunization Health check-up Medical referral services Nutrition and health education for women Non-formal education for children aged 3 \u2013 6 years, and pregnant and nursing mothers in rural, urban and tribal areas</li><li>\u2022 Supplementary nutrition</li><li>\u2022 Immunization</li><li>\u2022 Health check-up</li><li>\u2022 Medical referral services</li><li>\u2022 Nutrition and health education for women</li><li>\u2022 Non-formal education for children aged 3 \u2013 6 years, and pregnant and nursing mothers in rural, urban and tribal areas</li><li>\u2022 ICDS Beneficiaries (Irrespective of income of family) -</li><li>\u2022 ICDS Beneficiaries</li><li>\u2022 Children 0 \u2013 6 years age Pregnant and lactating mothers Women in reproductive age group Adolescent girls 11 \u2013 18 years Heart of ICDS system : Anganwadi Focal point for ICDS services delivery is Anganwadi Worker ; Each Anganwadi has 1 Anganwadi worker and 1 helper 1 Anganwadi centre per 400\u2013800 population in rural and urban projects 1 Anganwadi centre per 300\u2013800 population in tribal projects 1 Mini-Anganwadi centre per 150\u2013400 population (rural & urban); 150-300 (tribal) 1 Anganwadi on Demand (AOD) for settlement \u2265 40 children under 6 years age</li><li>\u2022 Children 0 \u2013 6 years age</li><li>\u2022 Pregnant and lactating mothers</li><li>\u2022 Women in reproductive age group</li><li>\u2022 Adolescent girls 11 \u2013 18 years</li><li>\u2022 Heart of ICDS system : Anganwadi</li><li>\u2022 Heart of ICDS system</li><li>\u2022 Anganwadi</li><li>\u2022 Focal point for ICDS services delivery is Anganwadi Worker ; Each Anganwadi has 1 Anganwadi worker and 1 helper 1 Anganwadi centre per 400\u2013800 population in rural and urban projects 1 Anganwadi centre per 300\u2013800 population in tribal projects 1 Mini-Anganwadi centre per 150\u2013400 population (rural & urban); 150-300 (tribal) 1 Anganwadi on Demand (AOD) for settlement \u2265 40 children under 6 years age</li><li>\u2022 Focal point for ICDS services delivery</li><li>\u2022 Anganwadi Worker</li><li>\u2022 1 Anganwadi centre per 400\u2013800 population in rural and urban projects 1 Anganwadi centre per 300\u2013800 population in tribal projects 1 Mini-Anganwadi centre per 150\u2013400 population (rural & urban); 150-300 (tribal) 1 Anganwadi on Demand (AOD) for settlement \u2265 40 children under 6 years age</li><li>\u2022 1 Anganwadi centre per 400\u2013800 population in rural and urban projects</li><li>\u2022 1 Anganwadi centre per 300\u2013800 population in tribal projects</li><li>\u2022 1 Mini-Anganwadi centre per 150\u2013400 population (rural & urban); 150-300 (tribal)</li><li>\u2022 1 Anganwadi on Demand (AOD) for settlement \u2265 40 children under 6 years age</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Administrative unit of ICDS in a rural area - Community Development Block [100,000 population (rural/urban) or 35,000 (tribal)]</li><li>\u27a4 Administrative unit of ICDS in a rural area</li><li>\u27a4 Ref : Park 26 th edition (page 681)</li><li>\u27a4 Ref : Park 26 th edition (page 681)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "321ad86c",
      "audio": ""
    },
    {
      "text": "In an effort to enhance the understanding of public health nutrition programs among your medical students, you're covering the history of such initiatives in India. Can you recall the year in which the Mid-day Meal Programme, aimed at improving the nutritional status of school-age children, was launched?",
      "options": [
        {
          "label": "A",
          "text": "1951",
          "correct": false
        },
        {
          "label": "B",
          "text": "1961",
          "correct": true
        },
        {
          "label": "C",
          "text": "1971",
          "correct": false
        },
        {
          "label": "D",
          "text": "1995",
          "correct": false
        }
      ],
      "correct_answer": "B. 1961",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-151658.png"
      ],
      "explanation": "<p><strong>Ans. \u00a0B. 1961</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The Mid-day Meal Programme (MDMP) is also known as School Lunch Programme . This programme has been in operation since 1961 throughout the country.</li><li>\u2022 Mid-day Meal Programme</li><li>\u2022 School Lunch Programme</li><li>\u2022 programme</li><li>\u2022 operation since 1961</li><li>\u2022 Mid-day Meal Programme (MDMP)</li><li>\u2022 Mid-day Meal Programme</li><li>\u2022 The major objective of MDMP : To attract more children for admission to schools and retain them so that literacy improvement of children could be brought about. The meal is a supplement and not a substitute to the home diet The meal should supply 1/3 of the total energy requirement and 1/2 of the total protein requirement. MDMP is being operationalized under the Ministry of Human Resource & Development National Institute of Nutrition, Hyderabad is of the view that minimum number of feeding days in year be 250 to have the desired impact on children</li><li>\u2022 The major objective of MDMP : To attract more children for admission to schools and retain them so that literacy improvement of children could be brought about.</li><li>\u2022 The major objective of MDMP</li><li>\u2022 attract more children for admission</li><li>\u2022 The meal is a supplement and not a substitute to the home diet</li><li>\u2022 meal is a supplement</li><li>\u2022 The meal should supply 1/3 of the total energy requirement and 1/2 of the total protein requirement.</li><li>\u2022 meal should supply 1/3 of the total energy requirement</li><li>\u2022 1/2 of the total protein requirement.</li><li>\u2022 MDMP is being operationalized under the Ministry of Human Resource & Development</li><li>\u2022 MDMP</li><li>\u2022 operationalized</li><li>\u2022 Ministry of Human Resource</li><li>\u2022 Development</li><li>\u2022 National Institute of Nutrition, Hyderabad is of the view that minimum number of feeding days in year be 250 to have the desired impact on children</li><li>\u2022 Mid-day Meal Scheme (MDMS) (National Programme of Nutritional Support to Primary Education): Launched in 1995 with the main objective universalization of primary education by increasing enrolment , retention and attendance and simultaneously impacting on the nutrition of students in primary classes. It aims at providing 450\u2013700 calories and 12\u201320 gm proteins per day to all children class I to VIII.</li><li>\u2022 Mid-day Meal Scheme</li><li>\u2022 Launched in 1995</li><li>\u2022 main objective universalization</li><li>\u2022 primary education</li><li>\u2022 increasing enrolment</li><li>\u2022 retention</li><li>\u2022 attendance</li><li>\u2022 Principles for formulating mid-day meals : Meal should be a supplement only not a substitute for home diet Meal should provide 1/3 calories and 1/2 proteins Meal cost should be low Complicated cooking process must not be involved Use locally available foods Keep changing menu frequently</li><li>\u2022 Principles for formulating mid-day meals :</li><li>\u2022 Principles for formulating mid-day meals</li><li>\u2022 Meal should be a supplement only not a substitute for home diet</li><li>\u2022 Meal should provide 1/3 calories and 1/2 proteins</li><li>\u2022 Meal cost should be low</li><li>\u2022 Complicated cooking process must not be involved</li><li>\u2022 Use locally available foods</li><li>\u2022 Keep changing menu frequently</li><li>\u2022 A model menu for mid-day school meal :</li><li>\u2022 A model menu for mid-day school meal</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Mid-day Meal Programme (MDMP) or School Lunch Programme launched in 1961 , under the Ministry of Human Resource & Development</li><li>\u27a4 Mid-day Meal Programme</li><li>\u27a4 School Lunch Programme</li><li>\u27a4 1961</li><li>\u27a4 Ministry of Human Resource</li><li>\u27a4 Development</li><li>\u27a4 Midday meal program provides - 1/3 calories and 1/2 proteins.</li><li>\u27a4 Amount of cereals in Mid-day meal program 100 grams</li><li>\u27a4 Ref : Park 26 th edition (page 751)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 751)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "85f3e1bc",
      "audio": ""
    },
    {
      "text": "During a community health class, you are discussing various health and educational interventions in India. You want the class to understand the intent behind the Mid-Day Meal Scheme. This scheme was primarily launched with the objective to reduce school dropouts and to provide basic education for all. In which year was the Mid-Day Meal Scheme initiated?",
      "options": [
        {
          "label": "A",
          "text": "1951",
          "correct": false
        },
        {
          "label": "B",
          "text": "1961",
          "correct": false
        },
        {
          "label": "C",
          "text": "1971",
          "correct": false
        },
        {
          "label": "D",
          "text": "1995",
          "correct": true
        }
      ],
      "correct_answer": "D. 1995",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-151942.png"
      ],
      "explanation": "<p><strong>Ans. D. 1995</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Mid-day meal scheme is also known as National Programme of Nutritional Support to Primary Education . It was launched as a centrally sponsored scheme on 15 th August 1995 and revised in 2004 .</li><li>\u2022 Mid-day meal scheme</li><li>\u2022 National Programme of Nutritional Support</li><li>\u2022 Primary Education</li><li>\u2022 centrally sponsored scheme on 15 th August 1995</li><li>\u2022 revised in 2004</li><li>\u2022 Mid-day Meal Scheme (MDMS) (National Programme of Nutritional Support to Primary Education): Launched in 1995 with the main objective universalization of primary education by increasing enrolment , retention and attendance and simultaneously impacting on the nutrition of students in primary classes . It aims at providing 450\u2013700 calories and 12\u201320 gm proteins per day to all children class I to VIII.</li><li>\u2022 Mid-day Meal Scheme</li><li>\u2022 Launched in 1995</li><li>\u2022 universalization of primary education</li><li>\u2022 increasing enrolment</li><li>\u2022 retention</li><li>\u2022 attendance</li><li>\u2022 simultaneously impacting</li><li>\u2022 nutrition of students</li><li>\u2022 primary classes</li><li>\u2022 Principles for formulating mid-day meals : Meal should be a supplement only not a substitute for home diet Meal should provide 1/3 calories and 1/2 proteins Meal cost should be low Complicated cooking process must not be involved Use locally available foods Keep changing menu frequently</li><li>\u2022 Principles for formulating mid-day meals : Meal should be a supplement only not a substitute for home diet Meal should provide 1/3 calories and 1/2 proteins Meal cost should be low Complicated cooking process must not be involved Use locally available foods Keep changing menu frequently</li><li>\u2022 Principles for formulating mid-day meals</li><li>\u2022 Meal should be a supplement only not a substitute for home diet Meal should provide 1/3 calories and 1/2 proteins Meal cost should be low Complicated cooking process must not be involved Use locally available foods Keep changing menu frequently</li><li>\u2022 Meal should be a supplement only not a substitute for home diet</li><li>\u2022 Meal should provide 1/3 calories and 1/2 proteins</li><li>\u2022 Meal cost should be low</li><li>\u2022 Complicated cooking process must not be involved</li><li>\u2022 Use locally available foods</li><li>\u2022 Keep changing menu frequently</li><li>\u2022 A model menu for mid-day school meal:</li><li>\u2022 A model menu for mid-day school meal:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Mid-day Meal Scheme launched in 1995</li><li>\u27a4 Mid-day Meal Scheme</li><li>\u27a4 1995</li><li>\u27a4 Meal should provide - 1/3 calories and 1/2 proteins .</li><li>\u27a4 1/3 calories and 1/2 proteins</li><li>\u27a4 Ref : Park 26 th edition (page 751)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 751)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0d42ed78",
      "audio": ""
    },
    {
      "text": "While reviewing the National Nutrition Policy of 1993 with your students, you want them to differentiate between direct or short-term and indirect or long-term interventions. Which of the following would NOT be considered a direct or short-term intervention according to the National Nutrition Policy of 1993?",
      "options": [
        {
          "label": "A",
          "text": "Fortification of essential foods",
          "correct": false
        },
        {
          "label": "B",
          "text": "Popularization of low-cost nutritious food",
          "correct": false
        },
        {
          "label": "C",
          "text": "Control of micronutrient deficiency",
          "correct": false
        },
        {
          "label": "D",
          "text": "Nutritional surveillance",
          "correct": true
        }
      ],
      "correct_answer": "D. Nutritional surveillance",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.\u00a0D. Nutritional surveillance</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Nutritional Surveillance - Keeping a watch over nutrition , in order to make decisions that will lead to improvement in nutrition of the population . The main strategy is the Detection of malnutrition (nutritional survey).</li><li>\u2022 Nutritional Surveillance</li><li>\u2022 watch over nutrition</li><li>\u2022 make decisions</li><li>\u2022 lead to improvement in nutrition</li><li>\u2022 population</li><li>\u2022 Detection of malnutrition</li><li>\u2022 Approach : Diagnostic-interventional Sample : Representative, 50 - 100 size group Objectives : To aid health and development To provide input for program management and evaluation (to policy makers) To give timely warning and intervention (to prevent short-term food crises).</li><li>\u2022 Approach : Diagnostic-interventional</li><li>\u2022 Approach</li><li>\u2022 Sample : Representative, 50 - 100 size group</li><li>\u2022 Sample</li><li>\u2022 Objectives : To aid health and development To provide input for program management and evaluation (to policy makers) To give timely warning and intervention (to prevent short-term food crises).</li><li>\u2022 Objectives</li><li>\u2022 To aid health and development To provide input for program management and evaluation (to policy makers) To give timely warning and intervention (to prevent short-term food crises).</li><li>\u2022 To aid health and development</li><li>\u2022 health and development</li><li>\u2022 To provide input for program management and evaluation (to policy makers)</li><li>\u2022 input for program management</li><li>\u2022 evaluation</li><li>\u2022 To give timely warning and intervention (to prevent short-term food crises).</li><li>\u2022 timely warning</li><li>\u2022 intervention</li><li>\u2022 All 3 options are considered as a direct or short-term intervention according to the National Nutrition Policy of 1993</li><li>\u2022 3 options</li><li>\u2022 direct or short-term intervention</li><li>\u2022 National Nutrition Policy of 1993</li><li>\u2022 National Nutrition Policy, 1993</li><li>\u2022 National Nutrition Policy (India) was introduced in 1993 to combat the problem of undernutrition . It aims to address this problem by utilising direct (short term) and indirect (long term) interventions.</li><li>\u2022 National Nutrition Policy</li><li>\u2022 1993 to combat</li><li>\u2022 problem of undernutrition</li><li>\u2022 Direct intervention - Short-term</li><li>\u2022 Nutrition interventions for especially vulnerable groups. Fortification of essential foods. (Option A) Popularization of low-cost nutritious food. (Option B) Control of micro-nutrient deficiencies among vulnerable groups. (Option C)</li><li>\u2022 Nutrition interventions for especially vulnerable groups.</li><li>\u2022 Fortification of essential foods. (Option A)</li><li>\u2022 Popularization of low-cost nutritious food. (Option B)</li><li>\u2022 Control of micro-nutrient deficiencies among vulnerable groups. (Option C)</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 National Nutrition Policy (India) was introduced in 1993 to combat the problem of undernutrition .</li><li>\u27a4 National Nutrition Policy</li><li>\u27a4 1993 to combat the problem of undernutrition</li><li>\u27a4 Direct short term intervention - Nutrition interventions for especially vulnerable groups; Fortification of essential foods; Popularization of low-cost nutritious food; Control of micro-nutrient deficiencies among vulnerable groups .</li><li>\u27a4 Direct short term intervention</li><li>\u27a4 .</li><li>\u27a4 Ref : Park 26 th edition (page 749)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 749)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "576ca750",
      "audio": ""
    },
    {
      "text": "In a lecture about public health initiatives correlating with economic planning, you are explaining the National Program for Prevention and Control of Fluorosis (NPPCF) to mbbs students. Understanding the significance of economic planning in public health, during which five-year plan was the NPPCF initiated in India?",
      "options": [
        {
          "label": "A",
          "text": "9 th five-year plan",
          "correct": false
        },
        {
          "label": "B",
          "text": "10 th five-year plan",
          "correct": false
        },
        {
          "label": "C",
          "text": "11 th five-year plan",
          "correct": true
        },
        {
          "label": "D",
          "text": "12 th five-year plan",
          "correct": false
        }
      ],
      "correct_answer": "C. 11 th five-year plan",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. 11thfive-year plan</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The National Programme for Prevention and Control of Fluorosis (NPPCF) was a new health initiative during 11th Five Year Plan , initiated in 2008-09 and is being expanded in a phased manner . This was launched by the Ministry of Health & Family Welfare , Government of India . The objective of the program was to prevent and control fluorosis in India through various interventions like safe drinking water supply , health education , and of healthcare providers for the comprehensive management and treatment of fluorosis.</li><li>\u2022 National Programme for Prevention and Control of Fluorosis</li><li>\u2022 new health initiative</li><li>\u2022 11th Five Year Plan</li><li>\u2022 2008-09</li><li>\u2022 expanded in a phased manner</li><li>\u2022 launched by the Ministry of Health & Family Welfare</li><li>\u2022 Government of India</li><li>\u2022 objective of the program</li><li>\u2022 prevent and control fluorosis in India</li><li>\u2022 interventions</li><li>\u2022 safe drinking water supply</li><li>\u2022 health education</li><li>\u2022 healthcare providers</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 National Programme for Prevention and Control of Fluorosis (NPPCF) was initiated under 11th Five Year Plan in 2008.</li><li>\u27a4 National Programme for Prevention and Control of Fluorosis</li><li>\u27a4 11th Five Year Plan in 2008.</li><li>\u27a4 Ref : Textbook of Community Medicine- Rajvir Bhalwar- 4 th edition (page 561)</li><li>\u27a4 Ref : Textbook of Community Medicine- Rajvir Bhalwar- 4 th edition (page 561)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "65739fa9",
      "audio": ""
    },
    {
      "text": "In a discussion about social security initiatives in India, you are teaching 2nd Year MBBS students about the Annapurna Scheme, which aims to support the food needs of indigent senior citizens. When was this scheme launched?",
      "options": [
        {
          "label": "A",
          "text": "2000",
          "correct": true
        },
        {
          "label": "B",
          "text": "2001",
          "correct": false
        },
        {
          "label": "C",
          "text": "2004",
          "correct": false
        },
        {
          "label": "D",
          "text": "2007",
          "correct": false
        }
      ],
      "correct_answer": "A. 2000",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. \u00a0A. 2000</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The Annapurna Scheme is a central sector scheme which aims to fulfill the needs of Senior Citizens who, despite being eligible, have not received benefits under the National Old Age Pension Scheme (NOAPS). It was launched by the Ministry of Rural Development in 2000\u20132001 Under this scheme, 10 Kgs of food grains is distributed per month free of cost</li><li>\u2022 central sector scheme</li><li>\u2022 Senior Citizens</li><li>\u2022 10 Kgs of food grains is distributed per month free of cost</li><li>\u2022 Annapurna Vs Antodaya</li><li>\u2022 Annapurna Vs Antodaya</li><li>\u2022 Antyodaya Anna Yojana and Annapurna scheme, both government oriented programs are linked with public distribution system. Annapurna scheme is for needy senior citizen age of 65 yrs & above and Antyodaya is for the poorest of the poor</li><li>\u2022 public distribution system. Annapurna scheme is for needy senior citizen age of 65 yrs & above and Antyodaya is for the poorest of the poor</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Annapurna Scheme was launched in 2000 for needy senior citizen age of 65 yrs & above</li><li>\u27a4 Annapurna Scheme</li><li>\u27a4 2000</li><li>\u27a4 needy senior citizen age of 65 yrs</li><li>\u27a4 Ref : Textbook of Community Medicine- Rajvir Bhalwar- 4 th edition (page 563)</li><li>\u27a4 Ref</li><li>\u27a4 : Textbook of Community Medicine- Rajvir Bhalwar- 4 th edition (page 563)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6fe008e6",
      "audio": ""
    },
    {
      "text": "As you prepare for a community health lecture on micronutrient deficiencies, you plan to highlight the critical standards set by public health initiatives. According to the guidelines of the National Iodine Deficiency Disorder Control Programme (NIDDCP), what is the recommended level of iodine content in salt at the consumption level?",
      "options": [
        {
          "label": "A",
          "text": "10 ppm",
          "correct": false
        },
        {
          "label": "B",
          "text": "15 ppm",
          "correct": true
        },
        {
          "label": "C",
          "text": "30 ppm",
          "correct": false
        },
        {
          "label": "D",
          "text": "50 ppm",
          "correct": false
        }
      ],
      "correct_answer": "B. 15 ppm",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-152829.png"
      ],
      "explanation": "<p><strong>Ans. B. 15 ppm</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Standards of Iodised salt (Level of Iodization in salt) as per National Iodine Deficiency Disorder Control Programme (NIDDCP)-</li><li>\u2022 Standards of Iodised salt</li><li>\u2022 National Iodine Deficiency Disorder Control Programme</li><li>\u2022 At production level: 30 ppm At consumer level: 15 ppm.</li><li>\u2022 At production level: 30 ppm</li><li>\u2022 At consumer level: 15 ppm.</li><li>\u2022 Some important Pointers related to NIDDCP -</li><li>\u2022 Some important Pointers related to NIDDCP</li><li>\u2022 Iodine deficiency as a major public health problem - if Goitre prevalence > 10% Daily requirement of Iodine: 150 mcg (<1 teaspoon over lifetime) supplied normally by well-balanced diets and drinking water WHO/UNICEF/ICCIDD recommended daily iodine intake -</li><li>\u2022 Iodine deficiency as a major public health problem - if Goitre prevalence > 10%</li><li>\u2022 Iodine deficiency</li><li>\u2022 public health problem</li><li>\u2022 Goitre prevalence > 10%</li><li>\u2022 Daily requirement of Iodine: 150 mcg (<1 teaspoon over lifetime) supplied normally by well-balanced diets and drinking water</li><li>\u2022 WHO/UNICEF/ICCIDD recommended daily iodine intake -</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Level of iodine content of salt at consumption level - 15 ppm and at production level 30 ppm</li><li>\u27a4 Level of iodine</li><li>\u27a4 salt at consumption level</li><li>\u27a4 15 ppm</li><li>\u27a4 production level 30 ppm</li><li>\u27a4 \u200b\u200b\u200b\u200b\u200b\u200b\u200b Ref : Textbook of Community Medicine- Rajvir Bhalwar- 4 th edition (page 560)</li><li>\u27a4 \u200b\u200b\u200b\u200b\u200b\u200b\u200b Ref : Textbook of Community Medicine- Rajvir Bhalwar- 4 th edition (page 560)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "33a45107",
      "audio": ""
    },
    {
      "text": "A 6-year-old girl is brought to a primary health care center in a rural area of India for a routine health check-up. Her parents are concerned about her nutritional status and have heard about government programs that offer supplementation for children. You recall that the National Iron Plus Initiative addresses the prevention and treatment of iron-deficiency anemia across different age groups. What is the launch year of the government initiative that you would discuss with the parents to ensure the child receives appropriate iron supplementation?",
      "options": [
        {
          "label": "A",
          "text": "2011",
          "correct": false
        },
        {
          "label": "B",
          "text": "2012",
          "correct": false
        },
        {
          "label": "C",
          "text": "2010",
          "correct": false
        },
        {
          "label": "D",
          "text": "2013",
          "correct": true
        }
      ],
      "correct_answer": "D. 2013",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-153142.png"
      ],
      "explanation": "<p><strong>Ans. \u00a0D. 2013</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 In 2013 , MoHFW expanded the NNACP and renamed it as a National Iron Plus Initiative (NIPI) programme .</li><li>\u2022 2013</li><li>\u2022 MoHFW expanded the NNACP</li><li>\u2022 renamed</li><li>\u2022 National Iron Plus Initiative</li><li>\u2022 programme</li><li>\u2022 National Iron PLUS Initiative is an attempt to look at Iron Deficiency Anaemia in which beneficiaries will receive iron and folic acid supplementation irrespective of their Iron/hemoglobin status . Thus its Primary level of prevention (Specific protection)</li><li>\u2022 National Iron PLUS Initiative</li><li>\u2022 Iron Deficiency Anaemia</li><li>\u2022 beneficiaries</li><li>\u2022 iron and folic acid supplementation</li><li>\u2022 Iron/hemoglobin status</li><li>\u2022 Primary level of prevention</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 National Iron Plus Initiative was launched in 2013</li><li>\u27a4 National Iron Plus Initiative</li><li>\u27a4 2013</li><li>\u27a4 IFA SUPPLEMENTATION - Prophylactic doses and regimen</li><li>\u27a4 IFA SUPPLEMENTATION</li><li>\u27a4 Ref : Textbook of Community Medicine- Rajvir Bhalwar- 4 th edition (page 557)</li><li>\u27a4 Ref</li><li>\u27a4 : Textbook of Community Medicine- Rajvir Bhalwar- 4 th edition (page 557)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7a2b7ec5",
      "audio": ""
    },
    {
      "text": "A 35-year-old food inspector is participating in a workshop about food safety regulations in India. He is asked about the historical context of food regulatory bodies in India. He recalls that the current regulatory body, the Food Safety and Standards Authority of India (FSSAI), was operationalized under the Food Safety and Standards Act of 2006. In which year was the FSSAI officially established?",
      "options": [
        {
          "label": "A",
          "text": "2004",
          "correct": false
        },
        {
          "label": "B",
          "text": "2006",
          "correct": false
        },
        {
          "label": "C",
          "text": "2008",
          "correct": true
        },
        {
          "label": "D",
          "text": "2010",
          "correct": false
        }
      ],
      "correct_answer": "C. 2008",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. 2008</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The Food Safety and Standards Authority of India (FSSAI) was established in the year 2008 . FSSAI Act 2006 is being implemented by all states/UT governments .</li><li>\u2022 Food Safety</li><li>\u2022 Standards Authority of India</li><li>\u2022 year 2008</li><li>\u2022 FSSAI Act 2006</li><li>\u2022 implemented by all states/UT governments</li><li>\u2022 FOOD SAFETY AND STANDARDS AUTHORITY OF INDIA (FSSAI)</li><li>\u2022 FOOD SAFETY AND STANDARDS AUTHORITY OF INDIA</li><li>\u2022 Background : Established under Food Safety and Standards Act, 2006 Head office: New Delhi Objectives: To introduce a single statute relating to food To provide for the scientific development of the food processing industry</li><li>\u2022 Background : Established under Food Safety and Standards Act, 2006</li><li>\u2022 Background</li><li>\u2022 Food Safety and Standards Act, 2006</li><li>\u2022 Head office: New Delhi</li><li>\u2022 Objectives: To introduce a single statute relating to food To provide for the scientific development of the food processing industry</li><li>\u2022 Objectives:</li><li>\u2022 To introduce a single statute relating to food To provide for the scientific development of the food processing industry</li><li>\u2022 To introduce a single statute relating to food</li><li>\u2022 To provide for the scientific development of the food processing industry</li><li>\u2022 Function : Lay down Science-based standards for articles of food and to regulate their manufacture, storage, distribution, sale and import to ensure availability of safe and wholesome food for human consumption Various Central Acts like Prevention of Food Adulteration Act 1954, Milk and Milk Products Order 1992, etc. to be repealed Single reference point for all matters relating to food safety and standards Administrative Ministry for the implementation - Ministry of Health & Family Welfare, GoI</li><li>\u2022 Function : Lay down Science-based standards for articles of food and to regulate their manufacture, storage, distribution, sale and import to ensure availability of safe and wholesome food for human consumption Various Central Acts like Prevention of Food Adulteration Act 1954, Milk and Milk Products Order 1992, etc. to be repealed Single reference point for all matters relating to food safety and standards</li><li>\u2022 Function</li><li>\u2022 Lay down Science-based standards for articles of food and to regulate their manufacture, storage, distribution, sale and import to ensure availability of safe and wholesome food for human consumption Various Central Acts like Prevention of Food Adulteration Act 1954, Milk and Milk Products Order 1992, etc. to be repealed Single reference point for all matters relating to food safety and standards</li><li>\u2022 Lay down Science-based standards for articles of food and to regulate their manufacture, storage, distribution, sale and import to ensure availability of safe and wholesome food for human consumption</li><li>\u2022 Various Central Acts like Prevention of Food Adulteration Act 1954, Milk and Milk Products Order 1992, etc. to be repealed</li><li>\u2022 Single reference point for all matters relating to food safety and standards</li><li>\u2022 Administrative Ministry for the implementation - Ministry of Health & Family Welfare, GoI</li><li>\u2022 Administrative Ministry for the implementation</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Food Safety and Standards Authority of India (FSSAI) was established in the year 2008</li><li>\u27a4 Food Safety</li><li>\u27a4 Standards Authority of India</li><li>\u27a4 year 2008</li><li>\u27a4 Administrative Ministry for the implementation - Ministry of Health & Family Welfare, GoI</li><li>\u27a4 Administrative Ministry for the implementation</li><li>\u27a4 Ref : Park 26 th edition (page 749)</li><li>\u27a4 Ref : Park 26 th edition (page 749)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7d49cd3c",
      "audio": ""
    },
    {
      "text": "A dietician at a public hospital in India is reviewing the guidelines to ensure the food provided meets the regulatory requirements. She understands that there are specific standards set to achieve a minimum level of quality for foodstuffs under Indian conditions. These standards, known for their rigorous testing and quality assurance, are critical in preventing foodborne illnesses. Which of the following represents these standards?",
      "options": [
        {
          "label": "A",
          "text": "Codex Alimentarius",
          "correct": false
        },
        {
          "label": "B",
          "text": "PFA standards",
          "correct": true
        },
        {
          "label": "C",
          "text": "Agmark Standards",
          "correct": false
        },
        {
          "label": "D",
          "text": "Bureau of Indian Standards",
          "correct": false
        }
      ],
      "correct_answer": "B. PFA standards",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. \u00a0B. PFA standards</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Codex Alimentarius: Joint FAO/WHO standards for international markets ; Food standards in India are based on Codex Alimentarius</li><li>\u2022 Option A. Codex Alimentarius: Joint FAO/WHO standards</li><li>\u2022 international markets</li><li>\u2022 Codex Alimentarius</li><li>\u2022 Option C. Agmark standards: Purely voluntary ; express degree of excellence above PFA standards.</li><li>\u2022 Option C. Agmark standards: Purely voluntary</li><li>\u2022 Option D. Bureau of Indian Standards: Purely voluntary ; express degree of excellence above PFA standards</li><li>\u2022 Option D. Bureau of Indian Standards: Purely voluntary</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 FOOD SAFETY AND STANDARDS AUTHORITY OF INDIA (FSSAI)</li><li>\u27a4 FOOD SAFETY AND STANDARDS AUTHORITY OF INDIA</li><li>\u27a4 Background : Established under Food Safety and Standards Act, 2006 Head office : New Delhi Function : Lay down Science-based standards for articles of food and to regulate their manufacture, storage, distribution, sale and import to ensure availability of safe and wholesome food for human consumption Various Central Acts like Prevention of Food Adulteration Act 1954, Milk and Milk Products Order 1992, etc. to be repealed Single reference point for all matters relating to food safety and standards</li><li>\u27a4 Background : Established under Food Safety and Standards Act, 2006</li><li>\u27a4 Background</li><li>\u27a4 Head office : New Delhi</li><li>\u27a4 Head office</li><li>\u27a4 Function : Lay down Science-based standards for articles of food and to regulate their manufacture, storage, distribution, sale and import to ensure availability of safe and wholesome food for human consumption Various Central Acts like Prevention of Food Adulteration Act 1954, Milk and Milk Products Order 1992, etc. to be repealed Single reference point for all matters relating to food safety and standards</li><li>\u27a4 Function</li><li>\u27a4 Lay down Science-based standards for articles of food and to regulate their manufacture, storage, distribution, sale and import to ensure availability of safe and wholesome food for human consumption Various Central Acts like Prevention of Food Adulteration Act 1954, Milk and Milk Products Order 1992, etc. to be repealed Single reference point for all matters relating to food safety and standards</li><li>\u27a4 Lay down Science-based standards for articles of food and to regulate their manufacture, storage, distribution, sale and import to ensure availability of safe and wholesome food for human consumption</li><li>\u27a4 Various Central Acts like Prevention of Food Adulteration Act 1954, Milk and Milk Products Order 1992, etc. to be repealed</li><li>\u27a4 Single reference point for all matters relating to food safety and standards</li><li>\u27a4 Establishment of the Authority : Ministry of Health & Family Welfare, Government of India is the Administrative Ministry for the implementation of FSSAI</li><li>\u27a4 Establishment of the Authority : Ministry of Health & Family Welfare, Government of India is the Administrative Ministry for the implementation of FSSAI</li><li>\u27a4 Establishment of the Authority</li><li>\u27a4 Ref : Park 26 th edition (page 749)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 749)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "069402b4",
      "audio": ""
    },
    {
      "text": "A policy advisor is consulting with a team of public health officials on the historical legal framework for food safety in India. They are reviewing past legislation to understand how food quality standards have evolved. The advisor asks the team to identify the year in which the Prevention of Food Adulteration Act, a pivotal health mandate aimed at addressing food adulteration, was enacted. Which year did this legislative action take place?",
      "options": [
        {
          "label": "A",
          "text": "1950",
          "correct": false
        },
        {
          "label": "B",
          "text": "1954",
          "correct": true
        },
        {
          "label": "C",
          "text": "1960",
          "correct": false
        },
        {
          "label": "D",
          "text": "1964",
          "correct": false
        }
      ],
      "correct_answer": "B. 1954",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. \u00a0B. 1954</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Enacted by the Indian Parliament in 1954 , with the objective of ensuring pure and wholesome food to the consumers and to protect them from fraudulent and deceptive trade practices , the Prevention of Food Adulteration (PFA) Act was amended in 1964, 1976 and lately in 1986 .</li><li>\u2022 Enacted</li><li>\u2022 Indian Parliament in 1954</li><li>\u2022 ensuring pure and wholesome food</li><li>\u2022 consumers</li><li>\u2022 protect them from fraudulent</li><li>\u2022 deceptive trade practices</li><li>\u2022 Prevention of Food Adulteration</li><li>\u2022 Act</li><li>\u2022 amended</li><li>\u2022 1964, 1976</li><li>\u2022 1986</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Some important pointers related to PFA -</li><li>\u27a4 Some important pointers related to PFA</li><li>\u27a4 According to Prevention of Food Adulteration (PFA) Act 1954 : \u2013 Level of iodisation in salt is 30 ppm at production level and 15 ppm at consumer level PFA standards: Laid under \u2018Prevention of Food Adulteration Act 1954\u2019; to obtain a minimum level of quality of food stuffs attainable under Indian conditions</li><li>\u27a4 According to Prevention of Food Adulteration (PFA) Act 1954 : \u2013 Level of iodisation in salt is 30 ppm at production level and 15 ppm at consumer level</li><li>\u27a4 Prevention of Food Adulteration</li><li>\u27a4 Act 1954</li><li>\u27a4 Level of iodisation</li><li>\u27a4 salt is 30 ppm</li><li>\u27a4 production level</li><li>\u27a4 15 ppm</li><li>\u27a4 consumer level</li><li>\u27a4 PFA standards: Laid under \u2018Prevention of Food Adulteration Act 1954\u2019; to obtain a minimum level of quality of food stuffs attainable under Indian conditions</li><li>\u27a4 minimum level of quality of food</li><li>\u27a4 Ref : Park 26 th edition (page 748)</li><li>\u27a4 Ref : Park 26 th edition (page 748)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f35ee339",
      "audio": ""
    },
    {
      "text": "A food safety officer is conducting a training session on food safety protocols as mandated by the Food Safety and Standards Authority of India (FSSAI). She emphasizes a particular systematic approach that the FSSAI encourages for identifying and controlling hazards throughout the food chain. What does the acronym HACCP, as endorsed by FSSAI, stand for?",
      "options": [
        {
          "label": "A",
          "text": "Hazard Analysis and Critical Control Points",
          "correct": true
        },
        {
          "label": "B",
          "text": "Health Analysis and Critical Control Points",
          "correct": false
        },
        {
          "label": "C",
          "text": "Hazard Analysis and Critical Care Points",
          "correct": false
        },
        {
          "label": "D",
          "text": "Health Analysis and Critical Care Points",
          "correct": false
        }
      ],
      "correct_answer": "A. Hazard Analysis and Critical Control Points",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Hazard Analysis and Critical Control Points</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Hazard Analysis and Critical Control Points (HACCP) is the cornerstone of FSSAI . HACCP is a structured approach that focuses on identifying potential food safety hazards and establishing critical control points to prevent, eliminate , or reduce these hazards to an acceptable level , which is critical for maintaining food safety standards.</li><li>\u2022 Hazard Analysis</li><li>\u2022 Critical Control Points</li><li>\u2022 cornerstone of FSSAI</li><li>\u2022 HACCP</li><li>\u2022 structured approach</li><li>\u2022 focuses on identifying potential food safety hazards</li><li>\u2022 establishing critical control points</li><li>\u2022 prevent, eliminate</li><li>\u2022 reduce these hazards</li><li>\u2022 acceptable level</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 HACCP is a systematic preventive approach to food safety , focusing on the identification and control of hazards throughout the food chain , a process endorsed by the FSSAI.</li><li>\u27a4 HACCP</li><li>\u27a4 systematic preventive approach</li><li>\u27a4 food safety</li><li>\u27a4 focusing</li><li>\u27a4 identification</li><li>\u27a4 control of hazards</li><li>\u27a4 food chain</li><li>\u27a4 HACCP - Hazard Analysis and Critical Control Points</li><li>\u27a4 Ref : https://foodregulatory.fssai.gov.in/HACCP-certification</li><li>\u27a4 Ref</li><li>\u27a4 : https://foodregulatory.fssai.gov.in/HACCP-certification</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5d30e5be",
      "audio": ""
    },
    {
      "text": "A medical resident is rotating in a public health department and is reviewing the quality control measures for pasteurized milk. Which of the following is NOT a standard test for assessing the quality of pasteurized milk?",
      "options": [
        {
          "label": "A",
          "text": "Phosphatase test",
          "correct": false
        },
        {
          "label": "B",
          "text": "Standard plate count",
          "correct": false
        },
        {
          "label": "C",
          "text": "Coliform count",
          "correct": false
        },
        {
          "label": "D",
          "text": "Paper chromatography test",
          "correct": true
        }
      ],
      "correct_answer": "D. Paper chromatography test",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-153823.png"
      ],
      "explanation": "<p><strong>Ans. \u00a0D. Paper chromatography test</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Effect/sufficiency/adequacy of pasteurization is assessed by \u2013</li><li>\u2022 Option A. Phosphatase test (MC): This test is widely used to check the efficiency of pasteurization .</li><li>\u2022 Option A. Phosphatase test (MC):</li><li>\u2022 check the efficiency</li><li>\u2022 pasteurization</li><li>\u2022 Option B. Standard plate count: The bacteriological quality of pasteurized milk is determined by the standard plate count . Enforced limit is 30,000 bacterial count per ml of pasteurized milk</li><li>\u2022 Option B. Standard plate count:</li><li>\u2022 bacteriological quality</li><li>\u2022 pasteurized milk</li><li>\u2022 standard plate count</li><li>\u2022 Option C. Coliform count: Coliform organisms are usually completely destroyed by pasteurization , and therefore, their presence in pasteurized milk is an indication either of improper pasteurization or post-pasteurization contamination . Standard is coliforms be absent in 1 ml of milk</li><li>\u2022 Option C. Coliform count:</li><li>\u2022 completely destroyed</li><li>\u2022 pasteurization</li><li>\u2022 presence in pasteurized milk</li><li>\u2022 improper pasteurization</li><li>\u2022 post-pasteurization contamination</li><li>\u2022 Some important pointers related to Pasteurization -</li><li>\u2022 Some important pointers related to Pasteurization -</li><li>\u2022 Pasteurization of milk is a type of - Primary prevention</li><li>\u2022 Chemical Disinfectants - Pasteurization (70\u00b0 Celsius for 30 minutes for pathogenic microorganisms except spores)</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Effect / sufficiency / adequacy of pasteurization of Milk is assessed by \u2013 Phosphatase test (MC used test).</li><li>\u27a4 Effect</li><li>\u27a4 sufficiency</li><li>\u27a4 adequacy of pasteurization</li><li>\u27a4 Milk is assessed</li><li>\u27a4 Phosphatase test</li><li>\u27a4 Methods of Pasteurization -</li><li>\u27a4 Methods of Pasteurization -</li><li>\u27a4 Ref : Park 26 th edition (page 745)</li><li>\u27a4 Ref : Park 26 th edition (page 745)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ee643071",
      "audio": ""
    },
    {
      "text": "A medical resident is studying the effects of various natural toxins on human health. Match the following toxins with the diseases they are commonly associated with:",
      "options": [
        {
          "label": "A",
          "text": "a- i, b- ii, c-iii",
          "correct": false
        },
        {
          "label": "B",
          "text": "a- iii, b- i, c-ii",
          "correct": false
        },
        {
          "label": "C",
          "text": "a- ii, b- iii, c-i",
          "correct": false
        },
        {
          "label": "D",
          "text": "a- ii, b- i, c-iii",
          "correct": true
        }
      ],
      "correct_answer": "D. a- ii, b- i, c-iii",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/14/picture48.jpg"
      ],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-154238.png"
      ],
      "explanation": "<p><strong>Ans. \u00a0D. a- ii, b- i, c-iii</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The cause of Nuerolathyrism is a toxin , Beta oxalyl amino alanine (BOAA) which is found in the seeds of the pulse , L.sativus (Khesari dhal).</li><li>\u2022 Nuerolathyrism is a toxin</li><li>\u2022 Beta oxalyl amino alanine</li><li>\u2022 seeds of the pulse</li><li>\u2022 L.sativus</li><li>\u2022 Epidemic dropsy - sanguinarine from argemone oil This toxic substance interferes with the oxidation of pyruvic acid which accumulates in the blood.</li><li>\u2022 Epidemic dropsy</li><li>\u2022 Endemic ascites - pyrrolizidine alkaloids in Jhunjhunia seeds were found to be hepatotoxins.</li><li>\u2022 Endemic ascites</li><li>\u2022 Lathyrism - Neurolathyrism is caused by eating the pulse \u2018Khesari Dal (Lathyrus sativus)\u2019. Diets containing over 30% of this dal consumed over a period of 2 - 6 months result in neurolathyrism. Toxin is present in lathyrus seeds is Beta oxalyl amino alanine (BOAA). It manifests as following stages: Latent stage; No-stick stage; One-stick stage; Two-stick stage and Crawler stage.</li><li>\u2022 Lathyrism</li><li>\u2022 Neurolathyrism</li><li>\u2022 \u2018Khesari Dal</li><li>\u2022 Interventions for prevention and control of lathyrism :</li><li>\u2022 Interventions for prevention and control of lathyrism</li><li>\u2022 Vitamin C prophylaxis Banning the crop Removal of toxin: Steeping method and Parboiling Education Genetic approach Socio-economic changes</li><li>\u2022 Vitamin C prophylaxis</li><li>\u2022 Banning the crop</li><li>\u2022 Removal of toxin: Steeping method and Parboiling</li><li>\u2022 Education</li><li>\u2022 Genetic approach</li><li>\u2022 Socio-economic changes</li><li>\u2022 Epidemic Dropsy \u2013 This is caused by contamination of mustard oil with \u2018Argemone oil\u2019 . Toxin \u2018Sanguinarine\u2019 is contained in argemone oil. It may lead to sudden noninflammatory edema of bilateral lower limbs, diarrhea, dyspnoea, cardiac failure and death; It can also lead to glaucoma; It may sometimes manifest as \u2018Sarcoids\u2019 (dilatation of skin capillaries). Epidemic dropsy may occur in all ages except breast-fed infants.\u200b\u200b\u200b\u200b\u200b\u200b Edema in Epidemic dropsy occurs due to proteinuria (specifically loss of albumin).</li><li>\u2022 Epidemic Dropsy</li><li>\u2022 contamination of mustard oil with \u2018Argemone oil\u2019</li><li>\u2022 Argemone oil may be detected by following tests:</li><li>\u2022 Nitric acid test Paper chromatography test : Most sensitive test</li><li>\u2022 Nitric acid test</li><li>\u2022 Paper chromatography test : Most sensitive test</li><li>\u2022 Paper chromatography test</li><li>\u2022 sensitive test</li><li>\u2022 Endemic Ascites :</li><li>\u2022 Endemic Ascites</li><li>\u2022 Toxin : Pyrrolizidine alkaloids (Hepatotoxins) Adulterant : Crotalaria plant (Jhunjhunia)</li><li>\u2022 Toxin</li><li>\u2022 Adulterant</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Ref : Park 26 th edition (page 746, 747)</li><li>\u27a4 Ref : Park 26 th edition (page 746, 747)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f079723d",
      "audio": ""
    },
    {
      "text": "In the context of food safety, A medical resident is reviewing food safety regulations concerning grain products. He notes that certain regulations specify maximum allowable concentrations of natural contaminants. What is the upper safe limit for ergot alkaloids in food material, as per safety guidelines?",
      "options": [
        {
          "label": "A",
          "text": "0.01 mg per 100 grams of food material",
          "correct": false
        },
        {
          "label": "B",
          "text": "0.02 mg per 100 grams of food material",
          "correct": false
        },
        {
          "label": "C",
          "text": "0.05 mg per 100 grams of food material",
          "correct": true
        },
        {
          "label": "D",
          "text": "0.10 mg per 100 grams of food material",
          "correct": false
        }
      ],
      "correct_answer": "C. 0.05 mg per 100 grams of food material",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. \u00a0C. 0.05 mg per 100 grams of food material</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The upper safe limit for the ergot alkaloids has been estimated to be 0.05 mg per 100 grams of the food material .</li><li>\u2022 upper safe limit</li><li>\u2022 ergot alkaloids</li><li>\u2022 estimated to be 0.05 mg per 100 grams</li><li>\u2022 food material</li><li>\u2022 Ergotism</li><li>\u2022 Ergotism</li><li>\u2022 Description: Occurs due to food toxicant - ergot fungus \u2018Claviceps fusiformis\u2019 (Toxin - Clavine alkaloids) Removal of ergot : \u2013 Float them in 20% salt water Hand-picking Air-floatation</li><li>\u2022 Description: Occurs due to food toxicant - ergot fungus \u2018Claviceps fusiformis\u2019 (Toxin - Clavine alkaloids)</li><li>\u2022 food toxicant</li><li>\u2022 Removal of ergot : \u2013 Float them in 20% salt water Hand-picking Air-floatation</li><li>\u2022 Removal of ergot</li><li>\u2022 Hand-picking Air-floatation</li><li>\u2022 Hand-picking</li><li>\u2022 Air-floatation</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Upper safe limit for ergot - 0.05 mg per 100 grams food material</li><li>\u27a4 Upper safe limit for ergot</li><li>\u27a4 0.05 mg</li><li>\u27a4 100 grams food material</li><li>\u27a4 Food items having a tendency for ergotism \u2013 Bajra, Rye, Sorghum, Wheat</li><li>\u27a4 Food items</li><li>\u27a4 tendency for ergotism</li><li>\u27a4 Ref : Park 26 th edition (page 747)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 747)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9f38528c",
      "audio": ""
    },
    {
      "text": "A physician is investigating a cluster of epidemic dropsy cases in a community. The common link appears to be the consumption of mustard oil, which may be contaminated with argemone oil. Which test is most sensitive for the detection of argemone oil contamination in food products?",
      "options": [
        {
          "label": "A",
          "text": "Nitric acid test",
          "correct": false
        },
        {
          "label": "B",
          "text": "Methylene blue test",
          "correct": false
        },
        {
          "label": "C",
          "text": "Phosphatase test",
          "correct": false
        },
        {
          "label": "D",
          "text": "Paper chromatography test",
          "correct": true
        }
      ],
      "correct_answer": "D. Paper chromatography test",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. \u00a0D. Paper chromatography test</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Nitric acid test: It can detect contamination of mustard oil with argemone oil , but not as sensitive as Paper Chromatography test</li><li>\u2022 Option A. Nitric acid test:</li><li>\u2022 detect contamination of mustard oil with argemone oil</li><li>\u2022 Option B. Methylene blue test: An indirect method for detection of microorganisms in milk (Test for Contamination of milk)</li><li>\u2022 Option B. Methylene blue test:</li><li>\u2022 indirect method</li><li>\u2022 detection of microorganisms</li><li>\u2022 milk</li><li>\u2022 Option C. Phosphatase test: Widely used test for Pasteurized Milk to check adequacy/sufficiency of pasteurization</li><li>\u2022 Option C. Phosphatase test:</li><li>\u2022 Pasteurized Milk</li><li>\u2022 adequacy/sufficiency of pasteurization</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Epidemic Dropsy - Is caused by contamination of mustard oil with \u2018Argemone oil\u2019</li><li>\u27a4 Epidemic Dropsy</li><li>\u27a4 contamination of mustard oil</li><li>\u27a4 \u2018Argemone oil\u2019</li><li>\u27a4 Toxin : \u2018Sanguinarine\u2019 is the toxin contained in argemone oil Mechanism - Sanguinarine interferes with oxidation of \u2018pyruvic acid\u2019, which accumulates in blood: It may lead to sudden non-inflammatory edema of bilateral lower limbs, diarrhea, dyspnoea, cardiac failure and death; It can also lead to glaucoma; It may sometimes manifest as \u2018Sarcoids\u2019 (dilatation of skin capillaries). Epidemic dropsy may occur in all ages except breast-fed infants The mortality of epidemic dropsy varies from 5 to 50% Edema in Epidemic dropsy occurs due to proteinuria (specifically loss of albumin).</li><li>\u27a4 Toxin : \u2018Sanguinarine\u2019 is the toxin contained in argemone oil</li><li>\u27a4 Toxin</li><li>\u27a4 \u2018Sanguinarine\u2019</li><li>\u27a4 toxin contained in argemone oil</li><li>\u27a4 Mechanism - Sanguinarine interferes with oxidation of \u2018pyruvic acid\u2019, which accumulates in blood: It may lead to sudden non-inflammatory edema of bilateral lower limbs, diarrhea, dyspnoea, cardiac failure and death; It can also lead to glaucoma; It may sometimes manifest as \u2018Sarcoids\u2019 (dilatation of skin capillaries). Epidemic dropsy may occur in all ages except breast-fed infants The mortality of epidemic dropsy varies from 5 to 50% Edema in Epidemic dropsy occurs due to proteinuria (specifically loss of albumin).</li><li>\u27a4 Epidemic dropsy may occur in all ages except breast-fed infants The mortality of epidemic dropsy varies from 5 to 50% Edema in Epidemic dropsy occurs due to proteinuria (specifically loss of albumin).</li><li>\u27a4 Epidemic dropsy may occur in all ages except breast-fed infants</li><li>\u27a4 The mortality of epidemic dropsy varies from 5 to 50%</li><li>\u27a4 Edema in Epidemic dropsy occurs due to proteinuria (specifically loss of albumin).</li><li>\u27a4 Paper chromatography test as the most sensitive method for detecting argemone oil (toxin Sanguinarine) contamination in food products.</li><li>\u27a4 Paper chromatography test as the most sensitive method for detecting argemone oil (toxin Sanguinarine) contamination in food products.</li><li>\u27a4 Paper chromatography test</li><li>\u27a4 sensitive method</li><li>\u27a4 detecting argemone oil</li><li>\u27a4 Ref : Park 26 th edition (page 747)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 747)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "cdd6499b",
      "audio": ""
    },
    {
      "text": "During a public health seminar on nutrition, a presentation is given on the various methods used to combat micronutrient deficiencies in populations. One method discussed is food fortification. Which of the following is NOT an example of food fortification?",
      "options": [
        {
          "label": "A",
          "text": "Fluoridation of water",
          "correct": false
        },
        {
          "label": "B",
          "text": "Iodization of salt",
          "correct": false
        },
        {
          "label": "C",
          "text": "Vitamin D in milk",
          "correct": false
        },
        {
          "label": "D",
          "text": "Vanaspati in Ghee",
          "correct": true
        }
      ],
      "correct_answer": "D. Vanaspati in Ghee",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-154814.png"
      ],
      "explanation": "<p><strong>Ans. D. Vanaspati in Ghee</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Example of fortification of food or water.</li><li>\u2022 Option A. Fluoridation of water as a prevention of dental caries</li><li>\u2022 Option A. Fluoridation of water</li><li>\u2022 prevention</li><li>\u2022 dental caries</li><li>\u2022 Option B. Iodization of salt for combating the problem of endemic goitre (According to Prevention of Food Adulteration (PFA) Act\u2019 1954.</li><li>\u2022 Option B. Iodization of salt</li><li>\u2022 combating the problem</li><li>\u2022 endemic goitre</li><li>\u2022 Level of iodisation - Minimum 30 ppm at production level and 15 ppm at consumer level;</li><li>\u2022 Level of iodisation</li><li>\u2022 Moisture content : < 6.0% by weight; Sodium chloride: > 96.0% by weight.</li><li>\u2022 Moisture content</li><li>\u2022 Option C. Vitamin D in milk: Food fortification (e.g., vanaspati, milk) with vitamins A and D (2500 IU Vitamin A and 175 IU Vitamin D per 100 grams).</li><li>\u2022 Option C. Vitamin D in milk: Food fortification</li><li>\u2022 vitamins A</li><li>\u2022 D</li><li>\u2022 Food fortification : Is a public health , measure where nutrients are added to food (in relatively small quantities), to maintain/improve the quality of diet of a group , community or a population. Food Fortification is an example of \u2018Primary Level of Prevention\u2019</li><li>\u2022 Food fortification</li><li>\u2022 public health</li><li>\u2022 nutrients are added to food</li><li>\u2022 maintain/improve the quality of diet</li><li>\u2022 group</li><li>\u2022 community</li><li>\u2022 \u2018Primary Level of Prevention\u2019</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Examples of fortification of food or water are -  Fluoridation of water; Iodization of salt; vanaspati ghee with vitamins A and D</li><li>\u27a4 Examples of fortification of food or water are</li><li>\u27a4 Food Adulteration diseases -</li><li>\u27a4 Ref : Park 26 th edition (page 748)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 748)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "68c2497e",
      "audio": ""
    },
    {
      "text": "While preparing for a public health policy exam, a medical student needs to cite the article from the Indian Constitution that defines \"Scheduled Tribes\" for her thesis on healthcare disparities. Which article of the Indian Constitution should she refer to for the accurate definition of \"Scheduled Tribes\"?",
      "options": [
        {
          "label": "A",
          "text": "Article 366",
          "correct": true
        },
        {
          "label": "B",
          "text": "Article 322",
          "correct": false
        },
        {
          "label": "C",
          "text": "Article 360",
          "correct": false
        },
        {
          "label": "D",
          "text": "Article 320",
          "correct": false
        }
      ],
      "correct_answer": "A. Article 366",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. \u00a0A. Article 366</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Article 322: The expenses of the Union or a State Public Service Commission , including any salaries , allowances and pensions</li><li>\u2022 Option B. Article 322:</li><li>\u2022 expenses</li><li>\u2022 Union or a State Public Service Commission</li><li>\u2022 salaries</li><li>\u2022 allowances</li><li>\u2022 pensions</li><li>\u2022 Option C. Article 360: This article gives the President the authority to declare a financial emergency in the country if there is a threat to India's financial stability or credit.</li><li>\u2022 Option C. Article 360:</li><li>\u2022 President the authority</li><li>\u2022 financial emergency</li><li>\u2022 country</li><li>\u2022 Option D. Article 320: Functions of Public Service Commissions (Union and State) like to conduct examinations for appointments to the services.</li><li>\u2022 Option D. Article 320:</li><li>\u2022 Public Service Commissions</li><li>\u2022 conduct examinations</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Scheduled Tribes [Article 366 (25)] - Includes tribes or communities as deemed under Article 342</li><li>\u27a4 Scheduled Tribes</li><li>\u27a4 tribes or communities</li><li>\u27a4 Article 342</li><li>\u27a4 Other Important Articles -</li><li>\u27a4 Article 21 - Right to life of citizens of India</li><li>\u27a4 Article 21</li><li>\u27a4 Right to life</li><li>\u27a4 Article 24 - Article of child rights - Prohibits employment of children below 14 years in factories; Prevents abuse of children at tender age</li><li>\u27a4 Article 24</li><li>\u27a4 Article of child rights</li><li>\u27a4 Article 45 - Provides for free and compulsory education for all children till 14 years of age.</li><li>\u27a4 Article 45</li><li>\u27a4 free and compulsory education</li><li>\u27a4 Ref : Park 26 th edition (page 795)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 795)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "63f1ce29",
      "audio": ""
    },
    {
      "text": "When planning public health interventions for tribal areas in India, it is crucial to understand the established norms for healthcare facilities. As per the norms, which of the following is correct regarding the establishment of health centers in tribal areas?",
      "options": [
        {
          "label": "A",
          "text": "One HSC per 5000 population",
          "correct": false
        },
        {
          "label": "B",
          "text": "One HSC per 3000 population",
          "correct": true
        },
        {
          "label": "C",
          "text": "One CHC per 50000 population",
          "correct": false
        },
        {
          "label": "D",
          "text": "One PHC per 50000 population",
          "correct": false
        }
      ],
      "correct_answer": "B. One HSC per 3000 population",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. One HSC per 3000 population</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 As per the present norms , tribal and hilly areas should have one Health Sub-centre (HSC) per 3,000 populations , one Primary Health Centre (PHC) per 20,000 populations , and a Community Health Centre (CHC) per 80,000 populations .</li><li>\u2022 present norms</li><li>\u2022 tribal and hilly areas</li><li>\u2022 one Health Sub-centre</li><li>\u2022 3,000 populations</li><li>\u2022 one Primary Health Centre</li><li>\u2022 20,000 populations</li><li>\u2022 Community Health Centre</li><li>\u2022 80,000 populations</li><li>\u2022 Healthcare Infrastructure for Tribal Population -</li><li>\u2022 27\u201340% shortfall in Health care institutions 27% shortfall in Subcentres (11 states) (8% shortfall in UT Dadra and Nagar Haveli) 40% shortfall in PHCs (7 states) 31% shortfall in CHCs (10 states) (1 CHC shortfall in UT Dadra and Nagar Haveli)</li><li>\u2022 27\u201340% shortfall in Health care institutions</li><li>\u2022 27% shortfall in Subcentres (11 states) (8% shortfall in UT Dadra and Nagar Haveli)</li><li>\u2022 40% shortfall in PHCs (7 states)</li><li>\u2022 31% shortfall in CHCs (10 states) (1 CHC shortfall in UT Dadra and Nagar Haveli)</li><li>\u2022 Some important Pointers related to Tribal Population -</li><li>\u2022 NTEP - Designated Microscopy Centre (DMC) - Most peripheral unit - Population covered: 50,000 in hilly/ tribal areas ICDS - 1 Anganwadi centre per 300\u2013800 population in tribal projects and 1 Mini-Anganwadi centre per 150\u2013300 population. Community Development Block covering a population of 35,000 (550 villages) Population Norms for Health Workers in India [Current Norms] Health Assistant (male and female) \u2013  1 per 20,000 population in tribal and hilly areas Health Worker/Multi-purpose worker (male and female) \u2013 1 per 3,000 population in tribal and hilly areas</li><li>\u2022 NTEP - Designated Microscopy Centre (DMC) - Most peripheral unit - Population covered: 50,000 in hilly/ tribal areas</li><li>\u2022 NTEP</li><li>\u2022 ICDS - 1 Anganwadi centre per 300\u2013800 population in tribal projects and 1 Mini-Anganwadi centre per 150\u2013300 population. Community Development Block covering a population of 35,000 (550 villages)</li><li>\u2022 ICDS</li><li>\u2022 Population Norms for Health Workers in India [Current Norms] Health Assistant (male and female) \u2013  1 per 20,000 population in tribal and hilly areas Health Worker/Multi-purpose worker (male and female) \u2013 1 per 3,000 population in tribal and hilly areas</li><li>\u2022 Population Norms for Health Workers in India</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 As per the present norms , tribal and hilly areas should have one Health Sub-centre (HSC) per 3,000 populations , one Primary Health Centre (PHC) per 20,000 populations , and a Community Health Centre (CHC) per 80,000 populations.</li><li>\u27a4 present norms</li><li>\u27a4 tribal</li><li>\u27a4 hilly areas</li><li>\u27a4 one Health Sub-centre</li><li>\u27a4 3,000 populations</li><li>\u27a4 one Primary Health Centre</li><li>\u27a4 20,000 populations</li><li>\u27a4 Community Health Centre</li><li>\u27a4 80,000 populations.</li><li>\u27a4 Ref : Park 26th edition (page 797)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26th edition (page 797)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "92ed088f",
      "audio": ""
    },
    {
      "text": "A 55-year-old male with a history of hypertension presents to your clinic. He reports that he has been compliant with his medication regimen but has recently been experiencing a return of his symptoms of high blood pressure. Upon further investigation, you discover that he purchased his medication from an online source that is not associated with a licensed pharmacy. This raises your concern about the authenticity of his medication. Which of the following statements is incorrect about counterfeit medicines?",
      "options": [
        {
          "label": "A",
          "text": "\u200b\u200b\u200b\u200b\u200b\u200bA drug/medicine is counterfeit if it is produced with an intention to cheat.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Includes mis-labelling, absence of active ingredients, a wrong ingredient, or the correct ingredient in an insufficient quantity.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Only generic products can be counterfeited.",
          "correct": true
        },
        {
          "label": "D",
          "text": "Anti-malarial are amongst the most commonly reported sub-standard and falsified medical products.",
          "correct": false
        }
      ],
      "correct_answer": "C. Only generic products can be counterfeited.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. \u00a0Only generic products can be counterfeited.</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 QUALITY CONTROL IN DRUG SECTOR IN INDIA</li><li>\u27a4 QUALITY CONTROL IN DRUG SECTOR IN INDIA</li><li>\u27a4 Quality control of drugs in India: Drugs and Cosmetics Act 1940 Drugs and Cosmetics Rules 1945 Central Drugs Standard Control Organisation (CDSCO): \u2013 Headed by: 1. Central level: Drugs Controller General, India (DGHS, MOHFW) 2. State level: State Drugs Controllers Main functions:</li><li>\u27a4 Quality control of drugs in India: Drugs and Cosmetics Act 1940 Drugs and Cosmetics Rules 1945</li><li>\u27a4 Drugs and Cosmetics Act 1940 Drugs and Cosmetics Rules 1945</li><li>\u27a4 Drugs and Cosmetics Act 1940</li><li>\u27a4 Drugs and Cosmetics Rules 1945</li><li>\u27a4 Central Drugs Standard Control Organisation (CDSCO): \u2013 Headed by: 1. Central level: Drugs Controller General, India (DGHS, MOHFW) 2. State level: State Drugs Controllers Main functions:</li><li>\u27a4 Central Drugs Standard Control Organisation</li><li>\u27a4 Main functions:</li><li>\u27a4 Main functions:</li><li>\u27a4 Main functions:</li><li>\u27a4 1. Quality control of imported drugs 2. Coordination of activities under State Drugs Control Authorities 3. Approval for importation/manufacture of new drugs 4. Laying standards for and act as \u2018Central Licensing Authority for blood and blood products, iv fluids, sera, vaccines, r-DNA products\u2019</li><li>\u27a4 Zonal offices: Mumbai, Kolkata, Ghaziabad, Chennai.</li><li>\u27a4 Zonal offices: Mumbai, Kolkata, Ghaziabad, Chennai.</li><li>\u27a4 Ref : Park 26th edition (page 550)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26th edition (page 550)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7516bd23",
      "audio": ""
    },
    {
      "text": "As on 2022, total number of essential drugs approved by Government of India under NLEM is?",
      "options": [
        {
          "label": "A",
          "text": "321 drugs",
          "correct": false
        },
        {
          "label": "B",
          "text": "309 drugs",
          "correct": false
        },
        {
          "label": "C",
          "text": "384 drugs",
          "correct": true
        },
        {
          "label": "D",
          "text": "356 drugs",
          "correct": false
        }
      ],
      "correct_answer": "C. 384 drugs",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. \u00a0384 drugs</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 NEW National Lists of Essential Medicines (NLEM) 2022</li><li>\u2022 NEW National Lists of Essential Medicines (NLEM) 2022</li><li>\u2022 384 Drugs included in NLEM 2022; 34 new drugs added Criteria followed for inclusion in NLEM : be useful in diseases which is a public health problem in India be licensed /approved Drugs Controller General (India) (DCGI) have proven efficacy and safety profile based on scientific evidence be comparatively cost effective be aligned with the current treatment guidelines recommended under National Health Programs of India . (e.g. Ivermectin part of Accelerated Plan for Elimination of Lymphatic Filariasis 2018). when more than one medicine are available from the same therapeutic class , one prototype /medically best suited medicine of that class to be included. price of total treatment is considered and not the unit price of a medicine fixed dose combinations are usually not included vaccines as and when are included in Universal Immunization Program (e.g. Rotavirus vaccine).</li><li>\u2022 384 Drugs included in NLEM 2022; 34 new drugs added</li><li>\u2022 384 Drugs</li><li>\u2022 34 new drugs added</li><li>\u2022 Criteria followed for inclusion in NLEM : be useful in diseases which is a public health problem in India be licensed /approved Drugs Controller General (India) (DCGI) have proven efficacy and safety profile based on scientific evidence be comparatively cost effective be aligned with the current treatment guidelines recommended under National Health Programs of India . (e.g. Ivermectin part of Accelerated Plan for Elimination of Lymphatic Filariasis 2018). when more than one medicine are available from the same therapeutic class , one prototype /medically best suited medicine of that class to be included. price of total treatment is considered and not the unit price of a medicine fixed dose combinations are usually not included vaccines as and when are included in Universal Immunization Program (e.g. Rotavirus vaccine).</li><li>\u2022 Criteria followed for inclusion in NLEM</li><li>\u2022 be useful in diseases which is a public health problem in India be licensed /approved Drugs Controller General (India) (DCGI) have proven efficacy and safety profile based on scientific evidence be comparatively cost effective be aligned with the current treatment guidelines recommended under National Health Programs of India . (e.g. Ivermectin part of Accelerated Plan for Elimination of Lymphatic Filariasis 2018). when more than one medicine are available from the same therapeutic class , one prototype /medically best suited medicine of that class to be included. price of total treatment is considered and not the unit price of a medicine fixed dose combinations are usually not included vaccines as and when are included in Universal Immunization Program (e.g. Rotavirus vaccine).</li><li>\u2022 be useful in diseases which is a public health problem in India</li><li>\u2022 public health problem in India</li><li>\u2022 be licensed /approved Drugs Controller General (India) (DCGI)</li><li>\u2022 licensed</li><li>\u2022 have proven efficacy and safety profile based on scientific evidence</li><li>\u2022 proven efficacy</li><li>\u2022 safety profile</li><li>\u2022 be comparatively cost effective</li><li>\u2022 comparatively cost effective</li><li>\u2022 be aligned with the current treatment guidelines</li><li>\u2022 aligned</li><li>\u2022 current treatment guidelines</li><li>\u2022 recommended under National Health Programs of India . (e.g. Ivermectin part of Accelerated Plan for Elimination of Lymphatic Filariasis 2018).</li><li>\u2022 National Health Programs of India</li><li>\u2022 when more than one medicine are available from the same therapeutic class , one prototype /medically best suited medicine of that class to be included.</li><li>\u2022 more than one medicine are available</li><li>\u2022 same therapeutic class</li><li>\u2022 one prototype</li><li>\u2022 price of total treatment is considered and not the unit price of a medicine</li><li>\u2022 price of total treatment</li><li>\u2022 fixed dose combinations are usually not included</li><li>\u2022 fixed dose combinations</li><li>\u2022 vaccines as and when are included in Universal Immunization Program (e.g. Rotavirus vaccine).</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 384 Drugs included in NLEM 2022; 34 new drugs added</li><li>\u27a4 384 Drugs</li><li>\u27a4 NLEM 2022; 34 new drugs added</li><li>\u27a4 Ref : National List of Essential Medicines (NLEM), 2022</li><li>\u27a4 Ref</li><li>\u27a4 : National List of Essential Medicines (NLEM), 2022</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f9650fd6",
      "audio": ""
    },
    {
      "text": "As a medical officer in a tertiary care hospital, you are part of a committee responsible for ensuring the safety, efficacy, and quality of drugs used within the institution. You are currently reviewing protocols for adherence to national standards in drug regulation. In this context, understanding the functions and scope of the Central Drug Standard Control Organization (CDSCO) is essential. Which of the following statements is NOT true regarding the Central Drug Standard Control Organization (CDSCO)?",
      "options": [
        {
          "label": "A",
          "text": "CDSCO control the quality of drugs imported into the country",
          "correct": false
        },
        {
          "label": "B",
          "text": "States has no role in controlling drugs in state.",
          "correct": true
        },
        {
          "label": "C",
          "text": "Approval of new drugs proposed to be imported or manufactured in the country",
          "correct": false
        },
        {
          "label": "D",
          "text": "Central License Approving Authority in respect of whole human blood and its products, sera and vaccines and r-DNA products.",
          "correct": false
        }
      ],
      "correct_answer": "B. States has no role in controlling drugs in state.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. States has no role in controlling drugs in states.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 These are the main functions -</li><li>\u2022 These are the main functions -</li><li>\u2022 1. Quality control of imported drugs (Option A)</li><li>\u2022 (Option A)</li><li>\u2022 2. Coordination of activities under State Drugs Control Authorities</li><li>\u2022 3. Approval for importation/manufacture of new drugs (Option C)</li><li>\u2022 (Option C)</li><li>\u2022 4. Laying standards for and act as \u2018Central Licensing Authority for blood and blood products, iv fluids, sera, vaccines, r-DNA products\u2019 (Option D)</li><li>\u2022 (Option D)</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 QUALITY CONTROL IN DRUG SECTOR IN INDIA</li><li>\u27a4 QUALITY CONTROL IN DRUG SECTOR IN INDIA</li><li>\u27a4 Quality control of drugs in India:</li><li>\u27a4 Drugs and Cosmetics Act 1940 Drugs and Cosmetics Rules 1945</li><li>\u27a4 Drugs and Cosmetics Act 1940</li><li>\u27a4 Drugs and Cosmetics Rules 1945</li><li>\u27a4 Central Drugs Standard Control Organisation (CDSCO):</li><li>\u27a4 Central Drugs Standard Control Organisation</li><li>\u27a4 Headed by: Central level: Drugs Controller General, India (DGHS, MOHFW) State level: State Drugs Controllers Zonal offices : Mumbai, Kolkata, Ghaziabad, Chennai. Other Pointers -</li><li>\u27a4 Headed by: Central level: Drugs Controller General, India (DGHS, MOHFW) State level: State Drugs Controllers</li><li>\u27a4 State level: State Drugs Controllers</li><li>\u27a4 State level: State Drugs Controllers</li><li>\u27a4 State level: State Drugs Controllers</li><li>\u27a4 State level: State Drugs Controllers</li><li>\u27a4 Zonal offices : Mumbai, Kolkata, Ghaziabad, Chennai.</li><li>\u27a4 Zonal offices</li><li>\u27a4 Other Pointers -</li><li>\u27a4 Two new drugs named Bedaquiline and Delamanid with anti-TB effect were approved for treatment of multidrug resistant TB by The Central Drugs Standard Control Organization (CDSCO)</li><li>\u27a4 Two new drugs</li><li>\u27a4 Bedaquiline</li><li>\u27a4 Delamanid with anti-TB effect</li><li>\u27a4 multidrug resistant TB</li><li>\u27a4 Central Drugs Standard Control Organization</li><li>\u27a4 Ref : Park 26 th ed 551</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th ed 551</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "61bd5655",
      "audio": ""
    },
    {
      "text": "A 45-year-old male patient presents with a cough, weight loss, and night sweats. He was previously treated for tuberculosis (TB) but has not shown improvement with standard first-line therapy. Sputum culture and sensitivity testing reveal resistance to both isoniazid and rifampicin. How should this patient's tuberculosis resistance profile be classified?",
      "options": [
        {
          "label": "A",
          "text": "Monoresistance",
          "correct": false
        },
        {
          "label": "B",
          "text": "Polydrug resistance",
          "correct": false
        },
        {
          "label": "C",
          "text": "Multidrug resistance",
          "correct": true
        },
        {
          "label": "D",
          "text": "Extensive drug resistance",
          "correct": false
        }
      ],
      "correct_answer": "C. Multidrug resistance",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.\u00a0 C. Multidrug resistance</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Monoresistance: Resistance to one first-line anti-TB drug only.</li><li>\u2022 Option A. Monoresistance:</li><li>\u2022 one first-line anti-TB drug only.</li><li>\u2022 Option B. Polydrug Resistance: Resistance to more than one first-line anti-TB drug , other than both isoniazid and rifampicin</li><li>\u2022 Option B. Polydrug Resistance:</li><li>\u2022 more than one first-line anti-TB drug</li><li>\u2022 Option D. Extensive Drug Resistant TB (XDR\u2013TB): Resistance to rifampicin and isoniazid as well as to any member of the quinolone family and at least one of the following second-line TB treatments : kanamycin, capreomycin, or amikacin</li><li>\u2022 Option D. Extensive Drug Resistant TB (XDR\u2013TB):</li><li>\u2022 rifampicin and isoniazid</li><li>\u2022 member of the quinolone family</li><li>\u2022 second-line TB treatments</li><li>\u2022 kanamycin, capreomycin, or amikacin</li><li>\u2022 XDR\u2013TB is MDR TB with further resistance to 3 \u2013 6 classes of second line drugs (older definition) Principles of treatment for MDR-TB and for XDR-TB are same. XDR-TB does not transmit easily in healthy populations, yet is capable of causing \u2018epidemics in populations which are already stricken by HIV</li><li>\u2022 XDR\u2013TB is MDR TB with further resistance to 3 \u2013 6 classes of second line drugs (older definition)</li><li>\u2022 Principles of treatment for MDR-TB and for XDR-TB are same.</li><li>\u2022 XDR-TB does not transmit easily in healthy populations, yet is capable of causing \u2018epidemics in populations which are already stricken by HIV</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Multidrug Resistant TB (MDR-TB): Resistance to Isoniazid and Rifampicin with or without resistance to other drugs and Polydrug Resistance is resistance to more than one first-line anti-TB drug , other than both isoniazid and rifampicin</li><li>\u27a4 Multidrug Resistant TB</li><li>\u27a4 Resistance</li><li>\u27a4 Isoniazid and Rifampicin</li><li>\u27a4 resistance to other drugs and Polydrug Resistance</li><li>\u27a4 resistance</li><li>\u27a4 one first-line anti-TB drug</li><li>\u27a4 Ref : Park 26 th edition (page 208)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 208)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a1271c6a",
      "audio": ""
    },
    {
      "text": "A medical resident is reviewing a sputum smear microscopy report for a patient suspected of having pulmonary tuberculosis. The report indicates the presence of acid-fast bacilli (AFB) on Ziehl-Neelsen staining. The resident must classify the smear result according to the NTEP guidelines for reporting smear microscopy results. The presence of 1 to 10 acid-fast bacilli (AFB) per oil immersion field on a sputum smear is classified as?",
      "options": [
        {
          "label": "A",
          "text": "Scanty",
          "correct": false
        },
        {
          "label": "B",
          "text": "1+",
          "correct": false
        },
        {
          "label": "C",
          "text": "2+",
          "correct": true
        },
        {
          "label": "D",
          "text": "3+",
          "correct": false
        }
      ],
      "correct_answer": "C. 2+",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-162032.png",
        "https://upload.wikimedia.org/wikipedia/commons/thumb/7/71/Mycobacterium_tuberculosis_Ziehl-Neelsen_stain_02.jpg/1280px-Mycobacterium_tuberculosis_Ziehl-Neelsen_stain_02.jpg"
      ],
      "explanation": "<p><strong>Ans. \u00a0C. 2+</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Zeihl Neelsen (ZN) Staining (AFB Staining)</li><li>\u2022 Zeihl Neelsen</li><li>\u2022 Staining</li><li>\u2022 Sputum smear of a suspected TB patient is used for the diagnosis Acid Fast Bacilli (AFB) of TB : \u2018Rod shaped\u2019 with \u2018beaded appearance\u2019 (Beads: Mycolic Acid) >10,000 bacilli per mL sputum must be present for a positive result Results of ZN staining : Minimum 100 fields examined</li><li>\u2022 Sputum smear of a suspected TB patient is used for the diagnosis</li><li>\u2022 Sputum smear</li><li>\u2022 suspected TB patient</li><li>\u2022 diagnosis</li><li>\u2022 Acid Fast Bacilli (AFB) of TB : \u2018Rod shaped\u2019 with \u2018beaded appearance\u2019 (Beads: Mycolic Acid)</li><li>\u2022 Acid Fast Bacilli</li><li>\u2022 of TB</li><li>\u2022 \u2018Rod shaped\u2019</li><li>\u2022 \u2018beaded appearance\u2019</li><li>\u2022 >10,000 bacilli per mL sputum must be present for a positive result</li><li>\u2022 >10,000 bacilli per mL sputum</li><li>\u2022 present</li><li>\u2022 positive result</li><li>\u2022 Results of ZN staining : Minimum 100 fields examined</li><li>\u2022 Results of ZN staining</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Grading criteria under ZN staining - 1-10 bacilli per oil immersion field - 2+ grade</li><li>\u27a4 Grading criteria</li><li>\u27a4 ZN staining</li><li>\u27a4 1-10 bacilli per oil immersion field</li><li>\u27a4 2+ grade</li><li>\u27a4 ZN staining Procedure -</li><li>\u27a4 ZN staining Procedure</li><li>\u27a4 Fix smear on slide : Pass slide 3 times over flame (smear upside) Carbol Fuschin cover : Steam gently for 5 minutes over direct flame Washing : with de-ionised water Decolourisation : 25% sulphuric acid Washing : With water Counter-staining : 1 minute with Loeffler\u2019s methylene blue Washing : With de-ionised water Dry the slide</li><li>\u27a4 Fix smear on slide : Pass slide 3 times over flame (smear upside)</li><li>\u27a4 Fix smear on slide</li><li>\u27a4 Carbol Fuschin cover : Steam gently for 5 minutes over direct flame</li><li>\u27a4 Carbol Fuschin cover</li><li>\u27a4 Washing : with de-ionised water</li><li>\u27a4 Washing</li><li>\u27a4 Decolourisation : 25% sulphuric acid</li><li>\u27a4 Decolourisation</li><li>\u27a4 Washing : With water</li><li>\u27a4 Washing</li><li>\u27a4 Counter-staining : 1 minute with Loeffler\u2019s methylene blue</li><li>\u27a4 Counter-staining</li><li>\u27a4 Washing : With de-ionised water</li><li>\u27a4 Washing</li><li>\u27a4 Dry the slide</li><li>\u27a4 Dry the slide</li><li>\u27a4 Ref : Park 26 th edition (page 212)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 212)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6a26ef59",
      "audio": ""
    },
    {
      "text": "During a seminar on tuberculosis control, a question is posed to the medical residents about the transmission dynamics of Mycobacterium tuberculosis. It is emphasized that understanding the mechanisms of transmission is crucial for implementing effective infection control strategies. It is estimated that a single cough can generate how many droplet nuclei?",
      "options": [
        {
          "label": "A",
          "text": "1000 droplet nuclei",
          "correct": false
        },
        {
          "label": "B",
          "text": "2000 droplet nuclei",
          "correct": false
        },
        {
          "label": "C",
          "text": "3000 droplet nuclei",
          "correct": true
        },
        {
          "label": "D",
          "text": "4000 droplet nuclei",
          "correct": false
        }
      ],
      "correct_answer": "C. 3000 droplet nuclei",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. 3000 droplet nuclei</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 A cough is estimated to generate 3000 droplet nuclei .</li><li>\u2022 cough</li><li>\u2022 generate 3000 droplet nuclei</li><li>\u2022 Droplet nuclei are small respiratory droplets that may carry tubercle bacilli and can remain suspended in the air for several hours . These droplets are typically less than 5 micrometers in size , which allows them to stay airborne and potentially be inhaled by other individuals , leading to the spread of infection .</li><li>\u2022 Droplet nuclei</li><li>\u2022 small respiratory droplets</li><li>\u2022 carry tubercle bacilli</li><li>\u2022 remain suspended</li><li>\u2022 air for several hours</li><li>\u2022 droplets</li><li>\u2022 less than 5 micrometers in size</li><li>\u2022 stay airborne</li><li>\u2022 potentially be inhaled</li><li>\u2022 individuals</li><li>\u2022 spread of infection</li><li>\u2022 TB bacteria remain alive : in sputum for 1 day and in droplet nuclei for 10 days</li><li>\u2022 TB bacteria remain alive</li><li>\u2022 sputum for 1 day</li><li>\u2022 droplet nuclei for 10 days</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 TB mode of transmission - Droplet infection, droplet nuclei. Droplet nuclei is a type of Indirect transmission.</li><li>\u27a4 TB mode of transmission</li><li>\u27a4 A cough is estimated to generate 3000 droplet nuclei .</li><li>\u27a4 cough</li><li>\u27a4 generate 3000 droplet nuclei</li><li>\u27a4 Ref : Textbook of Community Medicine, Rajvir Bhalwar (4th edition) (page 773)</li><li>\u27a4 Ref</li><li>\u27a4 : Textbook of Community Medicine, Rajvir Bhalwar (4th edition) (page 773)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1a3d0b6b",
      "audio": ""
    },
    {
      "text": "A 25-year-old woman with a newly diagnosed case of pulmonary tuberculosis is starting her antitubercular therapy (ATT). As the treating physician, you begin to educate her about the different medications she will be taking as part of her regimen. You explain that some drugs are bactericidal, killing the actively dividing bacteria, while others are bacteriostatic, inhibiting the growth and replication of the bacteria. Which of the following antitubercular drugs is known to be bacteriostatic?",
      "options": [
        {
          "label": "A",
          "text": "Isoniazid",
          "correct": false
        },
        {
          "label": "B",
          "text": "Rifampicin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Pyrazinamide",
          "correct": false
        },
        {
          "label": "D",
          "text": "Ethambutol",
          "correct": true
        }
      ],
      "correct_answer": "D. Ethambutol",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-162411.png"
      ],
      "explanation": "<p><strong>Ans. D. Ethambutol</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Ethambutol</li><li>\u2022 Ethambutol is bacteriostatic and is used in combination to prevent the emergence of resistance to other drugs . It is given orally . Its major side-effect is retrobulbar neuritis ; this however does not occur at the usual dosage. Ethambutol has replaced para-amino salicylic acid (PAS) almost entirely among adults.</li><li>\u2022 bacteriostatic</li><li>\u2022 combination to prevent</li><li>\u2022 emergence of resistance to other drugs</li><li>\u2022 orally</li><li>\u2022 major side-effect is retrobulbar neuritis</li><li>\u2022 Ethambutol</li><li>\u2022 replaced para-amino salicylic acid</li><li>\u2022 Antitubercular Drugs</li><li>\u2022 Antitubercular Drugs</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Important Facts of Antitubercular Drugs -</li><li>\u27a4 Important Facts of Antitubercular Drugs</li><li>\u27a4 Most effective anti-tubercular drug: Rifampicin Most bactericidal antitubercular drug: Rifampicin Most toxic antitubercular drug: Isoniazid Antitubercular drug causing rapid sputum conversion : Rifampicin Antitubercular drug causing orange discoloration of urine : Rifampicin Antitubercular drug first to develop resistance : Isoniazid Antitubercular drug contraindicated AIDS patients on Protease Inhibitors : Rifampicin Antitubercular drug contraindicated in HIV : Thiacetazone (Exfoliative dermatitis) Antitubercular drugs contained in all phases of all categories of DOTS : Rifampicin and Isoniazid Injectable Antitubercular drug: Streptomycin Antitubercular drug contraindicated in pregnancy : Streptomycin Antitubercular drug contraindicated in children < 6 years age : Ethambutol Antitubercular drug causing Optic neuritis (Red-Green color blindness): Ethambutol Antitubercular drug causing vestibular damage: Streptomycin Only Bacteriostatic drug in Primary ATT Drugs - Ethambutol</li><li>\u27a4 Most effective anti-tubercular drug: Rifampicin</li><li>\u27a4 Most effective</li><li>\u27a4 Rifampicin</li><li>\u27a4 Most bactericidal antitubercular drug: Rifampicin</li><li>\u27a4 Most bactericidal</li><li>\u27a4 Rifampicin</li><li>\u27a4 Most toxic antitubercular drug: Isoniazid</li><li>\u27a4 Most toxic</li><li>\u27a4 Isoniazid</li><li>\u27a4 Antitubercular drug causing rapid sputum conversion : Rifampicin</li><li>\u27a4 rapid sputum conversion</li><li>\u27a4 Rifampicin</li><li>\u27a4 Antitubercular drug causing orange discoloration of urine : Rifampicin</li><li>\u27a4 orange discoloration of urine</li><li>\u27a4 Rifampicin</li><li>\u27a4 Antitubercular drug first to develop resistance : Isoniazid</li><li>\u27a4 develop resistance</li><li>\u27a4 Isoniazid</li><li>\u27a4 Antitubercular drug contraindicated AIDS patients on Protease Inhibitors : Rifampicin</li><li>\u27a4 contraindicated AIDS</li><li>\u27a4 Protease Inhibitors</li><li>\u27a4 Rifampicin</li><li>\u27a4 Antitubercular drug contraindicated in HIV : Thiacetazone (Exfoliative dermatitis)</li><li>\u27a4 contraindicated in HIV</li><li>\u27a4 Thiacetazone</li><li>\u27a4 Antitubercular drugs contained in all phases of all categories of DOTS : Rifampicin and Isoniazid</li><li>\u27a4 contained in all phases</li><li>\u27a4 all categories of DOTS</li><li>\u27a4 Rifampicin</li><li>\u27a4 Isoniazid</li><li>\u27a4 Injectable Antitubercular drug: Streptomycin Antitubercular drug contraindicated in pregnancy : Streptomycin</li><li>\u27a4 Injectable</li><li>\u27a4 Streptomycin</li><li>\u27a4 contraindicated in pregnancy</li><li>\u27a4 Streptomycin</li><li>\u27a4 Antitubercular drug contraindicated in children < 6 years age : Ethambutol</li><li>\u27a4 contraindicated in children < 6 years age</li><li>\u27a4 Ethambutol</li><li>\u27a4 Antitubercular drug causing Optic neuritis (Red-Green color blindness): Ethambutol</li><li>\u27a4 Optic neuritis</li><li>\u27a4 Ethambutol</li><li>\u27a4 Antitubercular drug causing vestibular damage: Streptomycin</li><li>\u27a4 Only Bacteriostatic drug in Primary ATT Drugs - Ethambutol</li><li>\u27a4 Ref : Park 26 th edition (page 215)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 215)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "74ea0b65",
      "audio": ""
    },
    {
      "text": "A medical resident is conducting a seminar on tuberculosis (TB) screening methods. One topic of discussion is the use of the tuberculin skin test (TST), which is commonly used in the identification of TB infection. The resident is aware that while the TST is a valuable tool in TB control, it has certain characteristics and limitations that must be understood for proper interpretation and application. Which of the following statements is NOT true regarding the tuberculin skin test (TST)?",
      "options": [
        {
          "label": "A",
          "text": "Carried out by injecting 1 TU of PPD in 0.1 ml intradermally on the flexor surface of the left forearm",
          "correct": false
        },
        {
          "label": "B",
          "text": "Result of the test is read after 48-96 hours but 72 hours (3rd day) is the ideal.",
          "correct": false
        },
        {
          "label": "C",
          "text": "For HIV positive persons 2 mm induration is significant",
          "correct": true
        },
        {
          "label": "D",
          "text": "For persons with no risk factors for tuberculosis 15 mm is significant",
          "correct": false
        }
      ],
      "correct_answer": "C. For HIV positive persons 2 mm induration is significant",
      "question_images": [],
      "explanation_images": [
        "https://i.pinimg.com/474x/cd/b4/a4/cdb4a48dd959cbea9ac399486b7b48a1.jpg"
      ],
      "explanation": "<p><strong>Ans. C. For HIV positive persons 2 mm induration is significant</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Correct: The TST is indeed administered by injecting 1 TU (Tuberculin Unit) of purified protein derivative (PPD) intradermally on the forearm. This is the standard method of administration .</li><li>\u2022 Option A. Correct:</li><li>\u2022 TST</li><li>\u2022 indeed administered by injecting 1 TU</li><li>\u2022 purified protein derivative</li><li>\u2022 intradermally</li><li>\u2022 .</li><li>\u2022 Option B. Correct: The results of the TST are typically read between 48-96 hours after administration , with 72 hours being the ideal time frame for reading the result.</li><li>\u2022 Option B. Correct:</li><li>\u2022 TST</li><li>\u2022 read between 48-96 hours</li><li>\u2022 after administration</li><li>\u2022 Option D. Correct: In individuals with no known risk factors for tuberculosis , a larger induration (\u226515 mm) is necessary to be considered significant. This is because the likelihood of TB exposure or latent infection is lower in this group.</li><li>\u2022 Option D. Correct:</li><li>\u2022 individuals</li><li>\u2022 no known risk factors for tuberculosis</li><li>\u2022 larger induration</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Tuberculin Test and Mantoux Test (Pirquet test or PPD Test) are the tool for detecting TB infection</li><li>\u27a4 Tuberculin Test</li><li>\u27a4 Mantoux Test</li><li>\u27a4 detecting TB infection</li><li>\u27a4 Tuberculin/PPD</li><li>\u27a4 Tuberculin/PPD</li><li>\u27a4 Tuberculin : Purified protein derivative (PPD) has replaced the antigen old tuberculin (OT). Tuberculins have also been prepared from atypical mycobacterium: PPD-Y (M. Kansasii), PPD-B (Battey mycobacterium), Scrofula (M. scrofulaceum) Discovered by Von Pirquet (1907) Standard PPD (PPD-S) contains - 50,000 tuberculin units (TU) per mg [1TU= 0.00002 mg PPD] WHO advocates \u2019PPD-RT-23 with Tween-80\u2019 Dosage : First strength (1TU), Intermediate strength (5TU), Second strength (250TU) Tuberculin test conversion is defined as an increase of 10 mm or more within a 2-year period , regardless of age Tuberculin test in use : Mantoux intradermal test: More precise test of tuberculin sensitivity Heaf test: Quick, easy, reliable and cheap, preferred for testing large groups Tine multiple puncture test unreliable, not recommended Tuberculin test is the \u2018only way of estimating the prevalence of infection in a population\u2019 Tuberculin test has lost its sensitivity as an indicator of the true prevalence of infection, in countries with high coverage of BCG \u2013 True prevalence rates are exaggerated by infection with atypical mycobacteria and boosting effect of a second dose of tuberculin</li><li>\u27a4 Tuberculin : Purified protein derivative (PPD) has replaced the antigen old tuberculin (OT). Tuberculins have also been prepared from atypical mycobacterium: PPD-Y (M. Kansasii), PPD-B (Battey mycobacterium), Scrofula (M. scrofulaceum)</li><li>\u27a4 Tuberculin</li><li>\u27a4 Purified protein derivative</li><li>\u27a4 replaced</li><li>\u27a4 antigen old tuberculin</li><li>\u27a4 Discovered by Von Pirquet (1907) Standard PPD (PPD-S) contains - 50,000 tuberculin units (TU) per mg [1TU= 0.00002 mg PPD] WHO advocates \u2019PPD-RT-23 with Tween-80\u2019</li><li>\u27a4 Von Pirquet</li><li>\u27a4 Standard PPD (PPD-S) contains - 50,000 tuberculin units (TU) per mg [1TU= 0.00002 mg PPD] WHO advocates \u2019PPD-RT-23 with Tween-80\u2019</li><li>\u27a4 Standard PPD (PPD-S) contains - 50,000 tuberculin units (TU) per mg [1TU= 0.00002 mg PPD]</li><li>\u27a4 Standard PPD</li><li>\u27a4 contains</li><li>\u27a4 WHO advocates \u2019PPD-RT-23 with Tween-80\u2019</li><li>\u27a4 \u2019PPD-RT-23 with Tween-80\u2019</li><li>\u27a4 Dosage : First strength (1TU), Intermediate strength (5TU), Second strength (250TU)</li><li>\u27a4 Dosage</li><li>\u27a4 Tuberculin test conversion is defined as an increase of 10 mm or more within a 2-year period , regardless of age</li><li>\u27a4 Tuberculin test conversion</li><li>\u27a4 increase of 10 mm</li><li>\u27a4 more within a 2-year period</li><li>\u27a4 Tuberculin test in use : Mantoux intradermal test: More precise test of tuberculin sensitivity Heaf test: Quick, easy, reliable and cheap, preferred for testing large groups Tine multiple puncture test unreliable, not recommended</li><li>\u27a4 Tuberculin test in use</li><li>\u27a4 Mantoux intradermal test: More precise test of tuberculin sensitivity Heaf test: Quick, easy, reliable and cheap, preferred for testing large groups Tine multiple puncture test unreliable, not recommended</li><li>\u27a4 Mantoux intradermal test: More precise test of tuberculin sensitivity</li><li>\u27a4 Heaf test: Quick, easy, reliable and cheap, preferred for testing large groups</li><li>\u27a4 Tine multiple puncture test unreliable, not recommended</li><li>\u27a4 Tuberculin test is the \u2018only way of estimating the prevalence of infection in a population\u2019</li><li>\u27a4 Tuberculin test</li><li>\u27a4 \u2018only way of estimating</li><li>\u27a4 prevalence of infection</li><li>\u27a4 population\u2019</li><li>\u27a4 Tuberculin test has lost its sensitivity as an indicator of the true prevalence of infection, in countries with high coverage of BCG \u2013 True prevalence rates are exaggerated by infection with atypical mycobacteria and boosting effect of a second dose of tuberculin</li><li>\u27a4 Mantoux Test (Tool for detection of TB infection) (Pirquet Test)</li><li>\u27a4 Mantoux Test</li><li>\u27a4 Tuberculin test conversion : Increase of > 10 mm within 2 years period Dose : 1 TU of PPD in 0.1ml injected intradermally on forearm WHO advocated preparation: PPD\u2013RT\u201323 with Tween\u201380 Is a test of prognostic significance Has limited validity due to lack of specificity Readings: Result read after 72 hrs (3d) Only induration is measured: Induration >9 mm: Positive (Past OR current infection with TB) Induration 6-9 mm: Doubtful (M. tuberculosis or Atypical mycobacteria) Induration <6 mm: Negative</li><li>\u27a4 Tuberculin test conversion : Increase of > 10 mm within 2 years period</li><li>\u27a4 Tuberculin test conversion</li><li>\u27a4 Dose : 1 TU of PPD in 0.1ml injected intradermally on forearm</li><li>\u27a4 Dose</li><li>\u27a4 WHO advocated preparation: PPD\u2013RT\u201323 with Tween\u201380</li><li>\u27a4 Is a test of prognostic significance</li><li>\u27a4 Has limited validity due to lack of specificity</li><li>\u27a4 Readings: Result read after 72 hrs (3d)</li><li>\u27a4 Only induration is measured: Induration >9 mm: Positive (Past OR current infection with TB) Induration 6-9 mm: Doubtful (M. tuberculosis or Atypical mycobacteria) Induration <6 mm: Negative</li><li>\u27a4 Induration >9 mm: Positive (Past OR current infection with TB) Induration 6-9 mm: Doubtful (M. tuberculosis or Atypical mycobacteria) Induration <6 mm: Negative</li><li>\u27a4 Induration >9 mm: Positive (Past OR current infection with TB)</li><li>\u27a4 Induration 6-9 mm: Doubtful (M. tuberculosis or Atypical mycobacteria)</li><li>\u27a4 Induration <6 mm: Negative</li><li>\u27a4 Results of tuberculin test must be interpreted carefully : The person\u2019s medical risk factors determine at which increment (5 mm, 10 mm, or 15 mm) of induration the result is considered positive 5 mm or more is positive in :</li><li>\u27a4 Results of tuberculin test must be interpreted carefully : The person\u2019s medical risk factors determine at which increment (5 mm, 10 mm, or 15 mm) of induration the result is considered positive</li><li>\u27a4 Results of tuberculin test must be interpreted carefully</li><li>\u27a4 5 mm or more is positive in :</li><li>\u27a4 5 mm or more is positive in</li><li>\u27a4 HIV-positive person Recent contacts of TB case Persons with nodular or fibrotic changes on chest X-ray consistent with old healed TB Patients with organ transplants Other immunosuppressed patients 10 mm or more is positive in: Recent arrivals (less than 5 years) from high-prevalence countries Injection drug users Residents and employees of high-risk congregate settings (e.g., prisons, nursing homes,hospitals, homeless shelters, etc.) Mycobacteriology lab personnel Persons with clinical conditions that place them at high risk (diabetes, prolonged corticosteroid therapy, leukemia, end-stage renal disease, chronic malabsorption syndromes,low body weight) Children less than 4 years of age, or children and adolescents exposed to adults in high-risk categories 15 mm or more is positive in: Persons with no known risk factors for TB</li><li>\u27a4 HIV-positive person</li><li>\u27a4 Recent contacts of TB case</li><li>\u27a4 Persons with nodular or fibrotic changes on chest X-ray consistent with old healed TB</li><li>\u27a4 Patients with organ transplants</li><li>\u27a4 Other immunosuppressed patients</li><li>\u27a4 10 mm or more is positive in: Recent arrivals (less than 5 years) from high-prevalence countries Injection drug users Residents and employees of high-risk congregate settings (e.g., prisons, nursing homes,hospitals, homeless shelters, etc.) Mycobacteriology lab personnel Persons with clinical conditions that place them at high risk (diabetes, prolonged corticosteroid therapy, leukemia, end-stage renal disease, chronic malabsorption syndromes,low body weight) Children less than 4 years of age, or children and adolescents exposed to adults in high-risk categories</li><li>\u27a4 10 mm or more is positive in:</li><li>\u27a4 Recent arrivals (less than 5 years) from high-prevalence countries Injection drug users Residents and employees of high-risk congregate settings (e.g., prisons, nursing homes,hospitals, homeless shelters, etc.) Mycobacteriology lab personnel Persons with clinical conditions that place them at high risk (diabetes, prolonged corticosteroid therapy, leukemia, end-stage renal disease, chronic malabsorption syndromes,low body weight) Children less than 4 years of age, or children and adolescents exposed to adults in high-risk categories</li><li>\u27a4 Recent arrivals (less than 5 years) from high-prevalence countries</li><li>\u27a4 Injection drug users</li><li>\u27a4 Residents and employees of high-risk congregate settings (e.g., prisons, nursing homes,hospitals, homeless shelters, etc.)</li><li>\u27a4 Mycobacteriology lab personnel</li><li>\u27a4 Persons with clinical conditions that place them at high risk (diabetes, prolonged corticosteroid therapy, leukemia, end-stage renal disease, chronic malabsorption syndromes,low body weight)</li><li>\u27a4 Children less than 4 years of age, or children and adolescents exposed to adults in high-risk categories</li><li>\u27a4 15 mm or more is positive in: Persons with no known risk factors for TB</li><li>\u27a4 15 mm or more is positive in:</li><li>\u27a4 no known risk factors for TB</li><li>\u27a4 Ref : Park 26 th edition (page 213)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 213)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "26debb78",
      "audio": ""
    },
    {
      "text": "A pulmonologist is reviewing the eligibility criteria for the addition of Bedaquiline to the treatment regimen of patients with tuberculosis. Bedaquiline, a newer medication, is used in specific scenarios and patient populations based on the national guidelines to improve treatment outcomes while considering the risk of side effects. Which of the following patients with tuberculosis is NOT typically eligible for Bedaquiline therapy according to standard tuberculosis management guidelines?",
      "options": [
        {
          "label": "A",
          "text": "MDR TB with resistance to fluoroquinolones",
          "correct": false
        },
        {
          "label": "B",
          "text": "XDR TB",
          "correct": false
        },
        {
          "label": "C",
          "text": "Mixed pattern resistant TB",
          "correct": false
        },
        {
          "label": "D",
          "text": "Treatment failure of drug sensitive TB",
          "correct": true
        }
      ],
      "correct_answer": "D. Treatment failure of drug sensitive TB",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. \u00a0D. Treatment failure of drug sensitive TB</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The following group of patients are eligible for BDQ therapy :</li><li>\u2022 patients are eligible for BDQ therapy</li><li>\u2022 MDR/RR TB with resistance to any/all fluoroquinolones (FQ) or to any/all second-line injectable agents (SLI) (Option A) XDR-TB (Option B) Mixed pattern resistant TB (XDR-TB + additional first line I second line resistant TB) (Option C) Treatment failure of MDR-TB + FQ/SLI resistance or XDR-TB</li><li>\u2022 MDR/RR TB with resistance to any/all fluoroquinolones (FQ) or to any/all second-line injectable agents (SLI) (Option A)</li><li>\u2022 (Option A)</li><li>\u2022 XDR-TB (Option B)</li><li>\u2022 (Option B)</li><li>\u2022 Mixed pattern resistant TB (XDR-TB + additional first line I second line resistant TB) (Option C)</li><li>\u2022 (Option C)</li><li>\u2022 Treatment failure of MDR-TB + FQ/SLI resistance or XDR-TB</li><li>\u2022 New Anti-Tubercular Drugs</li><li>\u2022 New Anti-Tubercular Drugs</li><li>\u2022 Two new drugs named Bedaquiline and Delamanid with anti-TB effect were approved for treatment of multidrug resistant TB by The Central Drugs Standard Control Organization (CDSCO)</li><li>\u2022 Two</li><li>\u2022 Bedaquiline</li><li>\u2022 Delamanid</li><li>\u2022 anti-TB effect</li><li>\u2022 treatment of multidrug resistant TB</li><li>\u2022 Central Drugs Standard Control Organization</li><li>\u2022 Bedaquiline</li><li>\u2022 Bedaquiline</li><li>\u2022 Introduction: Diarylquinoline drug which targets Mycobacterial ATP synthase Extended half-life: Present even 5.5 months after stoppage Significant use in culture-conversion time for MDR-TB Patient selection criteria: Age 18 years or more with MDR-TB Contraindications: Pregnancy, Cardiac arrhythmia Dosage Week 0\u20132 - BDQ 400 mg daily + OBR (Optimized background regimen) Week 3\u201324 - BDQ 200 mg thrice a week + OBR (Optimized background regimen) Week 25 - End Continue other 2nd line drugs as per RNTCP</li><li>\u2022 Introduction: Diarylquinoline drug which targets Mycobacterial ATP synthase</li><li>\u2022 Diarylquinoline drug</li><li>\u2022 Mycobacterial ATP synthase</li><li>\u2022 Extended half-life: Present even 5.5 months after stoppage</li><li>\u2022 Significant use in culture-conversion time for MDR-TB</li><li>\u2022 Patient selection criteria: Age 18 years or more with MDR-TB</li><li>\u2022 Contraindications: Pregnancy, Cardiac arrhythmia</li><li>\u2022 Dosage Week 0\u20132 - BDQ 400 mg daily + OBR (Optimized background regimen) Week 3\u201324 - BDQ 200 mg thrice a week + OBR (Optimized background regimen) Week 25 - End Continue other 2nd line drugs as per RNTCP</li><li>\u2022 Week 0\u20132 - BDQ 400 mg daily + OBR (Optimized background regimen) Week 3\u201324 - BDQ 200 mg thrice a week + OBR (Optimized background regimen) Week 25 - End Continue other 2nd line drugs as per RNTCP</li><li>\u2022 Week 0\u20132 - BDQ 400 mg daily + OBR (Optimized background regimen)</li><li>\u2022 Week 3\u201324 - BDQ 200 mg thrice a week + OBR (Optimized background regimen)</li><li>\u2022 Week 25 - End Continue other 2nd line drugs as per RNTCP</li><li>\u2022 Delamanid</li><li>\u2022 Delamanid</li><li>\u2022 DCG India allow 50 mg usage as Combination regimen for Pulmonary MDT-TB.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Bedaquiline and Delamanid with anti-TB effect were approved for treatment of multidrug resistant TB by The Central Drugs Standard Control Organization (CDSCO).</li><li>\u27a4 Bedaquiline</li><li>\u27a4 Delamanid</li><li>\u27a4 anti-TB effect</li><li>\u27a4 treatment of multidrug resistant TB</li><li>\u27a4 Central Drugs Standard Control Organization</li><li>\u27a4 Bedaquiline is reserved for use in cases of MDR-TB and XDR-TB , where first-line treatments are either not effective or not tolerated.</li><li>\u27a4 Bedaquiline</li><li>\u27a4 MDR-TB and XDR-TB</li><li>\u27a4 Ref : Park 26 th edition (page 215)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 215)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b784e851",
      "audio": ""
    },
    {
      "text": "In the outpatient clinic, a resident physician is tasked with prescribing anti-tuberculosis therapy for an adult patient diagnosed with pulmonary tuberculosis. The patient\u2019s weight is 60 kg, and as per the latest protocols, Fixed-Dose Combinations (FDCs) are to be used to simplify the regimen and improve adherence. How many tablets of the Fixed-Dose Combination (FDC) regimen should be given to a patient weighing between 50 to 64 kg according to the National Tuberculosis Elimination Programme (NTEP)?",
      "options": [
        {
          "label": "A",
          "text": "3",
          "correct": false
        },
        {
          "label": "B",
          "text": "4",
          "correct": true
        },
        {
          "label": "C",
          "text": "5",
          "correct": false
        },
        {
          "label": "D",
          "text": "6",
          "correct": false
        }
      ],
      "correct_answer": "B. 4",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/26/screenshot-2024-08-26-114650.png",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/26/screenshot-2024-08-26-114710.png"
      ],
      "explanation": "<p><strong>Ans. B. 4</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Treatment Protocol : NEW Guidelines</li><li>\u2022 Treatment Protocol</li><li>\u2022 NEW Guidelines</li><li>\u2022 Patients are given fixed drug combinations (FDCs), on a Daily basis (1 November 2017 onwards PAN-India) Reduced pill burden: 3\u20134 drugs in a single pill (as against 7 tablets earlier) Lesser relapses Reduction in drug-resistance Greater compliance Paediatric patients are given easily-dissolvable and flavored drugs (instead of bitter tablets earlier) Weight bands : Patients get appropriate dosages as per body weight TB-HIV Coinfection : \u2018Intensified TB case finding and appropriate treatment\u2019 through single window delivery of services from all ART centres INH preventive therapy for prevention of TB among PLHIV Implementation of Pharmacovigilance by establishing adverse drug reaction monitoring centres at ART centres Patients not registered under DOTS are provided Intermittent (alternate day OR Thrice weekly) regimen.</li><li>\u2022 Patients are given fixed drug combinations (FDCs), on a Daily basis (1 November 2017 onwards PAN-India) Reduced pill burden: 3\u20134 drugs in a single pill (as against 7 tablets earlier) Lesser relapses Reduction in drug-resistance Greater compliance</li><li>\u2022 fixed drug combinations</li><li>\u2022 Daily basis</li><li>\u2022 Reduced pill burden: 3\u20134 drugs in a single pill (as against 7 tablets earlier) Lesser relapses Reduction in drug-resistance Greater compliance</li><li>\u2022 Reduced pill burden: 3\u20134 drugs in a single pill (as against 7 tablets earlier)</li><li>\u2022 Lesser relapses</li><li>\u2022 Reduction in drug-resistance</li><li>\u2022 Greater compliance</li><li>\u2022 Paediatric patients are given easily-dissolvable and flavored drugs (instead of bitter tablets earlier)</li><li>\u2022 Paediatric patients</li><li>\u2022 easily-dissolvable</li><li>\u2022 flavored drugs</li><li>\u2022 Weight bands : Patients get appropriate dosages as per body weight</li><li>\u2022 Weight bands</li><li>\u2022 TB-HIV Coinfection : \u2018Intensified TB case finding and appropriate treatment\u2019 through single window delivery of services from all ART centres INH preventive therapy for prevention of TB among PLHIV Implementation of Pharmacovigilance by establishing adverse drug reaction monitoring centres at ART centres Patients not registered under DOTS are provided Intermittent (alternate day OR Thrice weekly) regimen.</li><li>\u2022 TB-HIV Coinfection</li><li>\u2022 \u2018Intensified TB case finding and appropriate treatment\u2019 through single window delivery of services from all ART centres INH preventive therapy for prevention of TB among PLHIV Implementation of Pharmacovigilance by establishing adverse drug reaction monitoring centres at ART centres Patients not registered under DOTS are provided Intermittent (alternate day OR Thrice weekly) regimen.</li><li>\u2022 \u2018Intensified TB case finding and appropriate treatment\u2019 through single window delivery of services from all ART centres</li><li>\u2022 INH preventive therapy for prevention of TB among PLHIV</li><li>\u2022 Implementation of Pharmacovigilance by establishing adverse drug reaction monitoring centres at ART centres</li><li>\u2022 Patients not registered under DOTS are provided Intermittent (alternate day OR Thrice weekly) regimen.</li><li>\u2022 Patients not registered under DOTS</li><li>\u2022 provided Intermittent</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Treatment of TB under NTEP</li><li>\u27a4 Treatment of TB</li><li>\u27a4 NTEP</li><li>\u27a4 Treatment Regimen for Drug-Sensitive TB (DSTB) New and previously treated cases : 2 HRZE (IP 56 doses) + 4HRE (CP 112 doses) Fixed Dose Combinations (FDCs): Products containing two or more active ingredients in fixed doses, used for a particular indication(s) Adults: 4-FDC (IP \u2013 HRZE) and 3-FDC (CP \u2013 HRE) Paediatric patients: Dispersible 3-FDC (HRZ) and Dispersible 2-FDC (HR)</li><li>\u27a4 Treatment Regimen for Drug-Sensitive TB (DSTB) New and previously treated cases : 2 HRZE (IP 56 doses) + 4HRE (CP 112 doses)</li><li>\u27a4 Treatment Regimen</li><li>\u27a4 Drug-Sensitive TB</li><li>\u27a4 New</li><li>\u27a4 previously treated cases</li><li>\u27a4 2 HRZE</li><li>\u27a4 4HRE</li><li>\u27a4 Fixed Dose Combinations (FDCs): Products containing two or more active ingredients in fixed doses, used for a particular indication(s) Adults: 4-FDC (IP \u2013 HRZE) and 3-FDC (CP \u2013 HRE) Paediatric patients: Dispersible 3-FDC (HRZ) and Dispersible 2-FDC (HR)</li><li>\u27a4 Adults: 4-FDC (IP \u2013 HRZE) and 3-FDC (CP \u2013 HRE) Paediatric patients: Dispersible 3-FDC (HRZ) and Dispersible 2-FDC (HR)</li><li>\u27a4 Adults: 4-FDC (IP \u2013 HRZE) and 3-FDC (CP \u2013 HRE)</li><li>\u27a4 Paediatric patients: Dispersible 3-FDC (HRZ) and Dispersible 2-FDC (HR)</li><li>\u27a4 1. Weight Bands Based Treatment</li><li>\u27a4 Weight bands Adults - FIVE</li><li>\u27a4 Weight bands Adults - FIVE</li><li>\u27a4 Weight bands Paediatrics - SIX</li><li>\u27a4 Weight bands Paediatrics - SIX</li><li>\u27a4 2. Long term Follow-up -  After completion of treatment, the patients should be followed up clinically at the end of 6, 12,18 & 24 months.</li></ul>\n<p><strong>References:</strong></p><ul><li>\u21b3 Reference: Park 26 th edition (page 218)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8264e876",
      "audio": ""
    },
    {
      "text": "During a departmental meeting at a local health clinic, a discussion is held regarding the digitization of health records for better monitoring and follow-up of patients with tuberculosis (TB). A new medical officer who recently joined the clinic is learning about the various protocols and systems in place as per the National Tuberculosis Elimination Programme (NTEP). Which portal is utilized for the entry and management of treatment details of patients with tuberculosis, as mandated by the National Tuberculosis Elimination Programme?",
      "options": [
        {
          "label": "A",
          "text": "Nikshay",
          "correct": true
        },
        {
          "label": "B",
          "text": "Nitchay",
          "correct": false
        },
        {
          "label": "C",
          "text": "End TB portal",
          "correct": false
        },
        {
          "label": "D",
          "text": "TB mukt bharat",
          "correct": false
        }
      ],
      "correct_answer": "A. Nikshay",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/09/image-20231109192341-1.png"
      ],
      "explanation": "<p><strong>Ans. A. Nikshay</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 NIKSHAY: ICT-based Surveillance Support</li><li>\u2022 NIKSHAY: ICT-based Surveillance Support</li><li>\u2022 ICT enabled state-of-art surveillance system (Online monitoring software) to get notification of TB cases at diagnosis from both public and private sector including drug-resistant TB patients Continuous monitoring and treatment adherence for all TB patients registered Enable tracking of all notified TB patients across TB care cycle, geographies, transfers and referrals .</li><li>\u2022 ICT enabled state-of-art surveillance system (Online monitoring software) to get notification of TB cases at diagnosis from both public and private sector including drug-resistant TB patients</li><li>\u2022 ICT enabled state-of-art surveillance system</li><li>\u2022 notification of TB cases</li><li>\u2022 both public</li><li>\u2022 private sector</li><li>\u2022 drug-resistant TB patients</li><li>\u2022 Continuous monitoring and treatment adherence for all TB patients registered</li><li>\u2022 Continuous monitoring</li><li>\u2022 treatment adherence</li><li>\u2022 TB patients registered</li><li>\u2022 Enable tracking of all notified TB patients across TB care cycle, geographies, transfers and referrals .</li><li>\u2022 Enable tracking of all notified TB patients</li><li>\u2022 TB care cycle, geographies, transfers</li><li>\u2022 referrals</li><li>\u2022 NIKSHAY FLOW</li><li>\u2022 Nikshay Entry: Once the treatment regimen is finalized, all patients will be initiated on treatment after opening of the treatment card and entries are done in Nikshay Patient flow in Nikshay: Nikshay 1 : Initiating the patient on appropriate treatment regimen Nikshay 2: Transfer / referral flow after initiation of treatment Nikshay 3: Nikshay Aushadhi</li><li>\u2022 Nikshay Entry: Once the treatment regimen is finalized, all patients will be initiated on treatment after opening of the treatment card and entries are done in Nikshay</li><li>\u2022 Patient flow in Nikshay: Nikshay 1 : Initiating the patient on appropriate treatment regimen Nikshay 2: Transfer / referral flow after initiation of treatment Nikshay 3: Nikshay Aushadhi</li><li>\u2022 Nikshay 1 : Initiating the patient on appropriate treatment regimen Nikshay 2: Transfer / referral flow after initiation of treatment Nikshay 3: Nikshay Aushadhi</li><li>\u2022 Nikshay 1 : Initiating the patient on appropriate treatment regimen</li><li>\u2022 Nikshay 1</li><li>\u2022 Nikshay 2: Transfer / referral flow after initiation of treatment</li><li>\u2022 Nikshay 2:</li><li>\u2022 Nikshay 3: Nikshay Aushadhi</li><li>\u2022 Nikshay 3:</li><li>\u2022 NIKSHAY MITRA INITIATIVE (NMI)</li><li>\u2022 NIKSHAY MITRA INITIATIVE</li><li>\u2022 NMI is a part of Pradhan Mantri TB Mukt Bharat Abhiyaan launched by The President of India on September 9, 2022 Nikshay Mitra is a government project that enables people to adopt tuberculosis patients and take care of their nutritional and medical requirement, with an aim to combat stigma associated with the disease Nikshay Mitra has a number of choices for help, including dietary, diagnostic, occupational , and supplementary nutritional supplements . In addition, they can select a support period of one to three years. They can select the state, district, building, and medical facilities. The district TB officer will make it easier to become Nikshay Mitra. Objectives of the Initiative : Provide additional patient support to improve treatment outcomes of TB patients Augment community involvement in meeting India\u2019s commitment to end TB by 2025 Leverage Corporate Social Responsibility (CSR) activities Additional assistance that may be provided by the Nikshay Mitra to on-treatment TB patients : Nutritional support, Additional investigations for the diagnosed TB patients, Vocational support, Additional nutritional supplements</li><li>\u2022 NMI is a part of Pradhan Mantri TB Mukt Bharat Abhiyaan launched by The President of India on September 9, 2022</li><li>\u2022 NMI</li><li>\u2022 Pradhan Mantri TB Mukt Bharat Abhiyaan</li><li>\u2022 President of India</li><li>\u2022 Nikshay Mitra is a government project that enables people to adopt tuberculosis patients and take care of their nutritional and medical requirement, with an aim to combat stigma associated with the disease</li><li>\u2022 Nikshay Mitra</li><li>\u2022 government project</li><li>\u2022 adopt tuberculosis patients</li><li>\u2022 Nikshay Mitra has a number of choices for help, including dietary, diagnostic, occupational , and supplementary nutritional supplements . In addition, they can select a support period of one to three years. They can select the state, district, building, and medical facilities. The district TB officer will make it easier to become Nikshay Mitra.</li><li>\u2022 Nikshay Mitra</li><li>\u2022 number of choices</li><li>\u2022 dietary, diagnostic, occupational</li><li>\u2022 supplementary nutritional supplements</li><li>\u2022 Objectives of the Initiative : Provide additional patient support to improve treatment outcomes of TB patients Augment community involvement in meeting India\u2019s commitment to end TB by 2025 Leverage Corporate Social Responsibility (CSR) activities</li><li>\u2022 Objectives of the Initiative</li><li>\u2022 Provide additional patient support to improve treatment outcomes of TB patients Augment community involvement in meeting India\u2019s commitment to end TB by 2025 Leverage Corporate Social Responsibility (CSR) activities</li><li>\u2022 Provide additional patient support to improve treatment outcomes of TB patients</li><li>\u2022 Augment community involvement in meeting India\u2019s commitment to end TB by 2025</li><li>\u2022 Leverage Corporate Social Responsibility (CSR) activities</li><li>\u2022 Additional assistance that may be provided by the Nikshay Mitra to on-treatment TB patients : Nutritional support, Additional investigations for the diagnosed TB patients, Vocational support, Additional nutritional supplements</li><li>\u2022 Additional assistance</li><li>\u2022 Nikshay Mitra to on-treatment TB patients</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Some important Pointers about NTEP -</li><li>\u27a4 Nikshay Poshan Yojana:</li><li>\u27a4 Nikshay Poshan Yojana:</li><li>\u27a4 Financial incentive of Rs 500/- per month for each notified TB patient for duration for which the patient is on anti-TB treatment All TB patients notified on or after 1st April 2018 including all existing TB patients under treatment are eligible to receive incentive All TB patients who have been diagnosed and registered under NTEP will be referred for screening for Diabetes Two new drugs named Bedaquiline and Delamanid with anti-TB effect were approved for treatment of multidrug resistant TB by The Central Drugs Standard Control Organization (CDSCO)</li><li>\u27a4 Financial incentive of Rs 500/- per month for each notified TB patient for duration for which the patient is on anti-TB treatment</li><li>\u27a4 Financial incentive of Rs 500/- per month</li><li>\u27a4 All TB patients notified on or after 1st April 2018 including all existing TB patients under treatment are eligible to receive incentive</li><li>\u27a4 TB patients notified on or after 1st April 2018</li><li>\u27a4 All TB patients who have been diagnosed and registered under NTEP will be referred for screening for Diabetes</li><li>\u27a4 Two new drugs named Bedaquiline and Delamanid with anti-TB effect were approved for treatment of multidrug resistant TB by The Central Drugs Standard Control Organization (CDSCO)</li><li>\u27a4 Ref : Park 26 th edition (page 218)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 218)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bcdee059",
      "audio": ""
    },
    {
      "text": "A 5-year-old boy presents to a rural health clinic with a persistent cough, fever, and weight loss. His history reveals contact with an uncle who was recently diagnosed with pulmonary tuberculosis. The child is too young to produce a reliable sputum sample for direct acid-fast bacilli (AFB) testing, and the healthcare team must consider alternative diagnostic methods as per the National Tuberculosis Elimination Programme (NTEP) guidelines for pediatric tuberculosis cases. Which of the following diagnostic methods is NOT recommended for detecting tuberculosis in children who cannot provide a sputum sample, according to NTEP guidelines?",
      "options": [
        {
          "label": "A",
          "text": "Chest X ray",
          "correct": false
        },
        {
          "label": "B",
          "text": "Tuberculin skin test",
          "correct": false
        },
        {
          "label": "C",
          "text": "Gastric aspirate",
          "correct": false
        },
        {
          "label": "D",
          "text": "Serological tests",
          "correct": true
        }
      ],
      "correct_answer": "D. Serological tests",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. \u00a0D. Serological tests</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 In situations where M. tuberculosis is not detected or a specimen is not available , chest X-ray (option A) and Tuberculin skin test (TST) (Option B) by Mantoux technique using 2 TU of PPD RT 23 should be done. Gastric aspirate (Option C) can be used.</li><li>\u2022 M. tuberculosis</li><li>\u2022 not detected</li><li>\u2022 specimen is not available</li><li>\u2022 chest X-ray</li><li>\u2022 Tuberculin skin test</li><li>\u2022 Gastric aspirate</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Diagnosis of TB under NTEP/ RNTCP</li><li>\u27a4 1. Microscopy:</li><li>\u27a4 Microscopy:</li><li>\u27a4 ZN staining-based Conventional Microscopy (First main test performed) Light Emitting Diode-based Fluorescence Microscopy (LED FM)</li><li>\u27a4 ZN staining-based Conventional Microscopy (First main test performed)</li><li>\u27a4 Light Emitting Diode-based Fluorescence Microscopy (LED FM)</li><li>\u27a4 2. Culture (Diagnosis):</li><li>\u27a4 Culture</li><li>\u27a4 Solid Lowenstein Jensen (LJ) Medium Automated Liquid Culture Systems (BACTEC MGIT 960, Bactialert, VersaTrek)</li><li>\u27a4 Solid Lowenstein Jensen (LJ) Medium</li><li>\u27a4 Automated Liquid Culture Systems (BACTEC MGIT 960, Bactialert, VersaTrek)</li><li>\u27a4 3. Culture (Drug Sensitivity Testing):</li><li>\u27a4 Culture</li><li>\u27a4 Modified PST for MGIT 960 system (for both 1st and 2nd line drugs) Proportional Sensitivity Testing (1%) Economic variant using LJ Medium (as back-up)</li><li>\u27a4 Modified PST for MGIT 960 system (for both 1st and 2nd line drugs)</li><li>\u27a4 Proportional Sensitivity Testing (1%) Economic variant using LJ Medium (as back-up)</li><li>\u27a4 4. Rapid Molecular Diagnostic Testing:</li><li>\u27a4 Rapid Molecular Diagnostic Testing:</li><li>\u27a4 Line Probe Assay (MTB complex and INH/RIF resistance) Cartridge based nucleic acid amplification test (CBNAAT\u2013Xpert/MTB/Rif testing using GeneXpert system)</li><li>\u27a4 Line Probe Assay (MTB complex and INH/RIF resistance)</li><li>\u27a4 Cartridge based nucleic acid amplification test (CBNAAT\u2013Xpert/MTB/Rif testing using GeneXpert system)</li><li>\u27a4 5. Other Diagnostic Tests :</li><li>\u27a4 Other Diagnostic Tests</li><li>\u27a4 Chest X-ray (Mainly for screening. If used for diagnosis its known as Clinically diagnosed TB) Standardized Tuberculin Skin Test (Complimentary test in children) Interferon Gamma Release Assay (IGRA\u2013Not recommended for adults in India) Serological tests (Banned in India).</li><li>\u27a4 Chest X-ray (Mainly for screening. If used for diagnosis its known as Clinically diagnosed TB)</li><li>\u27a4 Standardized Tuberculin Skin Test (Complimentary test in children)</li><li>\u27a4 Interferon Gamma Release Assay (IGRA\u2013Not recommended for adults in India)</li><li>\u27a4 Serological tests (Banned in India).</li><li>\u27a4 Ref : Park 26 th edition (page 224)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 224)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9e5a6e93",
      "audio": ""
    },
    {
      "text": "During a public health internship, a medical resident is tasked with finding the updated recent protocol for tuberculosis (TB) contact tracing and prophylaxis. One key component of the protocol involves the administration of isoniazid as a chemoprophylactic agent to prevent the development of active TB in individuals who have been in close contact with TB patients. What is the recommended dose of isoniazid for chemoprophylaxis in individuals who have been identified as close contacts of patients with tuberculosis?",
      "options": [
        {
          "label": "A",
          "text": "10 mg/kg daily for 6 months",
          "correct": true
        },
        {
          "label": "B",
          "text": "5 mg/kg daily for 6 months",
          "correct": false
        },
        {
          "label": "C",
          "text": "10 mg/kg daily for 12 months",
          "correct": false
        },
        {
          "label": "D",
          "text": "5 mg/kg daily for 12 months",
          "correct": false
        }
      ],
      "correct_answer": "A. 10 mg/kg daily for 6 months",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. 10 mg/kg daily for 6 months</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The dose of INH for chemoprophylaxis is 10 mg/kg (instead of 5 mg/kg) administered daily for 6 months .</li><li>\u2022 dose of INH</li><li>\u2022 chemoprophylaxis is 10 mg/kg</li><li>\u2022 6 months</li><li>\u2022 INH Preventive Therapy</li><li>\u2022 INH Preventive Therapy</li><li>\u2022 1. INH Preventive Therapy in Children -</li><li>\u2022 INH Preventive Therapy in Children</li><li>\u2022 Children <6 years of age in close contact (But TB excluded) HIV infected children who either had a known exposure to an infectious TB case or are</li><li>\u2022 Children <6 years of age in close contact (But TB excluded)</li><li>\u2022 Children <6 years of age</li><li>\u2022 close contact</li><li>\u2022 HIV infected children who either had a known exposure to an infectious TB case or are</li><li>\u2022 exposure to an infectious TB case</li><li>\u2022 Tuberculin skin test (TST) positive (>=5mm induration) but have no active TB disease</li><li>\u2022 Tuberculin skin test</li><li>\u2022 positive</li><li>\u2022 All TST positive children who are receiving immunosuppressive therapy (e.g. Children with nephrotic syndrome, acute leukaemia, etc.) A child born to mother who was diagnosed to have TB in pregnancy provided congenital TB has been ruled out</li><li>\u2022 All TST positive children who are receiving immunosuppressive therapy (e.g. Children with nephrotic syndrome, acute leukaemia, etc.)</li><li>\u2022 TST positive children</li><li>\u2022 immunosuppressive therapy</li><li>\u2022 A child born to mother who was diagnosed to have TB in pregnancy provided congenital TB has been ruled out</li><li>\u2022 2. INH Preventive Therapy in Adults -</li><li>\u2022 INH Preventive Therapy in Adults</li><li>\u2022 Adults and adolescents living with HIV unlikely to have active TB Children living with HIV who do not have poor weight gain, fever or current cough unlikely to have active TB Children living with HIV if evaluation shows no TB</li><li>\u2022 Adults and adolescents living with HIV unlikely to have active TB</li><li>\u2022 Adults</li><li>\u2022 adolescents</li><li>\u2022 HIV</li><li>\u2022 unlikely</li><li>\u2022 active TB</li><li>\u2022 Children living with HIV who do not have poor weight gain, fever or current cough unlikely to have active TB</li><li>\u2022 Children living with HIV if evaluation shows no TB</li><li>\u2022 3 . Dose of IPT Used under NTEP -</li><li>\u2022 . Dose of IPT Used under NTEP -</li><li>\u2022 Adult and Adolescent: Isoniazid 300 mg + Pyridoxine 50 mg per day \u00d7 6 months Children above 12 months: Isoniazid 10 mg/kg + Pyridoxine 25 mg per day \u00d7 6 months</li><li>\u2022 Adult and Adolescent: Isoniazid 300 mg + Pyridoxine 50 mg per day \u00d7 6 months</li><li>\u2022 Children above 12 months: Isoniazid 10 mg/kg + Pyridoxine 25 mg per day \u00d7 6 months</li><li>\u2022 Other Important Pointers:</li><li>\u2022 Other Important Pointers:</li><li>\u2022 Antitubercular drugs contained in all phases of all categories of DOTS : Rifampicin and Isoniazid Most effective drug out of HRZES - H and R Antitubercular drug first to develop resistance: Isoniazid Most toxic antitubercular drug: Isoniazid Multidrug Resistant TB (MDR\u2013TB): Resistance to Isoniazid and Rifampicin \u2018with or without resistance to other drugs\u2019 Extensive Drug Resistant TB (XDR\u2013TB): Resistance to rifampicin and isoniazid AND to any member of the quinolone family AND to one of the injectable second-line drugs (kanamycin, capreomycin, or amikacin) XDR\u2013TB is MDR TB with further resistance to 3 \u2013 6 classes of second line drugs (Older definition)</li><li>\u2022 Antitubercular drugs contained in all phases of all categories of DOTS : Rifampicin and Isoniazid</li><li>\u2022 Antitubercular drugs</li><li>\u2022 all phases of all categories of DOTS</li><li>\u2022 Rifampicin</li><li>\u2022 Isoniazid</li><li>\u2022 Most effective drug out of HRZES - H and R</li><li>\u2022 effective drug</li><li>\u2022 HRZES - H and R</li><li>\u2022 Antitubercular drug first to develop resistance: Isoniazid</li><li>\u2022 Antitubercular drug</li><li>\u2022 Isoniazid</li><li>\u2022 Most toxic antitubercular drug: Isoniazid</li><li>\u2022 Multidrug Resistant TB (MDR\u2013TB): Resistance to Isoniazid and Rifampicin \u2018with or without resistance to other drugs\u2019</li><li>\u2022 Extensive Drug Resistant TB (XDR\u2013TB): Resistance to rifampicin and isoniazid AND to any member of the quinolone family AND to one of the injectable second-line drugs (kanamycin, capreomycin, or amikacin)</li><li>\u2022 XDR\u2013TB is MDR TB with further resistance to 3 \u2013 6 classes of second line drugs (Older definition)</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Dose of IPT Used under NTEP -</li><li>\u27a4 Dose of IPT Used under NTEP</li><li>\u27a4 Adult and Adolescent : Isoniazid 300 mg + Pyridoxine 50 mg per day \u00d7 6 months Children above 12 months : Isoniazid 10 mg/kg + Pyridoxine 25 mg per day \u00d7 6 months</li><li>\u27a4 Adult and Adolescent : Isoniazid 300 mg + Pyridoxine 50 mg per day \u00d7 6 months</li><li>\u27a4 Adult and Adolescent</li><li>\u27a4 Children above 12 months : Isoniazid 10 mg/kg + Pyridoxine 25 mg per day \u00d7 6 months</li><li>\u27a4 Children above 12 months</li><li>\u27a4 Ref : Park 26 th edition (page 225)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 225)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a13addd3",
      "audio": ""
    },
    {
      "text": "A 27-year-old woman who is 16 weeks pregnant presents to the clinic with a cough, night sweats, and a weight loss of 10 pounds over the last two months. A sputum sample is positive for acid-fast bacilli, and a chest X-ray is consistent with active pulmonary tuberculosis (TB). The patient is HIV negative. Her obstetrician must now collaborate with an infectious disease specialist to determine an appropriate treatment regimen that is safe for both the mother and the fetus. Which of the following anti-tuberculous medications is CONTRAINDICATED in this pregnant patient?",
      "options": [
        {
          "label": "A",
          "text": "Isoniazid",
          "correct": false
        },
        {
          "label": "B",
          "text": "Rifampicin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Pyrazinamide",
          "correct": false
        },
        {
          "label": "D",
          "text": "Streptomycin",
          "correct": true
        }
      ],
      "correct_answer": "D. Streptomycin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Streptomycin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Before initiating treatment for tuberculosis , women of childbearing age should be asked about current or planned pregnancy and counselled appropriately . A successful treatment of TB is important for successful outcome of pregnancy . With the exception of streptomycin, the first line anti-TB drugs are safe for use in pregnancy . Streptomycin is oto-toxic to the foetus and should not be used during pregnancy.</li><li>\u2022 Before initiating treatment</li><li>\u2022 tuberculosis</li><li>\u2022 women of childbearing age</li><li>\u2022 current or planned pregnancy</li><li>\u2022 counselled appropriately</li><li>\u2022 successful treatment of TB</li><li>\u2022 successful outcome of pregnancy</li><li>\u2022 first line anti-TB drugs</li><li>\u2022 safe for use in pregnancy</li><li>\u2022 Streptomycin</li><li>\u2022 oto-toxic</li><li>\u2022 foetus</li><li>\u2022 Other 3 options (Isoniazid, Rifampicin and Pyrazinamide) are safe to use in pregnancy</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Important Facts of Antitubercular Drugs</li><li>\u27a4 Important Facts of Antitubercular Drugs</li><li>\u27a4 Most effective anti-tubercular drug: Rifampicin Most bactericidal antitubercular drug: Rifampicin Most toxic antitubercular drug: Isoniazid Antitubercular drug causing rapid sputum conversion : Rifampicin Antitubercular drug causing orange discoloration of urine : Rifampicin Antitubercular drug first to develop resistance : Isoniazid Antitubercular drug contraindicated AIDS patients on Protease Inhibitors: Rifampicin Antitubercular drug contraindicated in HIV: Thiacetazone (Exfoliative dermatitis) Antitubercular drugs contained in all phases of all categories of DOTS: Rifampicin and Isoniazid Injectable Antitubercular drug: Streptomycin Antitubercular drug contraindicated in children < 6 years age: Ethambutol Antitubercular drug causing Optic neuritis (Red-Green color blindness): Ethambutol Antitubercular drug causing vestibular damage: Streptomycin Antitubercular drug contraindicated in pregnancy: Streptomycin</li><li>\u27a4 Most effective anti-tubercular drug: Rifampicin</li><li>\u27a4 Most effective</li><li>\u27a4 Rifampicin</li><li>\u27a4 Most bactericidal antitubercular drug: Rifampicin</li><li>\u27a4 Most bactericidal</li><li>\u27a4 Rifampicin</li><li>\u27a4 Most toxic antitubercular drug: Isoniazid</li><li>\u27a4 Most toxic</li><li>\u27a4 Isoniazid</li><li>\u27a4 Antitubercular drug causing rapid sputum conversion : Rifampicin</li><li>\u27a4 rapid sputum conversion</li><li>\u27a4 Rifampicin</li><li>\u27a4 Antitubercular drug causing orange discoloration of urine : Rifampicin</li><li>\u27a4 orange discoloration of urine</li><li>\u27a4 Rifampicin</li><li>\u27a4 Antitubercular drug first to develop resistance : Isoniazid</li><li>\u27a4 first to develop resistance</li><li>\u27a4 Isoniazid</li><li>\u27a4 Antitubercular drug contraindicated AIDS patients on Protease Inhibitors: Rifampicin</li><li>\u27a4 Antitubercular drug contraindicated in HIV: Thiacetazone (Exfoliative dermatitis)</li><li>\u27a4 Antitubercular drugs contained in all phases of all categories of DOTS: Rifampicin and Isoniazid</li><li>\u27a4 Injectable Antitubercular drug: Streptomycin</li><li>\u27a4 Antitubercular drug contraindicated in children < 6 years age: Ethambutol</li><li>\u27a4 Antitubercular drug causing Optic neuritis (Red-Green color blindness): Ethambutol</li><li>\u27a4 Antitubercular drug causing vestibular damage: Streptomycin</li><li>\u27a4 Antitubercular drug contraindicated in pregnancy: Streptomycin</li><li>\u27a4 Ref : Park 26 th edition (page 225)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 225)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1cc62be4",
      "audio": ""
    },
    {
      "text": "In a primary care clinic, a group of nursing students is being taught about the Bacille Calmette-Gu\u00e9rin (BCG) vaccine, its administration, and its role in tuberculosis prevention. The discussion covers various aspects of the vaccine, including production, dosage, administration, and duration of protection. Which of the following statements regarding the BCG vaccine is NOT accurate?",
      "options": [
        {
          "label": "A",
          "text": "Jeryl Lynn strain is used for production of BCG vaccine",
          "correct": true
        },
        {
          "label": "B",
          "text": "For vaccination, the usual strength is 0.1 mg in 0.1 ml volume",
          "correct": false
        },
        {
          "label": "C",
          "text": "The site of injection should be just above the insertion of the left deltoid muscle",
          "correct": false
        },
        {
          "label": "D",
          "text": "The duration of protection is from 15 to 20 years.",
          "correct": false
        }
      ],
      "correct_answer": "A. Jeryl Lynn strain is used for production of BCG vaccine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Jeryl Lynn strain is used for production of BCG vaccine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Correct: The typical dosage for the BCG vaccine is 0.1 mg in a 0.1 ml volume. This is a standard concentration used in the administration of the vaccine.</li><li>\u2022 Option B. Correct:</li><li>\u2022 Option C. Correct : The recommended site of injection for the BCG vaccine is intradermally just above the insertion of the deltoid muscle, often on the left arm. This is a common practice for ease of administration and monitoring of the site.</li><li>\u2022 Option C. Correct</li><li>\u2022 Option D. Correct: The duration of protection provided by the BCG vaccine is generally estimated to be between 15 to 20 years. This duration can vary based on individual immune response and other factors.</li><li>\u2022 Option D. Correct:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Strains of Commonly Used Vaccines</li><li>\u27a4 BCG - Danish-1331 strain (WHO recommended) OPV/IPV - P1, P2, P3 strains (Monovalent or Trivalent or Bivalent) Measles vaccine - Edmonston Zagreb strain (MC); Schwartz strain; Moraten strain Mumps vaccine - Jeryll Lynn strain Rubella vaccine - RA 27/3 Yellow Fever vaccine - 17 D strain Varicella vaccine - OKA strain Japanese Encephalitis vaccine - Nakayama strain; Beijing P3 strain; SA 14-14-2 (Used in India) Swine Flu Vaccine (killed) - A7/California/2009 Malaria vaccine SPf - 66 strain (Lytic Coktail); Pf 25 strain; RTS, S/AS01 (Mosquirix) HIV vaccines - mVA (modified Vaccinia Ankara) strain; rAAV (recombinant Adeno associated viral vaccine) strain; CTL (Cytotoxic T-lymphocytic) strain; AIDSVAX strain; Subunit Vaccine strain Typhoral vaccine - Ty 21 a Covaxin - Niv-2020-770</li><li>\u27a4 BCG - Danish-1331 strain (WHO recommended)</li><li>\u27a4 BCG - Danish-1331 strain</li><li>\u27a4 OPV/IPV - P1, P2, P3 strains (Monovalent or Trivalent or Bivalent)</li><li>\u27a4 Measles vaccine - Edmonston Zagreb strain (MC); Schwartz strain; Moraten strain</li><li>\u27a4 Measles vaccine</li><li>\u27a4 Mumps vaccine - Jeryll Lynn strain</li><li>\u27a4 Mumps vaccine</li><li>\u27a4 Rubella vaccine - RA 27/3</li><li>\u27a4 Rubella vaccine</li><li>\u27a4 Yellow Fever vaccine - 17 D strain</li><li>\u27a4 Yellow Fever vaccine</li><li>\u27a4 Varicella vaccine - OKA strain</li><li>\u27a4 Varicella vaccine</li><li>\u27a4 Japanese Encephalitis vaccine - Nakayama strain; Beijing P3 strain; SA 14-14-2 (Used in India)</li><li>\u27a4 Japanese Encephalitis vaccine</li><li>\u27a4 Swine Flu Vaccine (killed) - A7/California/2009</li><li>\u27a4 Swine Flu Vaccine</li><li>\u27a4 Malaria vaccine SPf - 66 strain (Lytic Coktail); Pf 25 strain; RTS, S/AS01 (Mosquirix)</li><li>\u27a4 Malaria vaccine SPf</li><li>\u27a4 HIV vaccines - mVA (modified Vaccinia Ankara) strain; rAAV (recombinant Adeno associated viral vaccine) strain; CTL (Cytotoxic T-lymphocytic) strain; AIDSVAX strain; Subunit Vaccine strain</li><li>\u27a4 Typhoral vaccine - Ty 21 a</li><li>\u27a4 Covaxin - Niv-2020-770</li><li>\u27a4 Ref : Park 26 th edition (page 226)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 226)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1d26eed1",
      "audio": ""
    },
    {
      "text": "Dr. Lokesh, a public health officer, is reviewing the historical efforts in global tuberculosis (TB) control to prepare for a lecture on infectious diseases. She notes that the World Health Organization (WHO) has transitioned from the STOP TB strategy to the more recent END TB strategy. Which of the following was NOT part of the WHO's previous STOP TB strategy?",
      "options": [
        {
          "label": "A",
          "text": "Pursue high quality DOTS expansion and enhancement",
          "correct": false
        },
        {
          "label": "B",
          "text": "Engage all care providers",
          "correct": false
        },
        {
          "label": "C",
          "text": "Empower people with TB and communities",
          "correct": false
        },
        {
          "label": "D",
          "text": "Case detection through predominantly passive case finding",
          "correct": true
        }
      ],
      "correct_answer": "D. Case detection through predominantly passive case finding",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D. Case detection through predominantly passive case finding</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Correct: The STOP TB strategy did focus on the expansion and enhancement of high-quality DOT S (Directly Observed Treatment, Short-course). DOTS is the foundation of TB control programs under this strategy, emphasizing direct observation of treatment to ensure compliance and effectiveness.</li><li>\u2022 Option A. Correct:</li><li>\u2022 STOP TB strategy</li><li>\u2022 expansion and enhancement of high-quality DOT</li><li>\u2022 Option B. Correct: Engaging all care providers was a key component of the STOP TB strategy . This included both public and private healthcare providers, aiming to ensure a coordinated and effective approach to TB treatment and prevention.</li><li>\u2022 Option B. Correct:</li><li>\u2022 Engaging all care providers</li><li>\u2022 key component of the STOP TB strategy</li><li>\u2022 Option C. Correct: Empowering people with TB and communities was also a vital aspect of the STOP TB strategy. This involved education, awareness, and community participation to improve TB control efforts and reduce stigma.</li><li>\u2022 Option C. Correct:</li><li>\u2022 Empowering people with TB</li><li>\u2022 communities</li><li>\u2022 vital aspect of the STOP TB strategy.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 STOP TB strategy:</li><li>\u27a4 STOP TB strategy:</li><li>\u27a4 Pursue high-quality DOTS expansion and enhancement. Address TB/HIV, MDR-TB and other challenges. Contribute to health system strengthening. Engage all care providers. Empower people with TB and communities. Enable and promote research.</li><li>\u27a4 Pursue high-quality DOTS expansion and enhancement.</li><li>\u27a4 Address TB/HIV, MDR-TB and other challenges.</li><li>\u27a4 Contribute to health system strengthening.</li><li>\u27a4 Engage all care providers.</li><li>\u27a4 Empower people with TB and communities.</li><li>\u27a4 Enable and promote research.</li><li>\u27a4 Elimination level for Tuberculosis (WHO and STOP TB Strategy): <1 case per million populations (to eliminate TB as a public health problem)</li><li>\u27a4 Elimination level for Tuberculosis</li><li>\u27a4 Ref : Park 26 th edition (page 233)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 233)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a434da64",
      "audio": ""
    },
    {
      "text": "As part of an initiative to contribute to the END TB strategy, a team of public health professionals is developing a comprehensive plan to combat tuberculosis (TB). They are focusing on the three pillars that underpin the strategy, which were set forth by the World Health Organization (WHO). Which of the following is NOT one of the pillars of the END TB strategy as set by the World Health Organization?",
      "options": [
        {
          "label": "A",
          "text": "Address TB/HIV, MDR TB and other challenges",
          "correct": true
        },
        {
          "label": "B",
          "text": "Integrated patient centred care and prevention",
          "correct": false
        },
        {
          "label": "C",
          "text": "Bold policies and supportive systems",
          "correct": false
        },
        {
          "label": "D",
          "text": "Intensified research and innovation",
          "correct": false
        }
      ],
      "correct_answer": "A. Address TB/HIV, MDR TB and other challenges",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-171552.png"
      ],
      "explanation": "<p><strong>Ans. A. Address TB/HIV, MDR TB and other challenges</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Integrated, patient-centered care and prevention: Focusing on early diagnosis , treatment, and care for all, including vulnerable populations.</li><li>\u2022 Option B. Integrated, patient-centered care and prevention:</li><li>\u2022 Focusing</li><li>\u2022 early diagnosis</li><li>\u2022 Option C. Bold policies and supportive systems: This involves strengthening health systems and improving social determinants of health.</li><li>\u2022 Option C. Bold policies and supportive systems:</li><li>\u2022 strengthening health systems</li><li>\u2022 Option D. Intensified research and innovation: Aiming to advance new tools for diagnosis , treatment , and vaccines .</li><li>\u2022 Option D. Intensified research and innovation:</li><li>\u2022 advance new tools</li><li>\u2022 diagnosis</li><li>\u2022 treatment</li><li>\u2022 vaccines</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 End TB Strategy 2016-2035</li><li>\u27a4 End TB Strategy 2016-2035</li><li>\u27a4 Goal: End the Global TB Epidemic</li><li>\u27a4 Ref : Park 26 th edition (page 233)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 233)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1fb44c5c",
      "audio": ""
    },
    {
      "text": "A medical student is assigned to prepare a presentation on tuberculosis research institutions in India as part of their infectious diseases rotation. They need to locate the leading research institution where significant work on tuberculosis (TB) is conducted, including clinical trials, drug resistance studies, and epidemiological research. The National Institute for Research in Tuberculosis (NIRT), a premier institute dedicated to TB research in India, is located in which city?",
      "options": [
        {
          "label": "A",
          "text": "Agra",
          "correct": false
        },
        {
          "label": "B",
          "text": "Bhopal",
          "correct": false
        },
        {
          "label": "C",
          "text": "Chennai",
          "correct": true
        },
        {
          "label": "D",
          "text": "Delhi",
          "correct": false
        }
      ],
      "correct_answer": "C. Chennai",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C. Chennai</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The National Institute for Research in Tuberculosis (NIRT), formerly known as the Tuberculosis Chemotherapy Centre , is situated in Chennai . It is one of the institutes of the Indian Council of Medical Research (ICMR) and plays a pivotal role in TB research in India . NIRT conducts a wide array of research activities related to tuberculosis, including basic science research, clinical trials, and epidemiological studies.</li><li>\u2022 National Institute for Research in Tuberculosis</li><li>\u2022 Tuberculosis Chemotherapy Centre</li><li>\u2022 Chennai</li><li>\u2022 one of the institutes</li><li>\u2022 Indian Council of Medical Research</li><li>\u2022 pivotal role in TB research in India</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 National reference Laboratories for TB in India</li><li>\u27a4 National reference Laboratories for TB in India</li><li>\u27a4 National Institute for Research in Tuberculosis (NIRT), Chennai National Tuberculosis Institute (NTI), Bangalore National Institute of TB and Respiratory Diseases (NITRD), Delhi Delhi and National Japanese Leprosy Mission for Asia (JALMA)\u2014Institute of Leprosy and other Mycobacterial Diseases, Agra Regional Medical Research Centre (RMRC), Bhubaneswar Bhopal Memorial Hospital and Research Centre (BMHRC), Bhopal</li><li>\u27a4 National Institute for Research in Tuberculosis (NIRT), Chennai</li><li>\u27a4 National Tuberculosis Institute (NTI), Bangalore</li><li>\u27a4 National Institute of TB and Respiratory Diseases (NITRD), Delhi</li><li>\u27a4 Delhi and National Japanese Leprosy Mission for Asia (JALMA)\u2014Institute of Leprosy and other Mycobacterial Diseases, Agra</li><li>\u27a4 Regional Medical Research Centre (RMRC), Bhubaneswar</li><li>\u27a4 Bhopal Memorial Hospital and Research Centre (BMHRC), Bhopal</li><li>\u27a4 Ref : Park 26 th edition (page 478)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 478)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "28c771c0",
      "audio": ""
    },
    {
      "text": "In a country with an ongoing effort to control tuberculosis, a public health official is tasked with planning and organizing local TB control efforts in line with the National Tuberculosis Elimination Program (NTEP). A critical aspect of this planning involves understanding the operational capacity of a Tuberculosis Unit (TU) to ensure comprehensive coverage. According to the National Tuberculosis Elimination Program (NTEP), a Tuberculosis Unit is designed to cater to what size of the population?",
      "options": [
        {
          "label": "A",
          "text": "5000.",
          "correct": false
        },
        {
          "label": "B",
          "text": "30000",
          "correct": false
        },
        {
          "label": "C",
          "text": "100000",
          "correct": false
        },
        {
          "label": "D",
          "text": "200000",
          "correct": true
        }
      ],
      "correct_answer": "D. 200000",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D. 200000</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 A major organizational change in NTEP is the creation of a sub-district level (Tuberculosis Unit-TU). TUs have been created based on a population -</li><li>\u2022 major organizational change</li><li>\u2022 NTEP</li><li>\u2022 creation of a sub-district level</li><li>\u2022 1 TB unit - 1 per 1.5-2.5 lac population</li><li>\u2022 1 DMC - 1 per 50000 -1 lac population</li><li>\u2022 Most peripheral unit under RNTCP - DMC</li><li>\u2022 DMCs are manned by a trained laboratory technician (LT) of the State health system .</li><li>\u2022 DMCs</li><li>\u2022 trained laboratory technician</li><li>\u2022 State health system</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 1 TB unit (RNTCP) is for a population of 2.0 Lac (Range - 1.5 -2.5 lac population)</li><li>\u27a4 1 TB unit</li><li>\u27a4 population of 2.0 Lac</li><li>\u27a4 RNTCP District microscopic center is recommended for 50000 - 1 lac population</li><li>\u27a4 RNTCP District microscopic center</li><li>\u27a4 50000 - 1 lac population</li><li>\u27a4 Ref : Park 26 th edition (page 478)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 478)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "095fbd8d",
      "audio": ""
    },
    {
      "text": "A group of public health professionals is evaluating the country\u2019s progress toward the targets set by the National Strategic Plan for Tuberculosis (TB) elimination. In the course of their review, they compare the set objectives against the milestones reached and strategize on how to address the gaps. Which of the following is NOT an objective within the National Strategic Plan to achieve the elimination of tuberculosis by 2025?",
      "options": [
        {
          "label": "A",
          "text": "0% having catastrophic expenditure due to TB",
          "correct": false
        },
        {
          "label": "B",
          "text": "70% increase in case finding",
          "correct": true
        },
        {
          "label": "C",
          "text": "80% reduction in TB incidence",
          "correct": false
        },
        {
          "label": "D",
          "text": "90% reduction in TB mortality",
          "correct": false
        }
      ],
      "correct_answer": "B. 70% increase in case finding",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.\u00a0B. 70% increase in case finding</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Under SDGs \u2013Specific Targets for SDG Target 3.3 on Infectious Diseases - Targets for TB are:</li><li>\u2022 Under SDGs</li><li>\u2022 Targets for SDG Target 3.3 on Infectious Diseases</li><li>\u2022 Option A. 0% patient having catastrophic expenditure due to TB</li><li>\u2022 Option A. 0% patient</li><li>\u2022 catastrophic expenditure</li><li>\u2022 Option C. 80% reduction in TB incidence (i.e. reduction from 211 per lakh to 43 per lakh)</li><li>\u2022 Option C. 80% reduction</li><li>\u2022 TB incidence</li><li>\u2022 Option D. 90% reduction in TB mortality (i.e. reduction from 32 per lakh to 3 per lakh)</li><li>\u2022 Option D. 90% reduction</li><li>\u2022 TB mortality</li><li>\u2022 Timeline of TB Programs in India</li><li>\u2022 Timeline of TB Programs in India</li><li>\u2022 1962: National TB Control Program (NTP) launched [Strategy: BCG vaccination, TB treatment] 1992-93 : Revised National TB Control Program (RNTCP) launched [Strategy: DOTS] 01 January 2020 : National TB Elimination Program (NTEP) launched</li><li>\u2022 1962: National TB Control Program (NTP) launched [Strategy: BCG vaccination, TB treatment]</li><li>\u2022 1962:</li><li>\u2022 1992-93 : Revised National TB Control Program (RNTCP) launched [Strategy: DOTS]</li><li>\u2022 1992-93</li><li>\u2022 01 January 2020 : National TB Elimination Program (NTEP) launched</li><li>\u2022 01 January 2020</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 SDG target (3.3) for Ending the epidemic of TB are 90% reduction in TB deaths ; 80% reduction in TB incidence rate and Zero TB-affected families facing catastrophic costs due to TB</li><li>\u27a4 SDG target</li><li>\u27a4 Ending the epidemic of TB</li><li>\u27a4 90% reduction in TB deaths</li><li>\u27a4 80% reduction</li><li>\u27a4 TB incidence rate</li><li>\u27a4 Zero TB-affected families</li><li>\u27a4 catastrophic costs</li><li>\u27a4 National Strategic Plan (NSP) - TB 2017-25</li><li>\u27a4 National Strategic Plan (NSP) - TB 2017-25</li><li>\u27a4 VISION : TB-Free India with zero deaths, disease and poverty due to TB GOAL: To achieve a rapid decline in burden of TB, morbidity and mortality while working towards elimination of TB in India by 2025 NSP sets out the strategic direction and key initiatives that the MoHFW will undertake from 2017-25 for working towards achieving the goals of eliminating TB by 2025 (Achieve SDG and End TB targets for India) Approach: \u2018DETECT-TREAT-PREVENT-BUILD\u2019 approach Strategic Focus Areas : Early diagnosis of all the TB patients Prompt treatment with the right drugs and regimens Patient financial and nutritional support Active case finding Contact tracing LTBI management in high risk population Airborne infection control</li><li>\u27a4 VISION : TB-Free India with zero deaths, disease and poverty due to TB</li><li>\u27a4 VISION</li><li>\u27a4 GOAL: To achieve a rapid decline in burden of TB, morbidity and mortality while working towards elimination of TB in India by 2025</li><li>\u27a4 GOAL:</li><li>\u27a4 NSP sets out the strategic direction and key initiatives that the MoHFW will undertake from 2017-25 for working towards achieving the goals of eliminating TB by 2025 (Achieve SDG and End TB targets for India)</li><li>\u27a4 Approach: \u2018DETECT-TREAT-PREVENT-BUILD\u2019 approach</li><li>\u27a4 \u2018DETECT-TREAT-PREVENT-BUILD\u2019 approach</li><li>\u27a4 Strategic Focus Areas : Early diagnosis of all the TB patients Prompt treatment with the right drugs and regimens Patient financial and nutritional support Active case finding Contact tracing LTBI management in high risk population Airborne infection control</li><li>\u27a4 Strategic Focus Areas</li><li>\u27a4 Early diagnosis of all the TB patients Prompt treatment with the right drugs and regimens Patient financial and nutritional support Active case finding Contact tracing LTBI management in high risk population Airborne infection control</li><li>\u27a4 Early diagnosis of all the TB patients</li><li>\u27a4 Prompt treatment with the right drugs and regimens</li><li>\u27a4 Patient financial and nutritional support</li><li>\u27a4 Active case finding</li><li>\u27a4 Contact tracing</li><li>\u27a4 LTBI management in high risk population</li><li>\u27a4 Airborne infection control</li><li>\u27a4 Ref : Park 26 th edition (page 483)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 483)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "eca3ac33",
      "audio": ""
    },
    {
      "text": "A medical resident is participating in a seminar discussing the various aspects of national tuberculosis control programs. One of the topics under discussion is the funding and support for these programs. The resident is aware that these initiatives are often supported by a combination of domestic and international sources. Which of the following is NOT typically a funding agency for National Tuberculosis Control Programs?",
      "options": [
        {
          "label": "A",
          "text": "Colombo plan",
          "correct": true
        },
        {
          "label": "B",
          "text": "SIDA",
          "correct": false
        },
        {
          "label": "C",
          "text": "WHO",
          "correct": false
        },
        {
          "label": "D",
          "text": "World Bank",
          "correct": false
        }
      ],
      "correct_answer": "A. Colombo plan",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A. Colombo plan.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The National TB Control programmes are being assisted by the following organizations:</li><li>\u2022 National TB Control programmes</li><li>\u2022 assisted</li><li>\u2022 World Bank (Option D ) Department for International Development (DFID) WHO (Option C) Global TB Drug Facility (GDF), Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) United States Agency for International Development (USAID) SIDA (Option B) DANIDA.</li><li>\u2022 World Bank (Option D )</li><li>\u2022 (Option D</li><li>\u2022 Department for International Development (DFID)</li><li>\u2022 WHO (Option C)</li><li>\u2022 (Option C)</li><li>\u2022 Global TB Drug Facility (GDF),</li><li>\u2022 Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM)</li><li>\u2022 United States Agency for International Development (USAID)</li><li>\u2022 SIDA (Option B)</li><li>\u2022 (Option B)</li><li>\u2022 DANIDA.</li><li>\u2022 The government of India provides 100 percent grant in- aid to the implementing agencies i.e., states/UTs, besides free drugs.</li><li>\u2022 government of India</li><li>\u2022 100 percent grant in- aid</li><li>\u2022 implementing agencies</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The programme is being assisted by the World Bank and the Department for International Development (DFID) via WHO. In addition, the RNTCP is supported by the Global TB Drug Facility (GDF), Global Fund to Fight AIDS , Tuberculosis and Malaria (GFATM), the United States Agency for International Development (USAID), SIDA and DANIDA. Government of India provides 100 per cent grantin- aid to the implementing agencies i.e., states/UTs, besides free drugs.</li><li>\u27a4 programme</li><li>\u27a4 World Bank and the Department for International Development</li><li>\u27a4 RNTCP</li><li>\u27a4 Global TB Drug Facility</li><li>\u27a4 Global Fund to Fight AIDS</li><li>\u27a4 Tuberculosis</li><li>\u27a4 Malaria</li><li>\u27a4 United States Agency</li><li>\u27a4 International Development</li><li>\u27a4 Ref : Park 26 th edition (page 484)</li><li>\u27a4 Ref</li><li>\u27a4 : Park 26 th edition (page 484)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "11b9ba74",
      "audio": ""
    }
  ]
}